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Abstract
Multiple Sclerosis (MS) is an acquired demyelinating disease of the central nervous 
system (CNS) which usually presents as a Clinically Isolated Syndrome (CIS). 
Longitudinal clinical and MRI studies of patients with CIS give insight into the 
clinical prognostic factors for the development of Relapsing Remitting (RR) and 
Secondary Progressive (SP) MS.
In this MD thesis, I have discussed the clinical and MRI correlations in a group of 65 
patients recruited between 1995 and 1999 and who have been followed for 
approximately 3 years. In Chapters 3.2 and 3.3, I evaluated baseline MRI brain and 
spinal cord findings as predictive tests for MS at 3 years.
In 2001, the International Panel on MS diagnosis published revised criteria on the 
diagnosis of MS. For the first time a diagnosis of MS could be made in patients with 
CIS suggestive of MS using MRI for evidence of Dissemination in Space (DIS) and 
Dissemination in Time (DIT). The accuracy of both the new MRI and clinical criteria 
was evaluated at one and 3 years, in Chapter 4.1. Although the new diagnostic criteria 
were found to specific for MS, their sensitivity was lower.
While, high specificity was achieved by the requirement of new Gadolinium 
enhancing lesions at a 3 month follow up scan in patients imaged initially within 3 
months of the onset of symptoms, the same requirement reduced sensitivity. New T2 
lesions are seen more often on the 3 month follow up scan than new Gadolinium 
enhancing lesions. Our next project in chapter 4.2, was to evaluate inclusion of new 
T2 lesions as a predictive test for MS at 3 years. Interestingly, new T2 lesions used as
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evidence for DIT were sensitive for a diagnosis of MS at 3 years without a loss in 
specificity. Finally, as an exploratory exercise in this section, we evaluated new T2 
lesions, regardless of evidence of MRI DIS. New T2 lesions were both sensitive and 
specific for a diagnosis of MS at 3 years. Further evaluation of a new T2 lesion at 3 
months together with optimum MRI evidence for DIS is therefore warranted.
Brain atrophy has been evaluated as a surrogate marker in MS. The cause and timing 
of atrophy and its association with inflammatory MRI lesions are not clear. In chapter
5.1, Ventricular Volume (VV) was analyzed as an atrophy marker in a cohort of 55 
patients followed for one year. In Chapter 5.2, Grey Matter (GM), White Matter 
(WM), Brain Parenchymal Fractions (BPF) and (VV) were analyzed as atrophy 
markers in 58 patients followed for 3 years. Significant GM atrophy and an increase 
in VV were seen in those who developed MS. There were moderate correlations 
between lesions and increase in VV and reduction in GMF and BPF.
In conclusion, although imaging of the brain is extremely helpful in patients with 
optic neuritis in order to assign risk of MS, imaging of the spinal cord is less useful. 
The new diagnostic criteria for the diagnosis of MS in patients with CIS are specific. 
Sensitivity of the diagnostic criteria may be improved by the inclusion of new T2 
lesions after 3 months as evidence of DIT. Regional atrophy affecting both GM and 
VV size was noted in patients with CIS, who went on to develop MS.
Pathogenic process including lesions and atrophy occur in the earliest clinical stages 
of MS and are only partially related. It is appropriate to measure both processes in 
future disease modifying treatment trials in patients with CIS or early MS.
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Thesis Description
This thesis is divided into two parts and six chapters. In Part 1, Chapters 1 and 2 are 
introductory in nature. Chapter 1 is a background chapter on Multiple Sclerosis (MS) 
with a focus on patients presenting with Clinically Isolated Syndromes (CIS). Chapter 
2 gives the principles of Magnetic Resonance Imaging (MRI). Conventional and more 
modem MRI techniques and their application to patients with CIS and MS are 
discussed.
Patient recruitment, clinical and MRI sequences that form the basis of the studies in 
Chapters 3 - 5 are explained in the introduction to Part 2. Chapters 3.2 and 3.3, 
evaluate baseline MRI findings in patients with CIS as predictive tests for MS. The 
McDonald criteria are applied in chapter 4.1, using MRI evidence of Dissemination in 
Space (DIS) and Time (DIT). New T2 lesions are also evaluated for evidence of DIT 
in Chpater 4.2. Chapter 5 evaluates Ventricular Volumes (VV), Grey Matter (GM) 
White Matter (WM) and Brain Parenchymal fraction (BPF) as markers of atrophy in 
patients presenting with CIS followed for 1 and 3 years.
Chapter 6 is a summary of the aims of the thesis which are the evaluation of MRI as a 
predictor for CDMS and testing atrophy as a surrogate marker. T2 lesions on the 
baseline MRI are sensitive indicators for CDMS at 3 years, but lack the specificity of 
the McDonald Criteria. The McDonald Criteria are more specific if a new T2 lesion is 
used as evidence of DIT. GMF and BPF atrophy together with increaseing VV are 
sensitive markers for tissue loss in the first 3 years in patients who develop MS. The 
relatively modest correlations between lesion load and atrophy suggest that the 
processes are partly independent and that both will required monitoring as surrogate 
markers of disability and when evaluating new therapeutic agents for MS.
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Chapter 1
1. Multiple Sclerosis and Clinically Isolated Syndromes
1.1. Multiple Sclerosis
1.1.1. Introduction
Multiple Sclerosis (MS) is a chronic, inflammatory, demyelinating, autoimmune 
disorder of the central nervous system (CNS) affecting approximately 1 million 
people globally and is the commonest cause of neurological impairment in young 
people. [Williams et al. 1995] Usually, the disease is characterised by episodic 
neurological events disseminated in time and space with increasing disability over 
many years. The first neurological episode generally occurs between the ages of 20 
and 40.[Weinshenker et al. 1989][Confavreux et al. 1980] Predominately females are 
affected in a 2:1 ratio.[Paty 1997]
Historically, the first descriptions of MS date back to “The Case of Augustus D’Este” 
in 1822, where he described his first episode of Optic Neuritis.[Firth 1948] Jean 
Martin Charcot was the first to study the disease at the Salpetriere, Paris in the latter 
decades of the 19th century. There has been much progress in the understanding and 
treatment of MS over the past 20 years. The expanded disability scale and more 
recently the MS Functional Composite Score are being used as clinical measures for 
monitoring disability.[Kurtzke 1983][Cutter et al. 1999] MRI has emerged as 
surrogate marker for disease progression with a high sensitivity for detecting MS 
lesions. [Noseworthy et al. 1984] The introduction of clinical measures of disability 
and MRI surrogate markers of disease progression has facilitated the conduct of large 
clinical trials, assessing disease modifying therapies.
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Symptoms and signs can occur in any part of the CNS. The symptoms and signs seen 
in 50% of patients at any time include cognitive changes, euphoria, depression, 
fatigue, optic neuritis, optic atrophy, retinal nerve fibre loss, nystagmus, vertigo, 
dysarthria, limb ataxia, ataxia of the gait and trunk, sensory loss, increased deep 
tendon reflexes, weakness in the legs, spasticity, extensor or flexor spasms, bladder 
disturbance and sexual dysfunction. [Paty 1997]
1.1.2. Aetiology
Data on the geographic distribution of MS, suggest that both genetic and 
environmental factors influence aetiology. The most widely held hypothesis is that 
MS is a genetically determined disease with onset triggered by an environmental 
factor. Epidemiological studies suggest that MS is a predominantly European disease 
with increased prevalence to areas where Europeans have migrated to. Using the 
founder father theory genetic studies (1.14) continue to search for susceptibility genes. 
A summary of recent theories on an environmental trigger is also listed (1.15).
1.1.3. Epidemiology of Multiple Sclerosis
In the United Kingdom, the age and sex adjusted incidence rate of MS is 7/100,000 
per year.[MacDonald et al. 2000] The prevalence of MS is 1-2/1000.[MacDonald et 
al. 2000] The lifetime risk is one in 400.[Compston and Coles 2002] The systematic 
study of MS in populations began in 1929 by Sydney Allison.[Allison 1931] Since 
1975 the global distribution of MS has been classified into high (>30/100,000), 
medium (5-29/100,000) and low (<5/100,000) prevalence bands.[Kurtzke 1975] High 
prevalence bands now include most of Europe, Israel, Canada, northern US, south­
eastern Australia, New Zealand, and easternmost Russia. Medium prevalence areas
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include southern US, most of Australia, South Africa, the southern Mediterranean 
basin, Russia into Siberia, the Ukraine and parts of Latin America. Low prevalence 
areas include the rest of Asia, Africa and northern South America. [Kurtzke 2000]
Age at migration appears to have an effect on MS risk. Migrants travelling from a 
high to a lower risk area may retain the MS risk of their birth place, if they are at least 
age 15 at migration. Migrants aged 11 -45 years travelling from a low to high risk area 
may increase their risk beyond that of the resident population. [Kurtzke 2000]
The recently reported prevalence of MS for Scotland of 184/100,000 is the highest 
described anywhere in the world for large populations.[Forbes et al. 1999] A “North 
South latitudinal gradient” for MS has been described with notable exceptions 
including Sardinia which has a prevalence of 152/100 000 compared with 35-90 in the 
rest of Italy. This may be due to genetic drift in a smaller and more isolated Sardinian 
population. [Granieri et al. 2000]
MS prevalence could in part vary due to variations in ascertainment. A capture 
recapture method has been used to take into account the number of unobserved cases, 
which showed latitudinal differences of 180 cases per 100,000 persons in the northern 
part of the United Kingdom compared with 160 cases per 100,000 in the southern part 
of the United Kingdom.[Forbes and Swingler 1999] The prevalence of MS in the 
Republic of Ireland was reported to be 66/100,000,[Hutchinson 1976] compared with 
a prevalence of 168 estimated in Northern Ireland. [McDonnell and Hawkins 
1998] [McDonnell and Hawkins 2000] The number of localized population based 
surveys on MS in the US is small compared with Western Europe and Canada. The 
association between latitude and risk of MS in the US was corroborated in a study to
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examine incidence of MS and its relation to latitude in two ongoing studies of US 
women in the Nurses' Health Study (NHS), which took place between 1976 and 1994, 
and in the Nurses' Health Study II (NHS II), which took place between 1989 and 
1995. [Heman et al. 1999]
1.1.4. Genetics
An increased risk recurrence in families suggests that genetic predisposition may 
influence susceptibility to MS. An environmental agent may trigger the disease 
process in a genetically susceptible population. Associations have been made with 
Class 11 major histocompatibility complex (MHC) in particular the DRB1*1501- 
DQB 1*0602 haplotype. Further genetic knowledge has the potential for insight into 
pathogenesis and novel treatments.
Two systematic screening approaches are being applied in the "GAMES" (The 
Genetic Analysis of Multiple Sclerosis in Europeans) project -  linkage and linkage 
disequilibrium. The hypothesis used for the research is based on the fact that the 
characteristic temperate global distribution of MS follows the migration pattern of 
Northern Europeans and the sharing of a common ancestor. Sawcer’s studies to date 
have yielded 10 markers of greatest interest for association with MS:
1. Three in the HLA region on chromosome 6p (D6S1615, D6S2444 and TNFCl)
2. Four regions previously identified by linkage analysis in UK multiplex 
families (two mapping to chromosome 17q GCT6E11 and D17S1535; one to 
chromosome lp GGAA30B06 and one to 19q D19S585)
3. Three novel linkage sites (D1S1590 at lq; D2S2739 at 2p; D4S416 at 4q). 
[Sawcer et al. 2002]
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1.1.5. Environmental factors
Infection has been implicated as the environmental trigger. Evidence in favour of this 
hypothesis includes study of transmission and the nature of MS in the Faroe Islands. It 
has been proposed that three separate “epidemics” of MS occurred beginning 1943 
and ending in 1973, which were introduced by asymptomatic British Troops between 
1941 and 1942 and that later “epidemics” resulted from transmission by affected but 
asymptomatic Faroese.[Kurtzke and Hyllested 1986]
A possible role of Chlamydia Pneumonia has been suggested. [Sriram et al 
1998][Sriram et al 1999] However, when this possible association was explored by 
other laboratories, Chlamydia Pneumonia specific DNA could not be detected in the 
Cerebrospinal Fluid (CSF) of patients with MS. [Boman et a l 2000] [Saiz et a l 2001]
1.1.6. Pathology 
Demyelination
Oligodendrocytes are responsible for synthesis and maintenance of the myelin sheath 
in the CNS. Immune mediated apoptotic death of the oligodendrocytes appears to be 
crucial in the pathogenesis of demyelination [Rodriguez and Lucchinetti 1999].
Demyelinating lesions
The inflammatory, potentially disabling, MS lesion is the hallmark of demyelination. 
MS plaques can be subdivided into active and inactive plaques. Myelin degradation 
products in plaques are a helpful means of determining activity. Remyelination 
appears to depend on several processes including myelinating oligodendrocytes and
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their interaction with axons.[Bruck et al. 2003] Four different patterns of plaque 
formation have been described.
1. Patterns I and II are similar to T-cell-mediated or T-cell plus antibody- 
mediated autoimmune encephalomyelitis.
2. Patterns III and IV suggest a primary oligodendrocyte dystrophy induced by a 
virus or toxin. [Lucchinetti et al 2000]
Axonal loss
Early pathological descriptions of MS were characterized by multifocal demyelination 
with preservation of axons. Recently, there has been a focus on axonal damage which 
is a key predictor of outcome in MS. Focal patches of axonal injury are quantified 
using intensely immunoreactive B-APP (B-amyloid precursor protein). Axonal 
transection has been seen in active MS lesions.[Trapp et al. 1998] Reduced axonal 
density has more recently been quantified in the Normal Appearing White Matter 
(NAWM) of both brain and spinal cord.[Evangelou et al. 2000][Lovas et al. 2000]. 
Axonal loss and gliosis are often marked in chronic lesions of patients with long 
disease durations and progressive MS.
1.1.7. Pathophysiology of demyelination
Demyelinated axons conduct more slowly than myelinated axons. Delays in visual, 
brain stem and somatosensory evoked potential conductions are used as diagnostic 
tools in electrophysiological laboratories. Conduction block may be temperature 
dependent and one such clinical manifestation is Uhthoffs phenomenon (increased 
symptoms and signs induced by heat).
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1.1.8. Immunology
Autoimmune diseases are more common in the first degree relatives of patients with 
MS, suggesting that common genetic susceptibility factors for autoimmunity co­
exist. [Broadley et al. 2000] Deregulation of the immune system in MS may be due to 
molecular mimicry by T-cells autoreactive for myelin components. Autoantigens 
implicated include myelin basic protein (MBP), proteolipid protein (PLP), myelin 
associated glycoprotein and myelin oligodendrocyte glycoprotein (MOG). MS is often 
considered to be a T-Helper Type 1 cell-mediated disease with proliferation and 
activation of CD4+ T-cells and secondary macrophage recruitment. Other cells 
implicated in the disease process include B-cells (plasma cells), CD8+ T-cells and 
reduced functional activity of natural killer cells. Inflammatory MS lesions are 
associated with up-regulation of cytokines including IL-2, y-IFN and TNF-a. IL-12 is 
produced by activation of chemokines including CCR5 and CXCR3. There is 
activation of class MHC II molecules on antigen-presenting microglia and 
macrophages, astrocytes and endothelial cells. Astrocytes and microglia release 
cytokines and growth promoting factors including insulin derived growth factor, 
which have potential to mediate tissue damage, repair and remyelination. Increased 
levels of adhesion molecules including (VCAM-1) have been found in the CSF and 
serum of MS patients and such upregulation may facilitate recruitment of circulating 
leukocytes. Selective adhesion molecule inhibition may therefore prevent the 
formation of new inflammatory lesions.
1.1.9. Diagnosis
Charcot developed diagnostic criteria for MS in 1868. He described a triad of: 
nystagmus, intention tremor and scanning speech.
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1.1.9.1. Schumacher criteria (Table 1.1)
In 1965, George Schumacher lead a panel of clinical neurologists and published the 
criteria listed in Table 1.1 [Schumacher et al 1965]:
Table 1.1 The Schumacher criteria for the diagnosis of MS
Objective neurological examination abnormalities attributable to CNS dysfunction 
History or Neurological examination indicating involvement of >2 parts of the CNS.
Objective neurological evidence of CNS disease predominately reflecting white 
matter involvement (fiber tract damage).
Involvement of the neuraxis must follow one of the following patterns:
>2 episodes of worsening, each lasting at least 24 hours and >1 month apart or
slow or stepwise progression of signs and symptoms over >6 months.
The age onset of the disease must be 10 - 50 years and the signs and symptoms 
cannot be better explained by another disease process.
(This decision must be made by a physician competent in clinical neurology)
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1.1.9.2.The Poser diagnostic criteria for MS
In 1982, American, Canadian and British MS experts produced revised criteria adding 
laboratory, neuroimaging, and neurophysiology results to the clinical 
evaluation.[Poser et a l 1983]
Table 1.2 The Poser criteria for the diagnosis of MS
Category Attacks Clinical
Evidence
Paraclinica 
1 Evidence
OB/IgG
*
Clinically Definite
CDMS Al 2 2
CDMS A2 2 1 and 1
Laboratory-Supported Definite
LSDMSB1 2 1 or 1 +
LSDMS B2 1 2 +
LSDMS B3 1 1 and 1 +
Clinically Probable
CPMSC1 2 1
CPMS C2 1 2
CPMS C3 1 1 and 1
Laboratory-Supported Probable
LSPMS 2 +
*OB/IgG: CSF oligocolonal bands and increased production of immunoglobulin G.
1.1.9.3.The McDonald criteria for the diagnosis of MS
In July 2001 revised criteria were published which incorporated patients with CIS and 
an abnormal MRI (Table 1.3 and applied in Chapter 4). Failure to satisfy the criteria 
results in possible MS, pending analysis, or not MS.[McDonald et a l 2001]
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Table 1.3 The McDonald criteria for the diagnosis of MS
Presentation Attacks Clinical Lesions MRI Lesions OB YEP Clinical Data
>2 >2
>2 1 DIS
or
>2 +
1 >2 DIT
Or
Second Attack
CIS 1 1 DIS + DIT
or
>2 + DIT +
or Second Attack
PPMS: Insidious >9 Brain +
progression or
suggestive of MS >2 Cord +
or
4-8 Brain+1 Cord +
or
4-8 Brain +
or Progression 1 year
OB = Positive CSF Oligoclonal Bands, YEP (+) = Abnormal visual evoked potential of the type seen in MS (Delayed with preserved waveform)
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MRI Dissemination in Space (DIS)
Three of four of the following: 1 gadolinium enhancing lesion or 9 T2 Lesions
> 1 infratentorial lesion
> 1 juxtacortical lesion
> 3 periventricular lesions
One spinal cord lesion can be substituted for one brain lesion. [Tintore et al .2001;
Barkhof et al. 1997],
MRI Dissemination in Time (DIT)
Time of first MRI scan Number MRI criteria for evidence of DIT
>3 months after CIS onset A gadolinium-enhancing lesion. If there is no
enhancing lesion at this time, a further scan, 3
months later, is required. A new T2- or
gadolinium-enhancing lesion is then sufficient.
<3 months after CIS onset A second scan done >3 months after the
clinical event showing a new gadolinium-
enhancing lesion or a new T2 lesion on a
further scan not < 3 months after the first scan.
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1.1.10. Investigations used in the diagnosis of MS
Theoretically, using the new diagnostic criteria, MS may be diagnosed by one clinical 
episode and MRI evidence of DIS and DIT or two clinical neurological episodes 
disseminated in time and space. Paraclinical laboratory investigations and MRI are 
often used in the diagnostic protocol in order to exclude conditions that can mimic 
MS such hereditary spastic paraplegias, ataxias, leucodystrophies, vasculopathies, 
CADASIL, granulomatous and vasculitic diseases. MRI brain and spinal cord are 
used to observe evidence of lesions disseminated in time and space. Oligoclonal bands 
present in the CSF but not in the serum are specific for intrathecal inflammation. 
Delayed visual evoked potentials are further evidence for conduction delay due to 
demyelination.
1.1.11. Different disease courses in MS
The clinical course of disease progression is heterogeneous. Approximately 85 - 90% 
of patients present with an acute CIS [Compston et al 1998], and subsequently evolve 
to a relapsing remitting MS (RRMS). A relapse is defined a subjective report or 
objective observation of neurological impairment lasting at least 24 hours. A clinical 
assessment excludes a pseudoattack, such as change in neurological status due to 
change in core body temperature or infection. Single paroxysmal episodes including 
tonic spasms do not constitute a relapse, but multiple episodes over 24 hours do.
Approximately 70 - 90% of patients initially have RRMS and later convert to 
Secondary Progressive MS (SPMS), with increasing disability and a paucity of 
relapses. About 10 - 15% of patients follow a progressive course from the onset of the 
disease: Primary Progressive MS (PPMS).[Thompson et al. 1997] [Thompson et al
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2000] Some patients with primarily progressive MS may have relapses: Relapsing 
Progressive Multiple Sclerosis. In large populations, 20% - 40% have benign disease, 
defined as having less than moderate disability after 15 years.[Lublin and Reingold 
1996] Female sex, younger age of onset, and presentation with optic neuritis and 
sensory symptoms are more likely to have a benign course, although many exceptions 
occur. The label Benign MS is potentially misleading because many of these patients 
subsequently become disabled [Hawkins and McDonnell 1999]
Patients with the greatest risk of disability are those with PPMS and RRMS patients 
who are older at onset, have pyramidal or cerebellar involvement at onset, and who 
have frequent or prolonged attacks with incomplete recovery.[Weinshenker 1995] The 
relative risk for reaching Expanded Disability Status Score (EDSS) 6 (walking 100 m 
with aids), 8 (wheelchair), and 10 (death from MS) has been calculated using a 
multivariate analysis for selected predictors of outcome in the London, Ontario 
cohort. [Ebers 2001] The greatest single predictor is progressive course (relative risk = 
6), followed by relapse rate in year 1 and year 2 (relative risk = 3). Determining the 
"year of progression" seems to be significant for the prognosis.[Minderhoud et al.
1988] The time between the first and second attack, polysymptomatic onset and time 
from onset to EDSS 3 all carry similar risk (relative risk = 2). When patients reach a 
score of 4 on the EDSS, the progression of disability is not affected by relapses 
suggesting a dissociation between recurrent acute focal inflammation and progressive 
degeneration [Confavreux et al. 2000; Confavreux et al. 2003]. The relapse rate may 
have an effect when the EDSS is less than 4.
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Figure 1.1 Diagrammatic representations of MS
1 Relapsing Remitting
Disability
2 Secondary Progressive
Time Time
3 Primary Progressive 4 Benign
Disability
Time Time
34
1.1.12. Measurements of impairment and disability
Disability is acquired by incomplete recovery following a relapse and disease 
progression. In 1955 John Kurtzke described a new scale for evaluating disability in 
MS, later known as the disability status scale (DSS) which was revised in 1983 John 
Kurtzke and called Expanded Disability Status Scale (EDSS). The scale was 
subdivided into steps (1.0, 1.5, 2.0, ....9.5). The lower portion was divided by 
Functional Systems (FS) grades namely: Pyramidal, Cerebellar, Brain Stem, Sensory, 
Bowel, Bladder, Visual, Cerebral, and Other.[Kurtzke 1983]
More recently a patient based measure of walking ability (12 Item MS walking scale 
MSWS-12) called the MS Functional Composite (MSFC) has been developed.[Hobart 
et al. 2003]
The EDSS is used throughout this thesis as a scale for disability. The MSFC has 
become popular since this project has begun and has been validated concurrently 
using MRI as a biological disease marker.[Kalkers et al 2001b] The MSFC has not 
been used in this longitudinal project, because baseline data are not available.
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Table 1.4 Kurtzke Expanded Disability Status Scale (EDSS)
0.0 - Normal Neurological Exam
1.0 - No disability, minimal signs on 1 FS 
1.5- No disability minimal signs on 2 of 7 FS
2.0 - Minimal disability in 1 of 7 FS
2.5 - Minimal disability in 2 FS
3.0 - Moderate disability in 1 FS; or mild disability in 3 - 4 FS, though fully 
ambulatory
3.5 - Fully ambulatory but with moderate disability in 1 FS and mild disability in 1 or 
2 FS; or moderate disability in 2 FS; or mild disability in 5 FS
4.0 - Fully ambulatory without aid, up and about 12hrs a day despite relatively severe 
disability. Able to walk without aid 500 meters
4.5 - Fully ambulatory without aid, up and about much of day, able to work a full day, 
may otherwise have some limitations of full activity or require minimal assistance. 
Relatively severe disability. Able to walk without aid 300 meters
5.0 - Ambulatory without aid for about 200 meters. Disability impairs full daily
activities
5.5 - Ambulatory for 100 meters, disability precludes full daily activities
6.0 - Intermittent or unilateral constant assistance (cane, crutch or brace) required to 
walk 100 meters with or without resting
6.5 - Constant bilateral support (cane, crutch or braces) required to walk 20 meters 
without resting
7.0 - Unable to walk beyond 5 meters even with aid, essentially restricted to 
wheelchair, wheels self, transfers alone; active in wheelchair about 12 hours a day
7.5 - Unable to take more than a few steps, restricted to wheelchair, may need aid to 
transfer; wheels self, but may require motorized chair for full day's activities
8.0 - Essentially restricted to bed, chair, or wheelchair, but may be out of bed much of 
day; retains self care functions, generally effective use of arms
8.5 - Essentially restricted to bed much of day, some effective use of arms, retains 
some self care functions
9.0 - Helpless bed patient, can communicate and eat
9.5 - Unable to communicate effectively or eat/swallow
10.0 -  Death
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1.1.13. Treatment of MS
Non pharmacological treatments for MS include physiotherapy, occupational therapy, 
and speech and language therapy. These services may be available in a 
multidisciplinary neurorehabilitation clinic. Other non pharmacological treatments, 
outside the domain of occupational therapy include eye patching and prisms for 
diplopia. Amantadine or Modafinil may be used for the treatment of fatigue. [Zifko et 
al. 2002] [Rammohan et a l 2002] Bladder dysfunction may be managed with 
anticholinergic agents and or intermittent self catheterisation. Trials of intravesical 
vanilloids and cannabinoids are ongoing. Laxatives and dietetic intervention are used 
for the treatment of constipation. Sildenafil is being used for male sexual dysfunction 
and trials are ongoing in female patients.[DasGupta and Fowler 2003] Clonazepam, 
Isoniazid and beta-blockers can be used for cerebellar tremor. Oral and intrathecal 
Baclofen, intramuscular Botulinum Toxin and oral Tizanidine are used for treatment 
of painful spasms associated with spasticity.
Symptomatic Treatments during a Relapse
Over 30 years ago Corticotrophin was shown to hasten recovery from acute 
relapses.[Rinne et al. 1968] [Rose et al. 1970] In 1983 methylprednisolone 
administered intravenously was shown to work more rapidly than corticotrophin and 
has superceded corticotrophin treatment.[Abbruzzese et al. 1983] [Thompson et al.
1989] Short courses of steroids may be used for treatment of relapses such as optic 
neuritis, diplopia, brainstem vertigo, and sensorymotor dysfunction. Controversy still 
remains as to the efficacy, route of administration and steroid dosage in MS 
therapy. [Andersson and Goodkin 1998] At present lg of intravenous
methyprednisolone, administered for three days is a widely used regimen.
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Disease modifying agents
The ultimate goal of disease modifying agent drug trials is to reduce the number of 
relapses and disability. The most recent therapeutic phase II and phase III studies of 
disease modifying agents have included both clinical (number of relapses) and MRI 
(new Gadolinium enhancing, T2 and T1 hypointense lesions) parameters as primary 
and secondary outcome measures.
Evidence from large double blinded placebo controlled clinical trials supports the use 
of interferon-beta-la (IFNbeta-la), interferon-beta-lb (IFNbeta-lb), and glatiramer 
acetate (GA) for treatment of RRMS.[PRISMS Study Group 1998][PRISMS 
2001][Paty and Li 1993;1995][Jacobs et al. 1996][Simon et al. 1998][Johnson et al. 
1998][Li and Paty 1999][Comi et al. 2001b] In January 2001 the Association of 
British Neurologists considered the evidence for the effectiveness of these drugs in 
clinically active RRMS to be conclusive (www.theabn.org/downloads/msdoc.pdf).
Comparison studies between disease modifying agents
In a randomized, controlled, multicenter trial comparing the efficacy and safety of 
IFNbeta-la (Rebif) 44 pg Sub-Cutaneously (SC) three times weekly and IFNbeta-la 
(Avonex) 30 pg Intra Muscularly (IM) once weekly in 677 patients with RRMS, 
IFNbeta-la 44 pg SC was found to be more effective than IFNbeta-la 30 pg IM on all 
primary and secondary outcomes investigated after 24 and 48 weeks of 
treatment. [Panitch et al. 2002] [Khan et al. 2002] In a prospective, non-randomized, 
open-label treatment trial of immunomodulatory therapy, the effect of IFNbeta-la 
(Avonex), IFNbeta-lb (Betaseron) Glatiramer Acetate (GA, Copaxone) and no 
treatment were compared on the relapse rate in RRMS. One hundred and fifty-six
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consecutive patients with clinically definite RRMS with an EDSS score of 4 or less 
were followed for 18 months. Compared to the untreated group (1.02), the mean 
annualized number of relapses was significantly reduced in the GA (0.49, P>0.0001) 
and IFNbeta-lb groups (0.55, P=0.001), in contrast to the IFNbeta-la treated patients 
(0.81, P=0.106) who did not show a significant reduction.[Khan et al. 2001] The 
INCOMIN study was a 2-year, prospective, randomised, multicentre study which 
compared altemate-day IFNbeta-lb 250 pg and once-weekly IFNbeta-la 30 pg in a 
cohort of 188 patients with RRMS. The study concluded that alternate day high-dose 
IFNbeta-lb was more effective than once weekly IFNbeta-la [Durelli et a l 2002].
Serum neutralizing antibodies
Serum neutralizing antibodies to IFNbeta have been found in about 20% of patients 
on SC IFNbeta-la preparations and 40% on IFNbeta-lb. These antibodies reduce the 
clinical efficacy on relapse rate, whether they have an impact long term disability and 
progression remains unclear. There is a lack of consensus on how these antibodies 
should be measured. The relative prevalence of antibodies induced by different 
IFNbeta products seems to be consistent between studies. SC IFNbeta-lb is the most 
immunogenic, followed by SC IFNbeta-la, with IM beta-la being the least 
immunogenic. Differences between IFNbeta products with regard to their 
biochemistry, formulation, route of administration, and dose frequency are likely to 
contribute to these observed differences in immunogenicity [Giovannoni et al. 2002].
Myelosuppressive treatment with mitoxantrone
Mitoxantrone has been approved by the Food and Drug Administration (FDA) for the 
treatment of patients with worsening RRMS or SPMS, following the results of a
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multicentre study of Mitoxantrone combined with Methylprednisolone in active 
disease.[Edan et al. 1997] Given the myelosuppressive and cardiotoxic effects of 
Mitoxantrone, indications for use are limited to patients with RRMS with frequent 
disabling relapses leading to future permanent severe disability and patients with 
SPMS whose EDSS increases by >1 point per year and who do not respond to other 
current therapies.[Gonsette 2003] The current regime includes an induction phase 
with a monthly IV dose of 12 mg/m , followed by a maintenance phase with 12 
mg/m every 3 months for 2 years (maximum cumulative dose of 140 mg/m ). The 
dosage is adapted to the body surface area. Side effects include: amenorrhoea, 
leukaemia and cardiotoxicity. Cardiotoxicity is reduced by slow infusion over 30 min. 
Records of three clinical trials including 1,378 patients who received Mitoxantrone 
revealed an incidence of CHF of <0.20% in patients with MS who received a mean 
cumulative dose of 60.5 mg/m Mitoxantrone.[Ghalie et al. 2002] A double blind 
placebo controlled trial of 194 patients with progressive MS treated with 
Mitoxantrone 12 mg/m , concluded Mitoxantrone was generally well tolerated and 
reduced disability progression and clinical exacerbations.[Hartung et al. 2002]
Prevention of breakdown of the Blood Brain Barrier (BBB)
A novel approach is treatment with Selective Adhesion Molecule Inhibitors (SAMI). 
Natalizumab is an adhesion molecule inhibitor which prevents trafficking across the 
Blood Brain Barrier (BBB). In a phase II study, Natalizumab reduced the numbers of 
new enhancing lesions by 90% and relapses by 50%. Phase III studies are in 
progress.[Miller et al. 2003]
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1.1.14. Future possibilities for remyelination
The degree of demyelination in MS may be related to the level of axonal loss. This 
may be partly due to the loss of oligodendrocytes which are trophic factors for axons. 
The extent of remyelination correlates with the presence of oligodendrocytes in the 
lesions.[Lassmann et a l 1997] Remyelination may restore function and be 
neuroprotective. Thus, there is much interest in mechanisms of remyelination in MS.
Although partial remyelination occurs in demyelinating lesions, longlasting myelin 
repair fails with increasing disability. The proliferative oligodendrocyte progenitor, 
the most efficient remyelinating cell, has been studied in the rodent and more recently 
has been identified in human white matter. [Scolding et al 1998]
Oligodendrocyte growth factors have been identified in MS lesions: (IGF1) and 
(PDGF), which is made by astrocytes. Nine growth factors have been identified in the 
rodent. [Franklin 2002] Manipulating the Growth factor environment may encourage 
myelin repair. Early exposure to fibroblast growth factor may be beneficial, whereas 
late exposure causes further damage. Schwann cells are a realistic candidate for 
remyelination. Neuronal stem cells may be applicable in the future. Injection of adult 
neurospheres induced recovery in a chronic MS rodent model.[Pluchino et a l 2003] 
Rat bone marrow stem cells have been shown to convert to neural stem cells and used 
to repair demyelinated cord lesions. The future of autolagous stem cell transplantation 
is unclear ethically and from a cell type standpoint.
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1.2. Clinically Isolated Syndromes CIS
1.2.1. Introduction to CIS and conversion to MS
Approximately 90% of patients with MS present with a CIS.[Compston et al. 1998] A 
CIS as an acute or subacute neurological episode suggestive of demyelination 
affecting the optic nerves, brainstem or spinal cord, in patients aged between 10 and 
50 years. The symptoms and signs may indicate a lesion in the spinal cord (50%), 
optic nerves (25%) and brain stem (15%).
Optic Neuritis and risk of conversion to MS
Optic neuritis is a common unilateral or bilateral cause of reversible loss of vision in 
individuals aged 20-49 with an incidence of 1-5 peri00, 000 per year.[Jin et al. 1998] 
It usually presents as a painful subacute loss of vision over a few days or weeks. The 
degree of visual loss may vary from blurring of vision to no perception of light. The 
pain is usually present on ocular movement and usually is not severe enough to affect 
sleep. Other symptoms and signs include deterioration in colour vision, visual field 
defects, reduced contrast sensitivity, a relative afferent papillary defect in the affected 
eye and temporary visual deterioration following exercise or heat (Uthoff). On fundus 
examination, the optic disc appears swollen in 36-58% of cases.[Optic Neuritis Study 
Group 1991] Signs of improvement were noted in the Optic Neuritis Treatment Trial 
placebo group within 3 and 5 weeks of onset of symptoms in 79% and 93% of 
patients respectively. [Optic Neuritis Study Group 1991]
The rate of conversion of a CIS to MS has been studied most in the case of optic 
neuritis and is approximately 30-70% (Tables 1.5 and 2.1). The risk for developing 
MS following childhood optic neuritis is considerably lower (Life Table analysis
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showed 13% developed MS by 10 years, 19% by 20 years, 22% by 30 years and 26% 
by 40 years.[Lucchinetti et a l 1997] The risk association between optic neuritis and 
MS varies according to country of origin. The lowest percentage conversion figures 
were reported form a Chilean retrospective study (4.3%) and a Brasilian prospective 
study (10.8%).[Alvarez and Cardenas 1989] [Lana-Peixoto and Lana-Peixoto 1991] 
The highest percentage conversion was reported in a prospective Finish study 
(75%).[Nikoskelainen et a l 1981] The low percentages in the Chilean study may be 
explained by its retrospective nature.[Alvarez and Cardenas 1989]
Conversion of a brainstem and spinal cord syndrome to MS
If the brainstem or spinal cord CIS is confirmed to be demyelinating in origin, then 
MRI is useful in determining the relative risk for future demyelinating episodes. The 
association between brainstem and spinal cord syndrome with MS is less clear 
because of the heterogeneity of the syndromes. The MS risk associated with complete 
spinal cord syndromes was found to be low 1/29 (3%).[Lipton and Teasdall 1973] 
Incomplete spinal cord syndromes are associated with a much higher risk of MS, 
12/15 (80%).[Ford et a l 1992] The duration of follow up has important implications 
on the rate of conversion of brainstem and spinal cord syndromes to MS. A short 
(3.08 years) study reported 35% conversion.[Sastre-Garriga et a l 2003] The longest 
(14.1 years) clinical and MRI follow up study reported 9/14 (64%) brainstem and 
14/21 (67%) spinal cord conversion rates to CDMS. [Brex et al 2002]
1.2.2. Counselling of patients with CIS
In view of the fact that patients with CIS are known to be at risk of MS, we tell all 
patients with optic neuritis and CIS about the association with MS using both written
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and verbal information. In many instances, patients have already learned of the MS 
association from an information search on the internet. In collaboration with the MS 
Society of Great Britain and Northern Ireland we have drafted an information sheet 
regarding optic neuritis and the associated risk of MS. (Appendix 1)
1.2.3. Information and treatment at the time of diagnosis of MS
At the time of diagnosis both written and verbal information should be given 
regarding treatment and prognosis. Discussion with a MS specialist nurse is also 
helpful. In the longer term the patient may benefit from discussions with and 
information from the MS society. Informal lectures and group discussions regarding 
issues pertaining to newly diagnosed patients are also helpful. Some patients with CIS 
may request not to have information regarding MS, fearing it may affect mortgages, 
life insurances etc., and it is essential their wishes are respected.
1.2.4. Diagnosis of MS in patients with CIS
In the past, a definitive diagnosis of MS could not be made at presentation on patients 
with a CIS. The publication of the McDonald criteria, has for the first time allowed a 
diagnosis of MS in patients with CIS and an abnormal MRI. [McDonald et a l 2001]
1.2.5. Oligoclonal Bands
The presence of oligoclonal bands in the CSF, demonstrated by means of 
isoelectrophoresis, has been associated with a higher risk of MS. [Miller et al. 1989] In 
one study, 7/43 with optic neuritis developed MS. Although, all had an abnormal 
MRI, 6/7 had oligoclonal bands, suggesting bands are less sensitive.[Tintore et al.
2001] In another study abnormal IgG levels in the CSF correlated more strongly than
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abnormal MRIs with the subsequent development of CDMS [Jacobs et al. 1997]. 
More recently the Barkhof MRI criteria for were found to have a better specificity 
than oligoclonal bands for the development of CDMS (70% versus 43%) [Tintore et 
al. 2001]. The presence of at least 2 lesions and oligoclonal bands resulted in an 
increased sensitivity but reduced specificity compared with the Barkhof criteria alone 
for the diagnosis of CDMS at three years. [Tintore et al. 2003]
1.2.6. Neurophysiology
Neurophysiology investigations, in particular Visual Evoked Potentials (VEP) have a 
role in determining dissemination in space, as may Somato Sensory (SSEP), Auditory 
and Brain Stem Evoked Potentials. However, they have a lower sensitivity compared 
with MRI. In a study of 51 patients with brain stem CIS, no statistically significant 
differences were found in neurophysiology parameters between patients who 
converted to CDMS compared to those who did not.[Sastre-Garriga et al. 2003]
1.2.7. McDonald criteria in patients with CIS
In patients with one attack, objective clinical evidence of one lesion 
(monosymptomatic presentation or CIS), there must be DIS, demonstrated by MRI or 
two or more MRI lesions consistent with MS plus positive CSF oligoclonal bands and 
DIT, demonstrated by MRI or a second clinical attack [McDonald et al. 2001].
1.2.8. Treatment of CIS patients with steroids and disease modifying agents
The effect of steroids on optic neuritis and the subsequent development of MS was 
assessed in 389 patients with acute optic neuritis randomized to receive IV 
methylprednisolone for 3 days (1 mg per kg) followed by oral prednisolone, (1 mg per
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kg) or placebo. Neurological status was assessed for 2 to 4 years. Post hoc analysis 
found IV methylprednisolone reduced the development of MS over a two-year period. 
The 5-year cumulative probability of CDMS was 30% and did not differ by treatment 
group. Steroids have been used for the treatment of optic neuritis, however there are 
side effects. The more serious side effects reported in the optic neuritis treatment trial 
include psychotic depression and pancreatitis. [Optic Neuritis Study Group 1997]
The CHAMPS study was the first study to evaluate the use of Interferon in patients 
after a first demyelinating event.[Jacobs et al 2000] 383 patients were recruited 
following their first clinical demyelinating event. Patients with optic neuritis, 
incomplete transverse myelitis, brain-stem and cerebellar syndromes, were included. 
The trial concluded that initiating treatment with IFNbeta-la at the time of a first 
demyelinating event was beneficial for patients with MRI brain lesions. The response 
to IFNbeta-la has been assessed using the Barkhof criteria and the treatment effect 
was more evident as the number of positive criteria increased. The number of patients 
needed to avoid one patient converting to CDMS decreased from 50 in patients with 1 
or 2 positive criteria to 5.6 in patients with 4 positive criteria.[Barkhof et al 2003] In 
the Etoms study 309 patients with CIS (98 optic neuritis) were randomized to receive 
IFNbeta-la 22pg once weekly or placebo.[Comi et al 2001a] MRI requirements 
included 4 asymptomatic brain lesions (or 3 lesions if one was Gadolinium 
enhancing). After 2 years the odds ratio for conversion to CDMS was 0.61 in the 
treatment group compared with placebo (p<0.001).
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Table 1.5 Longitudinal studies of optic neuritis and the risk of CDMS (1970 -  Present, MRI studies excluded)
Year Author (Country Retrospective R, Prospective P) [Reference Recent, Past] Pt F/U Mean /Med MS (%)
2000 Frith (Australia P) [Frith et al 2000] [Hely et al 1986] 71 13.25 Y 33 46%
1999 Druschky (Germany P)[Druschky et al 1999] 26 8 Y 14 54%
1999 Landy (Australia P)[Landy 1999; 1983] 134 0.5 -15 61%
Landy (Australia R) [Landy and Ohlrich 1970] 51 0 .5 -15 39%
1997 Corona-Vazquez (Mexico R) [Corona-Vazquez et al 1997] 110 2 Y 13 12%
1995 Rodriguez (USA R) [Rodriguez et al 1995] 156 13.2 Y 39%
1993 Congia (Italy R)[Congia et al 1993] 69 4 -1 3 53.6%
1991 Mapelli (Italy 1985 P) [Mapelli et al 1991; 1985] 40 12 10 25%
1991 Scholl (USA P)[Scholl et a l 1991] 81 3.5 Y 35 43%
1991 Lana-Peixoto (Brasil P)[Lana-Peixoto and Lana-Peixoto 1991] 88 4.6 Y 9 10.8%
1990 Sandberg-Wollheim (Sweden P)[Sandberg-Wollheim 1990; 1975] 86 12.1 Y 38.3%
1987 Francis (Compston UK P)[Compston et al 1978][Francis et al. 1987] 101 11.6 Y 51 51 88%
1989 Gronning (Norway R)[Gronning et al 1989] 34 12 Y 42%
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1989 Alvarez (Chile R)[Alvarez and Cardenas 1989]
1989 Anmarkrud (Norway R) [Anmarkrud and Slettnes 1989]
1988 Rizzo (USA P) [Rizzo, III and Lessell 1988] [Cohen et al 1979]
1983 Kinnunen (Finland) [Kinnunen 1983]
1983 Stendahl-Brodin (Sweden P) [Stendahl-Brodin and Link 1983]
1981 Nikoskelainen (Finland P)[Nikoskelainen et al 1981b]
1974 Nikoskelainen (Finland R)[Nikoskelainen and Riekkinen 1974]
1979 Perkin (UK P) [Perkin 1979; Rose 1970]
1976 Hutchinson (UK R) [Hutchinson1976]
1976 Kahana (Israel R) [Kahana et al 1976]
1973 Alter (Hawaii R) [Alter et al 1973]
1972 Sandberg (Norway R) [Sandberg 1972]
1972 Percy (Rochester R) [Percy et al 1972]
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23 9.7 Y 1 4.3%
30 2-11 Y 57%
60 14.9 Y 74%F,34% M
296 5.1 Y 19%
30 5 Y 10 33.3%
48 7 -1 0  Y 36 75%
117 10.2 Y 69/109 63.3%
78 0.5 -  5.5 Y 45 58%
132 1-15 14 Y 67 78%
105 9.5(3.3-15.6) Y 27 28%
28 10 Y 29%-39%
51 3-7 Y 47%
24 18 Y 17%
Table 1.6 Longitudinal studies of spinal cord and brainstem syndromes and the risk of CDMS
Year Author [reference recent, past] No. Years f/u Syndrome MS Number %
2003 Sastre Garriga [Sastre-Garriga et al. 
2003][Tintore et al. 2000]
51 3.08 BS 18/51 (35%)
2002 Brex [Brex et al. 2002][0'Riordan et al. 
1999] [Morrissey et al. 1993] [Miller et al. 1987]
71 14.1 ON, BS, SC ON 25/36 69%, BS 9/14 
64%, SC 14/21 67%
1997 Barkhof [Barkhof et al. 1997][Tas et al. 1995] 74 3.25 ON,SC,SS, M,BS 33/74 45%
1996 Paolino [Paolino ef a/. 1996] 44 2.17 BS 22 SC 22 30/44 68%
1995 Campi [Campi et al. 1995] 30 1.5 SC 8/30 27%
1994 Filippini [Filippini et al. 1994] 82 2.9 SC BSC 28/82 34%
1992 Ford [Ford et al. 1992] 38 15 SC (I) 12/15 80%
1991 Sharief [Sharief and Thompson 1991] 45 1.5 BS SC 13/45 29%
1973 Lipton [Lipton and Teasdalll973] 5 Y 2.42 SC (Complete) 1/29 3%
BS = Brain Stem, SC = Spinal Cord, ON = Optic Neuritis, SS = Somatosensory, M = Motor, C = Cerebrum, I = Incomplete
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Chapter 2
2. MRI and MS and CIS
2.1.Basic principles of MRI
In 1946 Bloch and Purcell independently developed theories on Nuclear Magnetic 
Resonance (NMR) for which they won the Nobel Prize in 1952. The basis of their 
theory was that a spinning charged hydrogen nucleus creates an electromagnetic field. 
Between 1950 and 1970 MRI was used for chemical and physical molecular analysis. 
Raymond Damadian, Lawrence Minkoff, and Michael Goldsmith performed the first 
live human MRI scan on the 3rd of July 1977. In 1981 Young scanned 10 patients with 
MS using an inversion recovery sequence. Conventional MRI was shown to be highly 
sensitive in detecting lesions.[Young et al 1981] MRI has become an essential tool in 
the diagnosis and management of MS and the evaluation of therapeutic agents for 
treatment of MS.
2.1.1. Hydrogen protons and spin
MRI is based on the nuclei with odd numbers of protons. The simple hydrogen 
nucleus contains a positively charged proton which spins creating a small magnetic 
field called a magnetic dipole moment (MDM). In the absence of any external 
magnetic field (Bo), the axes of the MDMs cancel one another out. If Bo is applied, the 
axes of the MDMs will align themselves like bar magnets, some parallel and some 
antiparallel with Bo. One in a million extra spins is parallel to make the net 
magnetization (Mo) point in the direction of Bo. This happens at a specific frequency 
(c o l ), the Larmor frequency, which is proportional to the Bq.
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Figure 2 .1  Hydrogen nuclei, spin and application of a magnetic field (B o)
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2.1.2. Magnetic fields and magnetic susceptibility
Bo is the static magnetic field. The variable magnetic field applied at the Larmor 
frequency is referred to as the radiofrequency pulse (RF). Mo is the induced 
magnetization of intensity (M). The magnetic permeability (p) or ability of a 
substance to concentrate magnetic fields is B divided by the acquired magnetic field 
(H). Substances magnetize when placed in a magnetic field according to their 
magnetic susceptibility (x), which is the ratio of the M to H. Magnetic permeability is 
1 plus x- In MRI, Bo in the order of one Tesla (IT) is 20,000 times the earth’s 
magnetic field. The field is not uniform and shim coils are required to reduce this 
problem.
Diamagnetic substances have no unpaired electrons and induce a weak magnetic field 
(M) when placed in Bo, which reduces the effective magnetic field. The majority of 
tissues in the body are diamagnetic. Paramagnetic substances have unpaired electrons 
and become magnetized when placed in Bo and demagnetize when the field is turned 
off. Their M is in the same direction as Bo. Gadolinium, the element on the periodic 
table with the greatest number of unpaired electrons, is a strongly paramagnetic
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substance. Haemosiderin and other iron containing substances have magnetic 
susceptibilities 100 to 1000 times stronger than paramagnetic substances and are 
superparamagnetic. Ferromagnetic substances (Iron (Fe), Cobalt (Co) and Nickel 
(Ni)) are strongly attracted by a magnetic field and become permanently magnetized. 
The type of magnets can be classified according to strength. Ultra high field magnets 
(>3.0 T) are mainly for MR Spectroscopy (MRS). High field magnets range from (1.0 
to 2.0T). Low field magnets range from (0.1 to 0.2 T) and ultra low field magnets are 
less than 0.1 T. Magnets may also be classified according to their design as 
permanent, resistive or superconducting. A superconducting 1.5 T Signa General 
Electric magnet at the NMR unit, was used in this study.
2.1.3. Performing MRI imaging: RF and MR signal
Spinning unpaired electrons in an external magnetic field align with the field, 
generating Mo which is parallel to B0. In order to measure M0, the RF pulse (an 
electromagnetic wave of frequency c d l ), is applied to a patient and causes some of the 
spins to change their alignment as a result of a resonance phenomenon. After the RF 
pulse is turned off, they generate the MR signal as they return to their original 
alignment.
2.1.4. Precession
In the absence of B 0, a proton rotates on its axis and creates a magnetic field. If an 
external magnetic field is then applied, the proton not only rotates about its own axis 
but also around the axis of Bo, in a process called precession.
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Figure 2.2: Precession of Hydrogen nuclei in a Magnetic Field
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2.1.5. The Larmor equation
The rate at which the proton precesses around the external magnetic field (Bo) is 
expressed using the Larmor equation: co = y Bo,
co = Angular precessional frequency of Hydrogen 
y = Gyromagnetic ratio 
Bo = External magnetic field.
2.1.6. Phase
Phase is the position of each magnetic moment on the precession path around Bo. 
Magnetic moments that are in phase are in the same place in the precession path 
around Bo. Out of phase magnetic moments are not in the same position on the 
precession path.
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2.1.7. Resonance and flip angle
Following application of the RF pulse, resonance occurs when magnetic moments 
move to the same position on the precession pathway, resulting in the RF pulse adding 
energy to the protons. The magnetization is flipped towards the x-y plane forming an 
angle 0 with the z axis. The 90° RF pulse applied in the x plane results in transverse 
magnetization vector flip into the x-y (Mxy) plane.
Figure 2.3 Flip Angle
Z
0=90(Bo)
Bi (RF) PulseX
2.1.8. T1 Relaxation Time (Longitudinal Magnetization)
At time t = 0, Mo is aligned with Bo, hence we measure no signal. Following the 
induction of a magnetic field Bj, or RF pulse, spins are excited creating a net 
magnetization in the orthogonal plane to Bo (often referred to as the xy plane of a 
system where z is parallel to Bo). There is a time constant (Ti) depending on the tissue 
type and strength of magnet, which determines how the spins return to be aligned with 
Bo following an exponential curve. Ti longitudinal relaxation time is recovery of 
magnetization along the axis of the Bo field after the RF pulse is turned off. This 
refers to the time for the spins to return to the longitudinal (z) axis. The spins relax
54
back to their lowest energy state. Water and fluids have a very long TI compared with 
solids which have a long TI and fat which has a short TI.
Figure 2.4 Radiofrequency Pulse (RF), TI Longitudinal Magnetization and T2 
Transverse Magnetization
MZ MZ
RF pulse ON N
X
T l Less Rapid
RF pulse OFF Mo
Mxv
T2 rapid
X
2.1.9. T2 Relaxation Time (Transverse Magnetization)
T2 relaxation time is rapid decay of the Mxy component after the RF pulse is turned off 
and occurs more rapidly than Tl recovery. T2 characteristics of a tissue are 
determined by how fast protons in a tissue dephase. A rapid dephase results in a short 
T2 and a slow dephase results in a longer T2. T2 transverse relaxation is shorter than 
Tl longitudinal relaxation. Water and fluids have a long T2, solids have a short T2 
and fat has an intermediate T2.
55
2.1.10. TR (Repetition Time) and TE (Echo Time)
The time between two successive 90° RF pulses is TR. Long TR eliminates Tl effect. 
TE is the time delay after the RF pulse at which signal measurement is taken. A 2 X 
TE forms a DSE sequence.
2.1.11. Image construction
Gradients give information on specific origin of each component of the signal. The 
gradient required in the z gradient is the slice select gradient. The range of frequencies 
sampled during acquisition determines the slice thickness which can be reduced by 
decreasing the bandwidth of the RF pulse or by increasing the slice select gradient. 
The slice select gradient (Gz) is turned on during the 90° pulse and then turned off. A 
180° pulse is then applied with (Gz) on. An echo is received during the readout period 
after time TR. A frequency encoding gradient (Gx) is applied in the x-direction. A 
phase encoding gradient is applied in the y direction after the RF pulse usually 
between and the 90° -180° pulses or between the 180° pulse and the echo.
Figure 2.5 Spin echo pulse sequence diagram
90° RF pulse 90° RF pulse
(TR) Time between RF pulses
Gz < 
Gy , o
----------------------------------------------------------►
*--------- 1—1_____________________________
...................  .............. w
----------------------►
(TE) Time between echoes
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2.1.12. K space
K space is the time-domain data, which shows the signal evolution during acquisition. 
A fourier transformation converts the signal from the time domain to the frequency 
domain so that the fourier transformation of K-space is the image. The centre of K- 
space contains the phase encoding step with the weakest gradient (most signal and 
overall form of the image). The periphery of K-space contains phase encoding steps 
with the largest gradients (least signal but most detail). The axes on a plot of raw data 
are Kx, Ky and Kz.[Hashemi and Bradley1997]
2.2. Conventional MRI techniques to monitor MS
Conventional MRI is an important tool in the diagnosis of MS, monitoring disease 
progression and evaluation of new disease modifying agents. Conventional MRI may 
be subdivided into: Dual Echo T2-weighted and post contrast Tl-weighted images.
2.2.1. T2 weighted sequences
Three types of T2 weighted sequences may be used: conventional spine echo (CSE), 
fast spin echo (FSE) and fast FLAIR. The CSE and FSE are equally good at showing 
MS lesions. FSE is quicker than CSE.
2.2.2. Conventional Spin Echo (CSE) sequence
Following a 90° pulse, the magnetization vector is flipped into the xy plane creating 
Mxy. Following the 90° pulse, there are dephasing effects due to external magnetic 
field inhomogeneities and spin-spin interactions. At a certain time, t=TE/2, after the 
90° pulse, the spins are out of phase. A 180° rephasing pulse is then applied. Spins flip 
into the xy plane and precess in the opposite direction. After another TE/2 time, at
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t=TE, the spins are back in phase and the spin echo is formed. This is sampled to 
create the image.
2.2.3. Fast image acquisition sequences FSE and RARE
Using spin echo imaging, it is possible to collect echoes at several different echo 
times within a single TR period. If N is the number of echoes, N lines of K-space can 
be encoded in a single TR, giving an N-fold reduction in scan time. This gives rise to 
the RARE (Rapid Acquisition with Relaxation Enhancement) or FSE.fHennig et al. 
1986] The Echo Train Length (ETL) refers to the number of echoes used in FSE and 
it is usually set to an even number (typically 8 or 16).
2.2.4. FLAIR
Fast- Fluid Attenuated Inversion Recovery (FLAIR) detects more lesions in MS than 
conventional spin echo sequences. Difficulties standardizing fast FLAIR acquisition 
parameters have limited its use in clinical trials. Other problems include high 
interscanner variability of MS lesion volumes and poor sensitivity for detecting 
lesions in the posterior fossa and spinal cord.[Gawne-Cain et al. 1997] [Filippi et al. 
1996] [Stevenson et al. 1997]
2.2.5. Conventional MRI and the diagnosis of MS
Various criteria have been introduced to improve the accuracy of MS diagnosis using 
MRI. The criteria of Paty and Fazekas have focused on the number size and location 
of T2 weighted lesions.[Paty et al. 1994][Fazekas et al. 1988] The Barkhof MRI 
criteria depend on the fulfilment of three of the four Dissemination in Space (DIS) 
criteria listed below and include Gadolinium enhancing lesions.[Barkhof et al. 1997]
58
Most recently the McDonald criteria use MRI for evidence of Dissemination in Time 
(DIT) and DIS. DIS is based on the Barkhof criteria modified to allow the 
replacement of a brain lesion by a cord lesion. [Tintore et al 2000] One or more 
Gadolinium enhancing lesions in patients with CIS imaged within three months of the 
onset of symptoms and again three months later is enough evidence for DIT or a new 
T2 weighted lesion on a scan performed thereafter.
Paty Four lesions
Three lesions including 1 periventricular lesion [Paty et al 1994]
Fazekas Three Lesions including two of the following characteristics: 
Infratentorial,
Periventricular,
Lesion > 6 mm [Fazekas et al 1988]
Barkhof One Gadolinium or 9 T2 weighted lesions 
One Infratentorial,
One Juxtacortical,
Three Periventricular Lesions [Barkhof et al 1997]
2.2.6 MRI characterization of clinical subtype in MS
RRMS is characterized by the presence of Gadolinium-DTPA enhancing 
lesions.[Thorpe et al 1996a] SPMS is associated with large confluent T2-weighted 
hypterintense brain lesions.[Thompson et al 1991] This may be due to the natural 
history of SPMS which is inherently associated with more severe abnormalities than 
RRMS.[Nijeholt and Barkhof 2003] PPMS patients may have relatively few brain 
lesions, which may be small, despite frequent severe disability. [Thompson et al 1991]
Primary and Secondary progressive MS differ with regard to MRI findings. In a 5 
year longitudinal study of 11 patients with SPMS and 10 patients with PPPMS, a 
significant relationship was noted between enhancing lesions and clinical relapses 
during the initial 6 months and increase in disability 5 years later. [Losseff et al
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1996a] A recent 5 year prospective follow up study of 41 patients with PPMS showed 
significant deterioration in all clinical and MRI measures (P < 0.01, P < 0.001 
respectively). The rates of change of MR measures were more consistent within rather 
than between patients.[Ingle et al 2003] In patients with PPMS, spinal cord MRI 
parameters correlate well with spinal cord symptoms. This illustrates the importance 
of spinal cord involvement in this subgroup of patients. [Nijeholt and Barkhof 2003]
2.2.7 Monitoring the treatment of MS
There have been major difficulties in measuring clinical endpoints in MS treatment 
trials with much enthusiasm for the use of MRI as surrogate marker. Surrogacy is 
defined as an outcome that can reliably predict clinical outcome. Unfortunately, 
conventional MRI scans have a limited correlation with disability so the primary 
outcome in definitive phase III treatment trials should be clinical. A task force of the 
US National MS Society was convened to provide international consensus guidelines 
on the use of MRI in MS clinical trials and their findings were published in 
1996.[Miller 1996] In summary their guidelines were:
1) Monthly MRI T2-weighted and Gadolinium-enhanced MRI are useful primary 
endpoints for short term exploratory trials of new agents.
2) The primary end point of a definitive trial is clinical. Serial MRI scans at 6- to 12- 
month intervals are useful secondary end points providing an index of pathological 
progression.
3) In trials of patients presenting with CIS, MRI findings can be used in the entry 
criteria, and as a secondary outcome measure, but conversion to CDMS should be the 
primary outcome.
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2.2.8 Gadolinium enhancement
Post contrast Gadolinium Tl weighted scans allow discrimination between active and 
inactive lesions. Gadolinium enhancement occurs as a result of BBB breakdown. 
Serial gadolinium enhanced imaging has demonstrated disease activity in the absence 
of relapses with new Gadolinium enhancing lesions occurring 10 times more 
frequently than relapses. [Barkhof et al. 1992] [Capra et al. 1992] [McFarland et al. 
1992] [Stone et al. 1995] Clinical worsening of MS has previously been associated 
with increased enhancement. [Smith et al. 1993]
2.2.9 Limitations of conventional MRI imaging
Conventional MRI is unable to distinguish between the different types of pathology 
occurring in MS namely inflammation, oedema, demyelination, remyelination, axonal 
loss and gliosis. Also, the relationship between conventional MRI measures of lesion 
load and clinical measures of disease progression are weak. The discrepancy between 
conventional MRI lesion load measures and clinical outcome means it would be 
unwise to rely solely on such MRI measures as primary efficacy variables in MS 
treatment trials. Newer non invasive MRI techniques are being evaluated as potential 
surrogate markers for disease progression in MS.
2.3. Non conventional MRI techniques
2.3.1. Tl hypoinense lesion analysis
Tl hypointense lesions are defined as lesions that are hypointense on moderately Tl- 
weighted conventional spin-echo sequences.[Barkhof et al. 2000] Tl-weighted
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hypointense lesions in MS patients correspond to areas of axonal loss. Tl -  
hypointense lesions are associated with:
1) Low magnetization transfer ratios (postmortem) [van Waesberghe et al 1999].
2) Low N-acetylaspartate concentrations [van Walderveen et a l 1999]
3) Decreased histological axonal density (Postmortem unfixed whole brains) [van 
Walderveen et a l 1998]
2.3.2. Magnetization Transfer
Magnetization Transfer (MT) is a continuous measure based on interactions between 
protons in a relatively free environment (tissue water) and where motion is restricted 
(macromolecules of myelin). Off-resonance irradiation is applied, which saturates the 
magnetization of less mobile protons. As free and bound protons are exchanged, the 
MRI signal intensity is reduced as a consequence of the protons’ transfer. MTR 
imaging provides a non-specific assessment of structural integrity as it is affected by 
changes of macromolecules, such as myelin.
2.3.3. Protein Magnetic Resonance Spectroscopy (MRS) in MS
Protein Magnetic Resonance Spectroscopy (MRS) is used to investigate metabolic 
changes in the brain. The primary peak is produced by N-acetyl aspartate (NAA) at
2.0 ppm with secondary peaks at 3.0 ppm (creatine/phosphocreatine (Cr)), 3.2 ppm 
(choline-containing compounds) and 3.54 ppm (myo-inositol). Changes in the signal 
intensity of N-acetylaspartate (NAA) which is localized in the neurons and neuronal 
processes enable assessment of axonal loss or dysfunction. [Provencher 1993] [ Arnold 
et al 1990] [Davie et a l 1994] Spectroscopy studies have shown a reduced N-acetyl­
aspartate in lesions suggesting axonal damage. Reductions in NAA have also been
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shown in normal appearing white matter in MS.[Davie et al. 1997][Fu et al. 1998] 
MRS reduced NAA has been shown to correlate with disability suggesting a strong 
correlation between axonal loss and disability. [Matthews et al. 1998][Grimaud et al. 
1999] [De Stefano et al. 1998] More recently spectroscopic data acquired using point 
resolved spectroscopic localization (PRESS) and processed using LC Model to 
estimate metabolite concentrations in mmol per litre has revealed changes in cortical 
grey matter (GM) and normal appearing white matter (NAWM).[Chard et al. 2002a]
2.3.4. Spinal cord imaging in MS
T2 weighted spinal cord lesions can be detected in 47-90% of patients with MS. In a 
study of 485 lesions collected from a cohort of 10 patients with relapsing remitting 
MS, 42 or (9%) were in the spinal cord. [Thorpe et al. 1996b] Thus if MRI brain alone 
is used as a marker of disease activity approximately 10 lesions will be missed. Spinal 
cord lesions often cause more symptoms than MRI brain lesions, hence the rationale 
for imaging of the spinal cord. [Kidd et al. 1996] In one large study with 91 MS 
patients (28 RR, 32 SP and 31 PP), there was correlation between the number of focal 
brain Tl lesions and the number of focal spinal T2 lesions (r=0.22; p<0.05).[Nijeholt 
et al. 1998] Although the presence of cord lesions can increase the confidence in 
making a diagnosis of MS, this does not appear the case with CIS presenting with 
optic neuritis (Chapter 3.3).
Cord atrophy has been used as a potential marker of axonal loss in longitudinal 
studies of patients with CIS, RRMS, PPMS and SPMS using an automated 
technique.[Losseff et al. 1996c] In one longitudinal study disability inversely 
correlated at entry and follow-up with the cord area and changes and disability
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correlated inversely with changes in cross-sectional area (r = -0.4, p = 0.04) 
suggesting cord area be a useful marker of disease evolution. [Filippi et al. 1997b]
2.3.5. Atrophy
Atrophy of both the brain and spinal cord (2.3.4) due to irreversible tissue loss has 
been described in all stages MS. Atrophy may develop following the appearance of 
inflammatory lesions. Significant correlations have been found between brain volume 
and MR neuronal markers indicating axonal loss. The pathological basis of atrophy in 
MS is due to loss of myelin and a marked degree of axonal loss.[Lassmann 2002] As a 
consequence of axonal loss in a lesion, there is Wallerian degeneration along the fibre 
pathways that traverse the lesion. A proportionately greater loss of small axons with 
relative preservation of lager axons has been noted in both the brain and spinal 
cord.[Ganter et al. 1999] [Evangelou et al. 2001] Cerebral atrophy correlates with 
proton MR spectroscopic NAA/Cr (r = 0.67, p < 0.001), suggesting damage to the 
normal-appearing tissue rather than the extent and intrinsic pathology of macroscopic 
lesions seems to be important in the destructive process.[De Stefano et al. 2002] 
Significant correlations have also been found between Tl hypointense lesion load and 
atrophy suggesting a direct link between hypointense abnormalities detected in Tl- 
weighted brain scans and cerebral atrophy. [Sailer et al. 2001]
The methodological requirements for global and regional brain volume measurements 
and spinal cord areas are reproducibility, sensitivity to change, stability over time, 
accuracy and practicality to implement. [Miller et al. 2002] Both global brain and 
upper cervical cord cross sectional areas are measured using highly reproducible 
techniques and sensitive to change within 6-12 months. [Losseff et al. 1996b][Losseff
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et al 1996c] Regional measurements of atrophy including ventricular volumes are 
also sensitive to tissue loss. [Fox et al 2000] [Redmond et a l 2000] The optic nerve is 
frequently involved in MS, however the small dimensions and artefact make 
measurement difficult. In a one year study of optic neuritis patients, atrophy of the 
affected optic nerve has been demonstrated. [Hickman et al 2002] Brain and cord 
atrophy have roles as markers of disease progression. [Simon 2001].
Segmentation techniques are used to calculate:
• Normalized CSF volume[Wolinsky et al 2001]
• Whole Brain Ratios (WBR) (Whole Brain -  CSF / Intradural Volume)
• Brain Intracranial Capacity Ratio (BICCR) = 100 X (GM + WM + lesions) / 
(GM + WM + lesions + CSF)[Collins et al 2001]
• Fuzzy Connectedness Segmentation FCS[Ge et al 2000]
• SPM-based segmentation[Chard et a l 2002c]
• Template driven segmentation of the brain[Guttmann et a l 2000]
• Sienax.[Zhang et a l 2001] and brain surface modelling[Smith et al 2001]
•
Registration based techniques include:
• MIDAS [Freeborough et a l 1997]
• Voxel Based Morphometry VBM[Ashbumer and Friston 2000]
2.3.6. Gradient echo sequences
Gradient echo also called gradient recalled echo (GRE) and partial flip angle 
techniques significantly reduce scanning time by using small flip angles and allowing 
very short TR values. An RF pulse yielding a smaller flip angle a  is used instead of
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the usual 90° pulse. An important application of the GRE is the ability to employ three 
dimensional (3D) imaging using high speed GRE due to very short TRs. GRE 
sequences are acquired one slice at a time (Sequential Scanning). The shorter scan 
time is determined by reducing the TR, using the following equation: Scan Time = TR 
x Ny x NEX, where TR = Repetition Time, Ny = Number of Phase Encoding Steps 
and NEX = Number of Excitations.
2.3.7. Diffusion sequences
Diffusion Tensor Imaging (DTI) has been used to investigate brain tissue 
microstructure in vivo. Reduced fractional anisotropy (FA) and increased mean 
diffusivity (MD) have been found in the in the genu, body and splenium of the corpus 
callosum in MS patients compared with controls which correlated with lesion load 
measures.[Ciccarelli et al. 2003b]
2.3.8. Tractography
Diffusion tractography has been used to determine paths of anatomical connection 
using diffusion tensor information. Fast marching tractography was used to generate 
maps of connectivity. Regions of voxels with highest connectivity to an anatomically 
defined starting point were identified for each tract investigated. Reproducibility of 
the technique using coefficient of variation was 1.2 - 18.6%, emphasising the 
importance of assessing normal controls before investigating white matter 
pathology. [Ciccarelli et al. 2003a] [Parker et al. 2002].
2.3.9. Functional Magnetic Resonance Imaging (FMRI)
Functional MRI is used to measure changes in signal that occur on brain activation 
due to the changes in concentration of deoxygenated haemoglobin. FMRI has been
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used to localize specific motor or sensory functions in the cortex or to monitor altered 
or adaptive responses following injury and/or during recovery. Changes have been 
shown in patients who have recovered from optic neuritis [Werring et al. 2000].
2.4. MRI in patients with CIS suggestive of MS
Multi-parametric MRI has been applied to patients with CIS in order to determine the 
value of MRI, in predicting early development of Poser CDMS. MRI studies have 
focused on the lesion load seen on T2 images. Longitudinal studies have assessed the 
predictive value of T2 abnormalities for the development of CDMS. Multifocal 
cerebral white matter lesions are present in 50-70% of patients presenting with a CIS.
Numerous studies have shown that the presence of cerebral white matter lesions in 
patients with CIS at the time of presentation is associated with an increased risk for 
the development of CDMS. Approximately 30% of patients with an abnormal MRI 
will develop MS after one year,[Brex et al. 19991] approximately 50% after 5 years 
[Morrissey et al. 1993], 80% after 10 years [O'Riordan et al. 1998b] and 88% after a 
mean of 14.1 years [Brex et al. 2002].
Longer term study of patients with CIS suggestive of MS followed for a mean of 14.1 
years has revealed that MRI lesion volume in the first 5 years of the disease is of 
prognostic value in assessing future disability. [Brex et al. 2002] The correlations 
between conventional MRI lesion load measures and disability were only moderate 
suggesting better surrogate markers are required. The longitudinal MRI studies of 
patients with CIS and the subsequent risk for the development of MS are presented in 
Table 2.1.
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Table 2.1 Longitudinal MRI studies of patients with CIS and the subsequent risk for the development of MS
Yr Author Syndrome Patient Mean/Med f/u MS/MRI+MSMRI-
2003 ONSG [Beck and Cleary 1997][Beck etal 1993] ON 388 10 Y 86/160 38/191
2003 Tintore [Tintore et al. 2000][Rio et al. 1997] ON, BS, SC, PS 139 1 Y 36/101 2/38
2002 Brex [Brex et al. 2002][0'Riordan et al. 1998b][Morrissey et 
al. 1993][Miller etal. 1988, 1989]
ON, BS, SC 71 14.1 Y 44/50 4/21
2000 Ghezzi[Ghezzi et al. 2000, 1999,19% ] ON 102 6.5 Y 42/71 0/31
1998 S6derstr6m[Soderstrom etal. 1998, 1995, 1994] ON 147 6 Y 42/75 5/41
1998 Deya [Deya et al. 1998] ON 28 4.5 Y 2/10 0/15
1997 Barkhof [Barkhof et al,1997][Tas et al. 1995] ON,SC,SS,MS,BS 74 3.25 Y 32/61 1/13
1997 Jacobs [Jacobs et al. 1991][Jacobs et al. 1997] ON 74 5.6 Y 16/42 5/32
19% Paolino [Paolino et al. 1996] BS SC 44 2.17 Y 18/22 12/22
1996 Frederiksen [Frederiksen et al. 1996][Frederiksen et al. 
1991]
ON 50 0.92 Y 7/31 0/29
1995 Campi [Campietal. 1995] SC 30 1.5 Y 8/11 0/19
1994 Filippini [Filippini etal.. 1994] Suspected MS 82 2.9 Y 19/36 1/25
1992 Ford [Ford et al. 1992] SC 15 3.25 Y 11/12 1/3
1991 Lee [Paty et al. 1988][Lee et al. 1991] ON SC 91 2 Y 52/118 3/66
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Part 2 
Chapter 3
3. Introduction, baseline MRI brain and spinal cord studies in CIS
3.1 Introduction to MRI studies in patients with CIS (Chapters 3, 4 and 5)
In 1995 a new prospective follow-up study of patients presenting with CIS was 
commenced. The study received ethical approval from the medical ethics committees 
of The National Hospital for Neurology and Neurosurgery and Moorfields Eye 
Hospital. Written, informed consent was obtained from patients before entry into the 
study and participation was voluntary.
3.1.1 Methods: Patients
Patients between 16 and 50 years of age with CIS suggestive of MS were recruited 
within 12 weeks of the onset of symptoms. A CIS is defined as an acute isolated event 
affecting one region of the central nervous system that is presumed to be 
demyelinating, with no previous history of possible demyelinating events. The 
development of maximal symptoms and signs must be evident within 14 days of 
symptom onset, and appropriate investigations carried out to exclude alternative 
diagnoses. Inclusion in the study is based solely on clinical features and is not 
influenced by MRI. Baseline assessments, both clinical and MRI, were performed less 
than three months from clinical onset
Careful history taking and examination excluded patients with a previous history of 
neurological symptoms which may have been suggestive of MS. Prior to entering the 
study each patient received a Patient Information Sheet. History and examination
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were performed at each research visit, in order to ascertain clinical relapses consistent 
with Clinically Probable and CDMS. Patients with a diagnosis of MS were referred to 
an appropriate follow up neurology clinic.
3.1.2 Methods: MRI
All MRI brain and spinal cord Images were acquired using a 1.5-Tesla Signa (General 
Electric, Milwaukee, WI, USA) imager at the NMR Unit, Institute of Neurology, 
Queen Square, London WC1N 3BG. Imaging was performed at baseline (within three 
months of the onset of symptoms). Imaging was performed again three months later, 
one and three years later. Repositioning for all follow up MRI scans was achieved by 
using a protocol based on identification of standardized anatomical 
landmarks.[Gallagher et al. 1997] The sequences are listed in the order in which they 
were done. The sequences performed but not used in this thesis are also outlined.
3.1.2.1 Brain volume sequence (baseline, one and three years)
Patients initially had a 3D inversion-prepared fast spoiled gradient recall (3d FSPGR) 
sequence (TR=T6 ms; TE=4.2 ms; TI=450 ms; matrix=256xl60; FOV=300x225 mm; 
interpolated during reconstruction to a final in-plane resolution 1.2x1.2 mm); NEX=1, 
with 124x1.5 mm slices covering the whole brain. This brain volume measurement 
sequence was not used in this thesis.
3.1.2.2 Spectroscopy (three months, one year and three years)
Single voxel spectroscopy was performed at three months, one and three years using a 
fast spin echo (FSE) axial localising scan (TR 3000 ms, TE 84 ms, Matrix 256x192, 5 
mm thickness, 1.5 mm gap). Then a single voxel was manually placed in the posterior
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parietal and centrum semi-ovale NAWM. The MRS acquisition was a PRESS 
sequence (TR=3000 ms, TE=30 ms; 192 averages). Absolute in vivo metabolic 
concentrations were estimated using the Linear Combination Model (LCModel) 
[Provencher 1993] and were not evaluated in this thesis.
3.1.2.3 Magnetization Transfer Ratio (MTR) (three months)
A dual-echo spin-echo sequence was performed with and without presaturation pulses 
using an interleaved sequence procucing 28 inherently coregistered 5-mm-thick axial 
PD (TR=1720 ms, TE=30 ms; 0.75 NEX) and T2-weighted images (TR=1720 ms, 
TE=80 ms; 0.75 NEX). Calculated MTR images were produced. This was not 
evaluated in this thesis [Brex et al. 2001b].
3.1.2.4 Gadolinium (baseline, three months one year and three years)
Each patient was then given 0.1 mmol/kg of gadolinium-DTPA intravenously. A Tl- 
weighted spin-echo brain image (TR=600ms TE=14 ms) was acquired 15 minutes 
after the injection. For each sequence, 46 x 3 mm contiguous axial slices were 
acquired with a field of view=24 cm, matrix=256 x 256 and number of excitations=l.
3.1.2.5 PD/T2 weighted brain imaging: baseline, three months one & three years
Proton density /T2 images were acquired using a dual echo fast spin echo (FSE) 
sequence with a repetition time (TR) 3200 ms, and effective time (TE) 15/90 ms.
3.1.2.6 MRI of the spinal cord (baseline, one year and three years)
Nine contiguous, 3mm thick, sagittal slices were obtained through the spinal cord 
using PD- and T2-weighted fast spin echo (FSE) images (TR 2500 ms, TE 56/98 ms)
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and a Tl-weighted spin-echo sequence (TR 500ms TE 19 ms), using phased array 
coils and a 48 cm field of view, with a Matrix 512x512. Sixty 1mm sagittal slices 
were acquired using an inversion prepared fast spoiled gradient echo (FSPGR) for 
cord volume analysis (TR 15.6 ms, TE 4.2 ms, TI 450 ms, flip angle 20, matrix 
256x256).
3.1.2.7 MRI hard copy analysis
All MRI brain and cord scans were reviewed by a consultant neuroradiologist (Dr IF 
Moseley 1995 -  2000, Dr KA Miszkiel 2000 -  2003). The baseline and follow up 
lesions loads were marked by the Neuroradiologist, who marked all Tl weighted Gd 
enhancing, T2 hyperintense and Tl hypointense lesions at baseline. In parallel 
processes, the month 3 studies were then compared side by side with the baseline 
scans in order to identify all new Gadolinium enhancing, T2 hyperintense and new Tl 
hypointense lesions. The process was repeated at one and three years.
3.1.2.8 Electronic image analysis: T2, Tl lesion volume analysis
All lesions marked on the hard copy were outlined on the on a Sun workstation (Sun 
Microsystems Inc, Mountain View, CA) using a semiautomated local thresholding 
technique, or manually [Plummer 1992] and from this lesion volumes were generated.
3.1.2.9 Electronic image analysis of atrophy: ventricular volumes and SPM99
The ventricles were measured on baseline, one and three years follow up Tl-weighted 
scans using the MIDAS interactive image analysis package and a semi-automated 
seed placing technique. [Freeborough et al. 1997] The baseline and 3-year follow-up 
T2-weighted images were segmented using a fully automated technique into Grey
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Matter (GM), White Matter (WM), CSF and other tissues using SPM99 [Chard et al 
2002c].
3.1.3. Statistical Tests used to Evaluate MRI Criteria
Conventional definitions have been used to evaluate the accuracy of MRI criteria as a 
test for Poser CDMS at 3 years. Based on the new MRI lesions after three months and 
one year as the test, and CDMS at 3 years as the disease, the number of True Positives 
(TP: new MRI criteria positive, CDMS positive), True Negatives (TN: new MRI 
criteria negative, CDMS negative), False Positives (FP: new MRI criteria positive, 
CDMS negative) and False Negatives (FN: new MRI criteria negative, CDMS 
positive) were calculated and used to determine:
Sensitivity: Probability of the test finding disease among those who have disease 
(TP/TP+FN)
Specificity: Probability of the test finding no disease among those who do not have 
the disease (TN/TN+FP)
Positive predictive value: Percentage people with a positive test who have the 
disease (TP/TP+FP)
Negative predictive value: Percentage people with a negative test who do not have 
disease (TN/TN+FN)
Accuracy = proximity to the true value (TP+TN/TP+TN+FN+FP)
73
3.2. Baseline MRI brain predictors of early conversion to CDMS in patients 
with CIS suggestive of MS
3.2.1 Aims
The aim of this chapter was to assess the relevance baseline MRI brain lesion load as 
a predictive test for the development of MS at three years using sensitivity, 
specificity, positive, negative predictive value and accuracy of baseline lesions for 
diagnosis of MS at three years.
3.2.2 Methods 
Patients
Since 1995, patients between 16 and 50 years of age with CIS suggestive of MS have 
been recruited consecutively and imaged within three months of the onset of 
symptoms. This study was conducted at the National Hospital for Neurology and 
Neurosurgery and Moorfields Eye Hospital. Local ethics approval was obtained and 
written informed consent was obtained form each patient, prior to scanning. Most 
patients were recruited from the Optic Neuritis Clinic at Moorfields Eye Hospital, so 
there is a bias towards optic neuritis in the study sample. A CIS is defined as an acute 
isolated event affecting any part of the central nervous system that is presumed to be 
demyelinating, with no previous history of demyelinating events. Patients were 
assessed clinically and with brain MRI at baseline, three months, one year and three 
years. Those with further relapses were diagnosed as having CDMS according to the 
Poser criteria. [Poser et al., 1983]
74
MRI brain
Proton density/T2-weighted images fast spin echo and T1-weighted spin-echo images 
were acquired on a 1.5T Signa scanner following intravenous injection of 0.1 
mmol/kg of Gadolinium An experienced neuroradiologist, who was blinded to the 
clinical diagnosis, reviewed all the images. The number and location of high signal 
T2/proton density lesions was noted and number gadolinium enhancing and T1 
hypointense lesions counted on both the MRI brain.
3.2.3 Results
Baseline clinical and MRI data
This study is based on the 63 patients who have been studied up to and including year 
three. Forty-four patients presented with optic neuritis, fourteen with a brain stem 
syndrome, four with a spinal cord syndrome and one patient presented with an MRI 
demyelinating lesion of the optic tract. The median age of onset of symptoms was 32 
years (range 17-50). There were 35 females and 28 males. Twenty-one of the 44 
patients (48%) with an abnormal and one out of 19 (5%) with a normal MRI brain 
scan developed CDMS at three years.
Baseline MRI lesion type as a predictor of CDMS at three years (Table 3.1)
One or more T2 lesions on baseline MRI brain were the most sensitive indicators of 
CDMS at 3 years (95%), but with low specificity 56%. One or more T1 hypointense 
or Gadolinium enhancing lesion although less sensitive (68% and 59% respectively) 
were more specific for CDMS at three years (75% and 85% respectively). The most 
sensitive lesion position was periventricular with a sensitivity of 91%, compared with 
cerebellar 45%, subcortical 73% and spinal cord 55%. Of these the spinal cord lesion
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was the most specific with a specificity of 76%. Increasing the number of 
periventricular lesions to three or more reduced sensitivity to 77% and increased 
specificity to 83%.
Increasing the baseline lesion number caused a progressive decrease in sensitivity, 
(three or more lesions: 86% and nine or more lesions: 59%). Specificity of three or 
more lesions was 68% and of nine or more lesions 83%. The specificity of nine or 
more gadolinium enhancing lesions was 100% however the sensitivity was only 14%.
Baseline Barkhof criteria as a predictor of CDMS at three years (Table 3.2)
The sensitivity of the Barkhof criteria [Barkhof et al 1997] including the spinal cord 
was 77% and the specificity was 80%.
3.2.4 Discussion
MRI scanning at baseline within three months of the onset of symptoms is a helpful 
indicator of patients at risk for the development of further episodes. Fulfilling the 
criteria for dissemination in time and space helps to delineate those at higher risk. 
Various stricter criteria such as selecting patients with more than two Gadolinium 
enhancing lesions indicate those patients with blood brain barrier (BBB) breakdown 
and ongoing inflammation. These patients are at most risk of developing symptoms; 
however the number of patients fulfilling this test is small. This results in high 
specificity and false negative rate so using this test is of limited value. The added 
value of follow-up MRI findings in improving sensitivity and specificity is assessed in 
Chapter 4.
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Table 3.1 Baseline MRI findings as predictors of CDMS at 3 years
Criterion T2 brain Cord T1 lesions Gd Cerebellar Ventricular (>3) Subcortical All locations
TP 21 12 15 13 10 20(17) 16 5
FN 1 10 7 9 12 2 (5 ) 6 2
TN 23 31 30 35 30 27 (34) 24 39
FP 18 10 10 6 11 14(7) 17 17
Sens 95% 55% 68% 59% 45% 91% (77%) 73% 71%
Spec 56% 76% 75% 85% 73% 66% (83%) 59% 70%
Ppv 54% 55% 60% 68% 48% 59%(71%0 48% 23%
Npv 96% 76% 81% 80% 71% 93%(87%) 80% 95%
Accuracy 70% 68% 71% 76% 63% 75%(81%) 63% 70%
Table 3.2 Combination of baseline MRI criteria as predictors of CDMS at 3 years
Criterion >3 lesions >4 lesions >9 lesions >3 Gd lesions >4 Gd lesions >9 Gd lesions Barkhof cord
TP 19 18 13 10 6 3 17
FN 3 4 9 12 16 19 5
TN 28 29 34 38 39 41 33
FP 13 12 7 3 2 0 8
Sens 86% 82% 59% 45% 27% 14% 77%
Spec 68% 71% 83% 93% 95% 100% 80%
Ppv 59% 60% 65% 7% 75% 100% 68%
Npv 90% 88% 79% 76% 71% 68% 87%
Accuracy 59% 48% 32% 21% 71% 70% 79%
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3.3 Spinal cord MRI in clinically isolated optic neuritis
3.3.1 Aims
The purpose of this study is to document the frequency of MRI abnormalities in 
both the brain and spinal cord and to determine the potential of spinal cord lesions 
to enable a diagnosis of MS and to predict the future clinical course.
3.3.2 Introduction
Using the new diagnostic criteria formulated by an international panel of experts, 
both brain and spinal cord MRI lesions may be used to diagnose MS in patients 
with clinically isolated optic neuritis [McDonald et al. 2001]. While spinal cord 
imaging is essential when the CIS involves the spinal cord to exclude other 
diagnoses, its value in diagnosis of patients with optic neuritis has not been 
systematically investigated. In recent years we have been prospectively recruiting 
patients with isolated optic neuritis for investigation with brain and spinal cord 
MRI. The purpose of this study is to document the frequency of MRI abnormalities 
in both regions and to determine their potential to enable a diagnosis of MS and to 
predict the future clinical course. We now report the findings in a cohort of 115 
patients with optic neuritis who have had both brain and spinal cord imaging at 
presentation, and have been followed up for periods ranging from 0 to 72 months 
(mean 18 months).[Dalton et al. 2003]
3.3.3 Methods 
Patients
Since 1995, patients between 16 and 50 years of age with optic neuritis have been 
recruited from the physicians’ clinic at Moorfields Eye Hospital. Approval was
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received from the medical ethics committee. Consent was obtained from all patients 
before entry into the study. Inclusion in the study was based solely on clinical 
features and was not influenced by MRI. Patients with a previous history of 
possible demyelinating events were excluded. Baseline clinical and MRI 
assessments were performed less than three months from clinical onset. 
Appropriate investigations were carried out to exclude alternative diagnoses.
MRI brain was performed at baseline and again after three months, one year and 
three years. Images were acquired using a 1.5-Tesla Signa (General Electric, 
Milwaukee, WI, USA) imager. Each patient was given 0.1 mmol/kg of gadolinium- 
DTPA prior to imaging. Proton density (PD)- and T2-weighted images were 
acquired using a dual echo fast spin echo (FSE) sequence with a repetition time 
(TR) 3200 ms, and effective time (TE) 15/90 ms. A T1-weighted spin-echo image 
(TR=600ms TE=14 ms) of the brain was acquired 15 minutes after the injection of 
the gadolinium-DTPA. For each sequence, 46 x 3 mm contiguous axial slices were 
acquired. The field of view=24 cm, matrix=256 x 256 and number of excitations=l.
MRI of the spinal cord was performed at baseline, one year and three years. Nine 
contiguous, 3mm thick, sagittal slices were obtained through the whole of the 
spinal cord with PD- and T2-weighted fast spin echo (FSE; TR 2500 ms, TE 56/98 
ms), and T1-weighted spin-echo (TR 500ms TE 19 ms) sequences following 
administration of gadolinium-DTPA. Both sequences employed phased array coils 
and a 48 cm field of view, with a 512x512 matrix.
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Clinical assessment
Patients were assessed clinically at baseline, three months, one year and three 
years. Those who experienced further relapses with new signs were classified as 
having clinically definite MS (CDMS) according to the criteria of Poser. [Poser et 
al. 1983] MS was diagnosed using the new McDonald criteria using clinical and/or 
MRI evidence of dissemination in time and space. Disability was measured using 
EDSS [Kurtzkel983].
Image analysis
The images were reviewed by an experienced neuroradiologist, who was blinded to 
the clinical diagnosis. The number and location of high signal PD/T2 lesions and 
gadolinium enhancing lesions was noted. The baseline, three month, one year and 
three year PD/T2-weighted and gadolinium enhanced T1-weighted scans were 
analyzed for evidence of Dissemination in Space (DIS) and Time (DIT) using the 
McDonald criteria. DIS, based on the criteria of Barkhof and Tintore [Barkhof et 
al. 1997][Tintore et al. 2000] consisted of three out of four of the following:
1. At least one gadolinium enhancing or nine T2 lesions
2. At least one infratentorial lesion
3. At least one juxtacortical lesion
4. At least three periventricular lesions
The criteria allowed the replacement of a brain lesion with a cord lesion in any of 
the above categories. One or more gadolinium enhancing lesions at three months 
(brain only) was used as evidence of Dissemination in Time (DIT) or a new T2- 
weighted lesion on the one or three year follow up scans (brain and spinal cord). 
Patients were also divided into those with no brain lesions, 1-8 brain lesions
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inclusive and 9 or more brain lesions and these subgroups were subsequently 
classified for MRI evidence of DIS.
3.3.4 Results 
Baseline clinical data
One hundred and fifteen patients with optic neuritis had imaging of the brain and 
spinal cord within three months of the onset of symptoms: 113 had unilateral and 2 
bilateral optic neuritis, age (mean, median, range) (32, 31, 16-49), gender (76 
female, 39 male) and disease duration in weeks (6, 5, 1-12).
MRI DIS: baseline data (Table 3.3)
Eighty-one (70%) patients had one or more brain lesions and 31 (27%) had one or 
more cord lesions. Forty one/115 (36%) had DIS using brain scanning alone 
(44/115 (38%) using brain and spinal cord). Patients were subdivided into those 
with a normal brain MRI (no lesions), 1-8 brain lesions and greater than 9 lesions.
Normal brain MRI
Of the 34 patients with a normal brain MRI scan, 4 (12%) had spinal cord lesions. 
Using the present diagnostic criteria, patients with cord lesions but without MRI 
brain lesions can not be included as having MRI evidence of DIS.
1-8 brain lesions
Of the 39 patients with between 1 and 8 lesions, 8 (21%) had spinal cord lesions. 
The number of patients with DIS on the baseline scan was increased by the
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inclusion of spinal cord lesions from 2 (5%) to 5 (13%). Lesion location in the 3 
patients requiring cord lesions for dissemination in space was:
1 Periventricular=3, gadolinium enhancing=l and cord=l.
2 Infratentorial= 1, juxtacortical=2, periventricular=2 and cord=3.
3 Infratentorial=2, periventricular=3 and cord=2.
Lesion location in the 34/39 patients with between 1 and 8 lesions who did not have 
DIS despite inclusion of the spinal cord was: cord lesions (4), infratentorial (5), 
juxtacortical (15), periventricular (19), periventricular >3 (6) discrete cerebral white 
matter neither periventricular nor juxtacortical (14) and gadolinium enhancing (6). 
Nine or more brain lesions
In the 42 patients with 9 or more brain lesions, 19 (45%) had spinal cord lesions. 
On brain MRI alone 39/42 (93%) had DIS and this number was unchanged when 
cord MRI findings were incorporated. When multiple cord lesions were allowed to 
substitute for an identical number of brain lesions, there was no alteration in the 
number of patients who had DIS. Only two patients with more than one cord lesion 
lacked DIS at baseline.
Follow up: MRI DIT and DIS and diagnosis of MS (Table 3.3)
The follow up study is ongoing and the present report includes all those currently 
followed-up at each time point: 94 have been studied at 3 months, 64 at one year 
(one of whom did not have cord MRI) and 44 at 3 years (3 of who did not have 
cord MRI). Although the new diagnostic criteria incorporating brain MRI findings 
markedly increase the number of patients with a diagnosis of MS at 3 months, one 
and three years, when compared with the number developing CDMS, imaging of 
the spinal cord had almost no additional impact on the diagnosis. As spinal cord
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imaging was not performed at three months, the impact of new spinal cord lesions 
on DIT could only be evaluated at one and three years. Overall, addition of cord 
MRI findings to brain MRI and clinical findings enabled a diagnosis of MS using 
the McDonald criteria in only one/64 (1.6%) and 2/44 (4.5%) additional patients 
who were followed up at one and 3 years respectively. These individuals all had 
between 1 and 8 brain lesions at baseline.
At one year, only one/11 patients with new spinal cord lesions did not have clinical 
(new relapse) or brain MRI (new brain lesion) evidence of DIT -  this single patient 
had a normal brain scan at baseline and one year. One further patient with a new 
brain lesion at one year and cord lesion at baseline had MRI evidence of DIS 
according to the McDonald criteria only if the spinal cord lesion was included. (4 
periventricular, 2 juxtacortical, 1 discrete and 1 cord lesion).
At three years, 2/10 patients with new spinal cord lesions did not have MRI 
evidence of DIS although both had new brain lesions and no further symptoms. In 
patients with an abnormal baseline scan, the occurrence of new T2 brain lesions as 
evidence of DIT at 3 months or 1 year had a sensitivity of 85% and specificity of 
79% for CDMS at 3 years. Adding new cord lesions at one year resulted in no 
increase in sensitivity and specificity dropped from 79% to 75% (Table 3.4).
3.3.5 Discussion
Patients with clinically isolated optic neuritis and asymptomatic brain lesions have 
an increased risk for the development of MS [Brex et al. 2002]. Although spinal
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cord imaging is mandatory in isolated spinal cord syndrome patients in order to 
detect treatable alternative disorders such as compressive lesions, its role is unclear 
in patients with optic neuritis. The key question is whether cord lesions increase the 
frequency of DIS and DIT and thereby enable a more frequent and earlier diagnosis 
of MS.
Overall, 27% of our patients had MRI evidence of spinal cord lesions at 
presentation. However, they contributed little to the diagnosis. Although there were 
4 patients with cord lesions but no brain lesions, these subjects do not have DIS 
according to current definitions and therefore a diagnosis of MS cannot be made 
using existing MRI criteria. Two of the 4 have been followed for three years and 
have had no further symptoms.
In patients with between one and eight brain lesions inclusive, cord imaging 
modestly increased the number of patients with DIS at baseline by 8%; however, at 
three months (the earliest time point at which a diagnosis of MS can be made) no 
additional patients were diagnosed with MS (although follow up MRI was confined 
to the brain at this time point). In those patients with 9 or more brain lesions, cord 
lesions were much more common, being found in almost one half of subjects, but 
their presence did not increase the number who fulfilled the MRI criteria for DIS or 
who developed MS at each follow up time point.
The present study is limited by the fact that cord imaging was not performed at 
three months. Nevertheless, brain MRI, on average, detects many more lesions than
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cord MRI and the latter is most often abnormal only when there are already at least 
9 brain lesions present and when the new criteria for DIS are very often already 
fulfilled by brain findings alone. In established MS, new cord lesions occur less 
often on follow up than new brain lesions [Thorpe et al. 1996b] [Silver et al. 2001] 
and usually when there are concurrent new brain lesions. Notably, the new spinal 
cord lesions seen at three years when compared with one year did not increase the 
number of patients exhibiting DIT over that period, and increased the number of 
patients with a diagnosis of MS at three years by only 2 out of a total of 44 (4.5%) 
(Table 3.3). We doubt therefore that additional cord imaging at month three would 
have affected the rate of early MS diagnosis.
In summary, using existing criteria, imaging of the spinal cord is of limited 
diagnostic value in patients with optic neuritis with between 1 and 8 MRI brain 
lesions. If in future the diagnostic criteria were revised to allow the presence of 
any cord lesions as evidence of DIS and DIT, then cord imaging would have a 
diagnostic role in more patients, but overall it appears that this will be a relatively 
small subgroup. Any such extension of the diagnostic criteria should first be 
validated by confirming its accuracy for predicting CDMS.
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Table 3.3 Impact of spinal cord lesions on the diagnosis of MS
Time Pts 0 brain 
lesions
1 -8  brain 
lesions
>9 brain 
lesions
Number pt brain lesions (c) Baseline 115 34(4) 39 (8) 42(19)
% patients with cord lesions 115 12% 21% 45%
Mean, (Range) cord lesions 115 0.1 (0-1) 0.4 (0-4) 1.2 (0-11)
DIS (b) 115 0 2(5%), 39(93%),
DIS (b + c) 5(13%) 39(93%)
New brain lesions 3 Months 94 1/28 (4%) 8/32 (25%) 23/34 (68%)
McDonald MS (b) 94 0/28 1/32 (3%) 17/34(50%)
McDonald MS (b+ base c) 94 0/28 1/32 (3%) 17/34(50%)
CDMS 94 0/28 0/32 9/34 (26%)
New brain lesions 1 year 64 0/17 11/22 (50%) 18/25 (72%)
New cord lesions 63 2/17 3/22 (14%) 6/24 (25%)
New brain or cord lesions 64 2/17(12%) 11/22 (50%) 19/25 (76%)
McDonald MS (b) 64 1/17(6%) 7/22 (32%) 22/25 (88%)
McDonald MS (b & c) 64 1/17(6%) 8/22 (36%) 22/25 (88%)
CDMS 64 1/17(6%) 1/22 (5%) 8/25 (32%)
New brain lesions 3 years 44 3/15 (20%) 11/15(73%) 12/14(86%)
New cord lesions 41 1/15 (7%) 4/14 (29%) 5/12 (42%)
New brain or cord lesions 44 3/15 (20%) 11/15(73%) 13/14(93%)
McDonald MS (b) 44 1/15(7%) 5/15 (33%) 14/14(100%)
McDonald MS (b+c) 44 1/15(7%) 7/15 (47%) 14/14(100%)
CDMS 3 years 44 1/15(7%) 4/15 (27%) 9/14 (64%)
(brain = b, cord = c)
86
Table 3.4: Relationship of new lesions after one year with CDMS after 3 years 
in patients with an abnormal baseline MRI brain (41 patients)
New Brain Lesions* New Brain & Cord
lesions*
CIS + 6 7
MS + 11 11
CIS- 22 21
M S- 2 2
Sensitivity (95% Confidence Interval) 85% (55% 98%) 85 % (55% 98%)
Specificity (95% Confidence Interval) 79% (59% 92%) 15 % (55% 89%)
PPV (95% Confidence Interval) 65% (38% 86%) 61% (36% 83%)
NPV (95% Confidence Interval) 92% (73% 99%) 91% (72% 99%)
Accuracy (95% Confidence Interval) 80% (65% 91%) 78% (62% 89%)
CIS+ = New lesions after one year and CIS after 3 years 
MS+ = New lesions after one year and CDMS after 3 years 
CIS- = No new lesions after one year and CIS after 3 years 
MS- = No new lesions after one year and MS after 3 years 
* Brain MRI findings only were available at 3 months; brain and cord at one year 
Footnote: Based on the new MRI lesions after one year as the test, and CDMS at 3 
years as the disease, the number of True Positives (TP: new MRI lesions positive, 
CDMS positive), True Negatives (TN: new MRI lesions negative, CDMS negative), 
False Positives (FP: new MRI lesions positive, CDMS negative) and False 
Negatives (FN: new MRI lesions negative, CDMS positive) were calculated and 
used to determine: sensitivity, specificity, positive predictive value, negative 
predictive value and accuracy.
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Figure 3.1 T2-weighted sagittal MRI through the spinal cord in a 30-year old 
female with isolated optic neuritis. Two intrinsic lesions are seen in the thoracic 
cord (arrowed).
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Chapter 4
4. Application of the McDonald criteria and new T2 lesions
4.1. Application of the McDonald criteria to patients with CIS suggestive of
MS
4.1.1. Aims
The aim of this study was to determine the accuracy of the new McDonald MRI and 
clinical criteria in a cohort of patients with CIS who have been followed for one and 
three years, respectively.
4.1.2. Introduction
Approximately 90% of patients with MS initially present with a clinically isolated 
inflammatory, demyelinating syndrome of acute onset in the central nervous system. 
The most common types of CIS are optic neuritis, brainstem and spinal cord 
syndromes in an individual without a previous history suggestive of demyelination 
and in whom appropriate investigations have excluded an alternative diagnosis.
Long-term follow-up studies indicate that between 30-80% [Hely et al. 1986] [Francis 
et al. 1987] [Rizzo, III and Lesselll988][Sandberg-Wollheim et al. 1990] [Rodriguez et 
al. 1995] [Jacobs et al. 1997] [O'Riordan et al. 1998b] [Barkhof et al. 1997][Soderstrom 
et al. 1998][Ghezzi et al. 1999][Ghezzi et al. 2000] [Morrissey et al. 1993] of patients 
with CIS will develop clinical evidence for Dissemination in Time (DIT) and Space 
(DIS) thereby fulfilling the traditional criteria for a diagnosis of CDMS.[Poser et 
al. 1983][Schumacher et al. 1965] About 50-70% of patients with CIS have 
disseminated lesions on brain MRI characteristic of MS at first presentation, and the 
presence of such lesions increases the likelihood of developing CDMS.[Jacobs et
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al. 1997][0'Riordan et al. 1998b] [Barkhof et al. 1997][Soderstrom et al. 1998][Ghezzi 
et al. 1999][Ghezzi et al. 2000] [Morrissey et al. 1993][Tintore et al. 2000] [Brex et 
#/. 2002] [Brex et al. 2001c] [Brex et al. 1999b] One year follow-up of patients with 
CIS frequently reveals new, clinically silent MRI lesions that also appear to increase 
the chances of developing CDMS.[Brex et al. 1999b][Brex et al.2001c] Diagnosis of 
MS in patients with CIS may be beneficial since the early course of MS with axonal 
loss [Trapp et al. 1998] may determine the relative risk of progression. [Weinshenker et 
al. 1989]
Recently, the International Panel of McDonald and colleagues has prepared new 
guidelines for the diagnosis of MS.[McDonald et al. 2001] These rely, as have the 
previous clinically based Poser criteria,[Poser et al. 1983] on objective evidence of 
Dissemination in Time (DIT) and Space (DIS). However, the revised criteria have 
included MRI evidence of DIS and DIT with potential to enable an earlier diagnosis, 
especially in patients with CIS.[McDonald et al. 2001]
At the time this study was performed, the McDonald criteria had not yet been 
evaluated in a population of patients with CIS. Assessment of the relevance of the 
new criteria in this subgroup should include an evaluation of an early MRI-supported 
diagnosis of MS in terms of specificity, positive predictive value and accuracy for the 
development of CDMS. An accurate diagnosis is essential since prognosis, 
counselling and advice regarding treatment is likely to be given to patients once a 
diagnosis of MS has been established.
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In a prospective follow up of a CIS cohort first seen between 1984 and 1987, it was 
found, by the early 1990s, that baseline brain T2 lesion load and number seen on a 0.5 
Tesla scanner were predictive of clinical outcome after 5 years.[Morrissey et al. 
1993] [Filippi et al. 1994]. However, since these early studies began, there were 
significant developments in MR technology, including the widespread use of higher 
field scanners (1.5 Tesla), gadolinium enhancement, routine acquisition of thinner 
slices, spinal cord imaging and measurements of atrophy. Therefore, in 1995, a new, 
prospective follow up study from first presentation of a separate cohort of patients 
with a CIS began. The purpose of this ongoing study is to obtain multiple MR 
measurements using a 1.5 Tesla scanner, and to determine, by serial clinical and MRI 
follow up at regular, pre-specified intervals, the prognostic significance of the early 
MR findings. Initial findings, with up to one year of follow up, have already been 
reported [Brex et al. 200la][Brex, et al. 200lb][Brex, et al 2001c][Brex et al.
2000] [Brex et al. 1999a] [O'Riordan et al. 1998a]. The present study analyses serial 
clinical and MRI data that was prospectively acquired for up to three years from this 
cohort of patients. By retrospective application of the new McDonald criteria to 
prospectively acquired data, it addresses the value of the new diagnostic criteria as 
follows:
1. Determining the frequency with which patients with CIS fulfil the new criteria 
for MS at three months, one year and three years, and comparing that with the 
frequency of Poser CDMS at each time point.
2. Evaluating the relationship between the new criteria for MS and the traditional 
criteria for Poser CDMS in terms of sensitivity, specificity, positive and 
negative predictive value and accuracy of the former for the latter.
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4.1.3. Methods
Patients
Since 1995, patients have been recruited from the wards and clinics of the National 
Hospital for Neurology and Neurosurgery and from the Neuro-Ophthalmology clinic 
at Moorfields Eye Hospital, London, UK. Patients between 16 and 50 years of age 
have been included. The study has received approval from the medical ethics 
committees of both hospitals. Written, informed consent is obtained from all patients 
before entry into the study and participation is voluntary at all stages. A CIS is 
defined as an acute isolated event affecting one region of the central nervous system 
that is presumed to be demyelinating, with no previous history of possible 
demyelinating events. The development of maximal symptoms and signs must be 
evident within 14 days of symptom onset, and appropriate investigations carried out to 
exclude alternative diagnoses. Inclusion in the study is based solely on clinical 
features and is not influenced by MRI. Baseline assessments, both clinical and MRI, 
must be performed less than three months from clinical onset
MRI acquisition protocols
MRI brain is performed at baseline (within three months of the onset of symptoms) 
and again after three months, one year and three years. Images are acquired using a 
1.5-Tesla Signa (General Electric, Milwaukee, WI, USA) imager. Each patient is 
given 0.1 mmol/kg of gadolinium-DTPA prior to imaging. Proton density (PD)- and 
T2-weighted images are acquired using a dual echo fast spin echo (FSE) sequence 
with a repetition time (TR) 3200 ms, and effective time (TE) 15/90 ms. A Tl- 
weighted spin-echo image (TR=600ms TE=14 ms) of the brain is acquired 15 minutes
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after the injection of the gadolinium-DTPA. For each sequence, 46 x 3 mm 
contiguous axial slices are acquired. The field of view=24 cm, matrix=256 x 256 and 
number of excitations=l.
MRI of the spinal cord is performed at baseline, one year and three years using PD- 
and T2-weighted fast spin echo (FSE) images (TR 2500 ms, TE 56/98 ms). A Tl- 
weighted spin-echo sequence (TR 500ms TE 19 ms) is also performed following 
administration of gadolinium-DTPA. Additional sequences for MR spectroscopy and 
magnetization transfer imaging are obtained at the month 3 visit and a 3D cord 
acquisition is obtained at baseline and one year to investigate cord atrophy. [Brex et al 
1999a] [Brex et al. 2001a]
Clinical assessment
All patients are assessed clinically at baseline, three months, one year and three years 
and those with further relapses with new signs disseminated in space and time (at least 
one month after the CIS) are classified as having CDMS according to the criteria of 
Poser.[Poser et al 1983] Disability is recorded at each visit using the Kurtzke 
EDSS. [Kurtzke 1983].
The clinical diagnosis of MS had in all instances made prior to application of the 
McDonald MRI criteria (see below), and although the clinician making the diagnosis 
had seen the scans and been aware of the presence or absence of MR abnormalities 
these had not been quantified. MS was diagnosed using the new McDonald criteria of 
clinical and/or MRI evidence of Dissemination in Time (DIT) and Space (DIS). The
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McDonald clinical criteria for DIS and DIT are those for CDMS; the MRI criteria are 
outlined in the next section.
Image Analysis
An experienced neuroradiologist, who was blinded to the clinical diagnosis, reviewed 
all the images. The number of high signal lesions on the PD/T2 weighted scans (called 
T2 lesions) was noted in each of the following regions: infratentorial, periventricular, 
juxtacortical, and discrete (in cerebral hemispheres but neither juxtacortical nor 
periventricular). All T2 lesions were marked on the PD-weighted scan and confirmed 
on the T2-weighted scan. Gadolinium enhancing lesions identified on the Tl- 
weighted scans were confirmed on both the PD- and T2-weighted scans. The MRI 
brain and cord images were reported as normal if they had no lesions compatible with 
demyelination, or if only the symptomatic lesion, as determined by a separate 
unblinded observer, was visible. They were reported as abnormal if one or more 
asymptomatic lesions compatible with demyelination were present.
In order to evaluate the new diagnostic criteria, the baseline, three-month, one year 
and three year proton density/T2-weighted and gadolinium enhanced T1-weighted 
scans were retrospectively analyzed for evidence of DIS and DIT.
Dissemination in space based on the criteria of Barkhof and Tintore [Barkhof, et al 
1997][Tintore et al. 2000] consisted of three out of four of the following:
1. At least one gadolinium enhancing or nine T2 lesions.
2. At least one infratentorial lesion
3. At least one juxtacortical lesion
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4. At least three periventricular lesions 
One cord lesion was allowed to replace one brain lesion. Figure 4.1 is a clinical 
example of the use of MRI as evidence for DIS.
Dissemination in time consisted of either one or more gadolinium enhancing lesions at 
least three months after the attack or one or more T2 lesions subsequent to a scan at 
least three months after the attack. Figure 4.2 is a clinical example of MRI as evidence 
for DIT.
Statistical Analysis
The validity of the new “test” -  i.e. the McDonald diagnostic criteria for MS - was 
assessed by comparing it with the “gold standard” for the disease which was defined 
as CDMS using the Poser criteria. Based on the clinical outcome at one year and three 
years the number of True Positives (TP: McDonald MS positive, CDMS positive), 
True Negatives (TN: McDonald MS negative, CDMS negative), False Positives (FP: 
McDonald MS positive, CDMS negative) and False Negatives (FN: McDonald MS 
negative, CDMS positive) were calculated and used to determine: Sensitivity, 
Specificity, Positive predictive value, Negative predictive value, and Accuracy.
4.1.4. Results
Baseline clinical data (Table 4.1)
The study is ongoing. Currently, 119 patients have been studied at baseline, 95 at 
three months, 79 at one year and 50 at three years. One patient died of an asthmatic 
attack prior to three years of follow up. Eighty-seven patients presented with acute
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unilateral optic neuritis, two patients had bilateral consecutive optic neuritis, 19 had a 
brain stem syndrome, 10 patients had a spinal cord syndrome and one patient had a 
hemianopia attributable to a lesion of the optic tract. The median age at onset of 
symptoms was 31 years (range 16-50). The median EDSS was 1 at baseline (range 0- 
8; one patient with a spinal cord syndrome had an EDSS of 8).
Baseline MRI data (Table 4.2)
The median time delay between onset of symptoms and baseline scan was five weeks 
(range 1-12). At baseline 85/119 patients (71%) had an abnormal brain MRI (i.e. one 
or more T2 lesions), and 36/119 (30%) had an abnormal cord scan. Thirty-three/36 
patients (92%) with cord lesions also had brain lesions; only three had cord lesions 
with a normal brain scan. Using the McDonald criteria, DIS was present in 43/119 
(36%) when brain MRI findings alone were considered; this rose to 47/119 (40%) 
when spinal cord findings were included.
Development of MS at follow-up
The median intervals between the baseline and follow up evaluations were: (i) three 
months -  12 weeks (range 8-22); (ii) one year -  12 months (range 11-19); three years 
-  37 months (range 29-67). Table 4.2 shows, for each follow up time point, the 
number of patients developing MS using the McDonald criteria and the numbers who 
developed CDMS using the Poser criteria. Patients with MS diagnosed using the new 
criteria are further subdivided to show the numbers with either an MRI based 
diagnosis, or CDMS, or both. Table 4.2 also shows the number of patients with an 
abnormal scan, MRI evidence of DIS and DIT, and a diagnosis of MS using the new
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MRI criteria alone, at each time point - these data are presented for brain MRI 
findings alone and for combined brain and cord findings.
Predictive value of the new diagnostic criteria for CDMS
Of those developing CDMS at each time point, the majority also had a diagnosis of 
MS based on the McDonald MRI criteria of DIS and DIT, i.e. 6/7 (86%) at three 
months, 13/16 (81%) at year one, and 17/19 (90%) at year three. At all time points, 
the addition of spinal cord MRI findings had a minimal impact on the proportion of 
patients with a diagnosis of MS using the new criteria.
The sensitivity, specificity, positive and negative predictive value and accuracy of the 
new diagnostic criteria for the development of CDMS after one and three years are 
presented in Tables 4.3 and 4.4. The predictive value of the baseline MRI findings is 
also provided.
CDMS at one year
A diagnosis of MS based on MRI evidence for DIS and DIT at three months provided 
a substantially higher specificity (87%) for Poser CDMS at one year than did baseline 
evidence for DIS whether using brain MRI alone (68%) or combined brain and spinal 
cord findings (67%). The positive predictive value and overall accuracy was also 
higher for MRI diagnosed MS at three months (56% and 83% respectively) than for 
either baseline brain MRI DIS (36% and 68% respectively) or baseline brain and cord 
DIS (40% and 71% respectively). A high sensitivity for CDMS at one year was
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achieved only for baseline DIS when using combined brain and cord MRI findings 
(88%).
CDMS at three years (Table 4.4)
A diagnosis of MS using the McDonald MRI criteria at one year provided a 
sensitivity of 83%, specificity of 83%, positive predictive value of 75% negative 
predictive value of 89% and overall accuracy of 83% for CDMS at three years. The 
specificity and positive predictive values of McDonald MRI criteria MS at three 
months were also high (93% and 83% respectively) but sensitivity (59%) was lower 
than specificity. Baseline DIS on brain MRI had a lower specificity and positive 
predictive value for CDMS at three years (77% and 63% respectively); the sensitivity 
of DIS was also low for brain MRI findings (63%), but was increased substantially by 
incorporation of spinal cord lesions (79%). Although an abnormal baseline scan had 
100% sensitivity for CDMS, the specificity (36%) and positive predictive value (49%) 
of this finding were much lower. Five patients were treated with beta interferon 
following diagnosis of MS. In all five, both CDMS and MRI DIS and DIT had 
developed before treatment was started. Eleven patients received short courses of 
steroids for relapses: five prior to their baseline scan, three between their baseline and 
three month scans, two between their three month and one year scans and one 
between their one and three year scans.
4.1.5. Discussion
An accurate and early diagnosis of MS is important in order to allow for the provision 
of information and discussion of prognosis and potential therapeutic interventions.
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The earliest clinical event in most MS patients is a CIS, and the presence of multifocal 
MRI abnormalities in such individuals confers a relatively high likelihood for the 
development of further clinical relapses leading to a diagnosis of CDMS. Because 
MRI reveals many clinically silent lesions, it is logical to integrate MRI evidence of 
DIS and DIT in order to achieve an earlier diagnosis of MS. The International Panel 
of McDonald and colleagues has recently developed such diagnostic criteria. In recent 
years, we have been recruiting CIS patients into a prospective follow up study 
involving serial clinical and MRI evaluations with the aim of identifying prognostic 
imaging markers early in the disease course. Patients were included based on clinical 
features alone; MRI findings were not a part of the inclusion criteria and patients with 
a normal scan were included. This dataset thus provides an opportunity to investigate 
the frequency with which such patients develop MS using the new criteria and the 
predictive value of those criteria for CDMS.
Using the new criteria, almost half the patients had a diagnosis of MS after one year 
compared with only one fifth using traditional clinical criteria. More frequent 
scanning between month three and month 12 may have further increased the 
diagnostic yield - additional new enhancing or T2 lesions may have occurred that 
were no longer visible on the month 12 scan.
The main restriction on an MRI-based diagnosis at the three month follow up was the 
criterion of DIT which at this time requires the presence of a gadolinium enhancing 
lesion since a new T2 lesion cannot be verified as having appeared more than three 
months from clinical onset. MRI diagnosed MS was nevertheless almost three times 
more common than CDMS at this stage (20% versus 7%).
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Spinal cord imaging had little effect on the proportion of patients who developed MS 
using the new criteria. This is partly because follow up cord imaging was obtained 
less often (specifically not at three months) but mainly because new lesions occur 
more often in the brain than the cord.[Brex et al. 2001c] Of the ten (8%) patients 
presenting with spinal cord syndromes, seven had spinal cord lesions and six had 
brain lesions suggesting that imaging of the spinal cord may be slightly more useful in 
this group. Further studies are needed of a larger cohort with isolated cord syndromes. 
Using the new criteria for the diagnosis of MS, cord imaging does not appear useful in 
patients with CIS presenting with optic neuritis or brain stem syndromes.
The McDonald criteria also include CSF findings in the diagnostic framework. The 
presence of CSF oligoclonal bands in addition to two MRI lesions can be used as an 
alternative criterion for DIS. Because lumbar puncture was only performed in a small 
number of patients with brain stem or spinal cord syndromes, the effect of CSF 
findings could not be evaluated in our study. In one recent report, the combination of 
MRI abnormalities using the criteria proposed by Paty, Fazekas or Barkhof and 
oligoclonal bands resulted in slight increase in accuracy for a diagnosis of CDMS 
compared to MRI data alone.[Paty et al. 1988] [Fazekas et al. 1988][Tintore et al.
2001] Future CIS cohorts who have systematic CSF and MRI studies will be required 
to address the impact of CSF findings on the new diagnostic criteria.
While an earlier diagnosis using the McDonald criteria is welcome to enable accurate 
counseling and management advice for patients, confirmation that they reliably 
predict the development of MS using traditional clinical criteria is necessary to 
confirm their clinical relevance. This requires a reasonable length of follow up, and
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for this reason we place more emphasis on the three year than one-year data for 
CDMS. In the present study, to date, fewer than half the patients have been followed 
for three years. Nevertheless the three-year cohort is similar to the original group in 
terms of age at onset, gender, type of CIS, frequency of MRI abnormalities and DIS at 
baseline (data not shown). The overall frequency of CDMS after three years (38%) is 
also similar to a previous study of 74 CIS patients (44%) who were followed for a 
similar period and in whom the predictive value of baseline MRI features were 
investigated [Barkhof et al. 1997].
In making a diagnosis of a lifelong condition such as MS, a high specificity for a test 
is more important than a high sensitivity, and the new criteria for MS at three months 
and one year were highly specific for CDMS at three years. A high positive predictive 
value for CDMS at three years was also seen for subjects who were diagnosed with 
MS using the new criteria after three months and one year (ranges 75-85%, Table 
4.4). These observations confirm the new criteria as being clinically relevant, an 
impression consolidated by the overall robust overall accuracy of the criteria for 
CDMS (ranges 80-87%, Table 4.4).
While the sensitivity of the new criteria at one year is high for the development of 
CDMS after three years, the sensitivity of the criteria at three months is lower. This 
reflects the lower frequency (23%) of MRI DIT at this early stage of follow up 
whereas almost 40% had CDMS after three years. The potential exists for more 
frequent interval scanning during the first year of follow up to increase sensitivity 
while maintaining a high specificity and positive predictive value. Further prospective 
studies are needed to address this.
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The new McDonald criteria do not allow the diagnosis of MS on a single MRI scan 
obtained within three months of a CIS as the criterion of DIT cannot be not met (it is 
possible for a single scan obtained more than three months after the episode to satisfy 
the new criteria). A question arises whether, in future diagnostic criteria, baseline 
MRI findings alone, within the first three months, might be reliably used to diagnose 
MS. The simple presence of T2 lesions is inadequate since many such patients do not 
develop CDMS within three years, thus resulting in a low specificity, positive 
predictive value and accuracy in spite of 100% sensitivity. Baseline MRI evidence for 
DIS improved specificity and positive predictive value, but not to the level achieved 
by the new diagnostic criteria after three months and one year of follow up. Our 
results therefore suggest that the additional requirement of DIT is warranted to give a 
more confident and accurate diagnosis. The relatively short delay may also optimize 
the timing of discussions of diagnosis and prognosis that have a major impact on the 
patient.
It is our understanding that the new criteria were developed in order to allow an 
earlier, yet reliable diagnosis, [McDonald et al. 2001] and were not intended to guide 
the timing of introduction of disease modifying treatments, though it is possible that 
some neurologists will apply them in this manner. There is currently no evidence that 
the long term prognosis is more favourably modified by therapeutic intervention at 
first presentation with a CIS - whether or not the new diagnostic criteria are fulfilled - 
than at the later stage of established relapsing remitting disease. Furthermore, a 
significant number of patients with CIS and baseline MRI abnormalities have a 
favorable long-term course without disease modifying therapy [Brex et al 2002].
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The development of disabilities in MS goes well beyond the three-year time frame 
reported in this study, and prolonged follow up studies are necessary to clarify the 
prognosis for the subgroup of CIS patients who fulfill the new diagnostic criteria at an 
early stage. A recent 14-year follow up of the first CIS cohort that was recruited in the 
mid 1980s has shown a significant relationship between T2 volume increase during 
the first 5 years and disability at year 14.[Brex et al. 2002] The pathological MRI 
changes during these early years are of prognostic significance and more detailed 
analysis using a range of modem, in vivo MR techniques is required. The McDonald 
criteria have also been applied by the Barcelona Group. Despite not having an MRI 
scan at three months, the results are comparable: One year after symptom onset more 
than three times as many CIS patients were diagnosed with MS using the new criteria 
(sensitivity 74%, specificity 86% and accuracy 80%).[Tintore et al. 2003].
Table 4.1 Baseline clinical features of patients presenting with CIS (n=119)
Age of onset (years) 32 (mean) 31 (median) range (16-50)
Sex M/F 49/70
Clinical Syndrome
Optic Neuritis 87
Bilateral Optic Neuritis 2
Brainstem Syndrome 19
Spinal Cord Syndrome 10
Demyelinating Optic Tract Lesion 1
Baseline EDSS 1 (mean) 1 (median) Range (0-8)
Onset-baseline scan (weeks) 6 (mean) 5 (median) Range (1-12)
Abnormal Baseline brain MRI 85/119
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Table 4.2: Frequency of abnormal MRI, DIS, DIT and MS diagnosed using the 
McDonald criteria and Poser criteria at three months, one and three years
MRI data 3 months 
n=95
1 year 
n=79
3 years 
n=50
Abn MRI Brain 67 (71%) 58 (73%) 40 (80%)
Brain+Cord 70 (74%) 62(79%) 42 (84%)
MRI DIS Brain 40 (42%) 40 (51%) 26 (52%)
Brain+Cord 42 (44%) 42 (53%) 29 (58%)
MRI DIT Brain 22 (23%) 42 (53%) 34 (68%)
Brain+Cord 46 (58%) 36 (72%)
McDMRI+ Brain 18(19%) 34 (43%) 24 (48%)
Brain+Cord 19 (20%) 35 (44%) 27 (54%)
McDMS Brain 19 (20%) 38 (48%) 28 (56%)
Brain+Cord 20 (21%) 38 (48%) 29 (58%)
CDMS 7 (7%) 16 (20%) 19 (38%)
McDMRI + CDMS- 13 22 10
McDMRI+ CDMS+ 6 13 17
McDMRI-CDMS+ 1 3 2
Abn MRI = 1 or more lesions
MRI DIS = MRI dissemination in space
MRI DIT = MRI dissemination in time
McDMRI+ = MRI evidence of DIS and DIT as defined by McDonald criteria 
McDMS = MS diagnosed using McDonald criteria 
CDMS = clinically definite MS by Poser criteria
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Table 4.3 Sensitivity, specificity, positive and negative predictive value and 
accuracy of the new diagnostic criteria at 3 months and baseline MRI findings 
for the development of CDMS at 1 yr (n=79)
McDMS at 3 McDMRI+ at 3 DIS baseline DIS baseline
months (all cases) months brain only brain & SC
Sensitivity 73% 67% 69% 88%
Specificity 87% 87% 68% 67%
PPV 58% 56% 36% 40%
NPV 93% 91% 90% 96%
Accuracy 84% 83% 68% 71%
McDMS (all cases) = MS diagnosed by MRI and/or clinical evidence for 
dissemination in space and time using the new McDonald criteria
McDMRI+ = MS diagnosed by MRI evidence of dissemination in space and time 
using the new McDonald criteria
DIS baseline brain only = Dissemination in space on brain MRI at baseline
DIS baseline brain & SC = Dissemination in space on brain and spinal cord MRI at 
baseline
PPV = positive predictive value 
NPV = negative predictive value
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Table 4.4: Sensitivity, specificity, positive, negative predictive value and accuracy of the new diagnostic 
criteria at 3 months & one year & baseline MRI findings for the development of CDMS at 3 years (50 patients)
McDMS at 3 months McDMS at 1 year Abnormal baseline MRI
All cases McDMRI+ All cases McDMRI+ >1 lesion DIS brain DIS B&SC
Sensitivity 65% 59% 94% 83% 100% 63% 79%
Specificity 93% 93% 83% 83% 36% 77% 77%
PPV 85% 83% 77% 75% 49% 63% 68%
NPV 82% 79% 96% 89% 100% 77% 86%
Accuracy 83% 80% 87% 83% 60% 72% 78%
McDMS = MS diagnosed by McDonald criteria
All cases = MS diagnosed using MRI and/or clinical evidence for DIS and DIT 
McDMRU- = MS diagnosed using MRI evidence of DIS and DIT 
>1 lesion = 1 or more lesions consistent with MS on brain MRI at baseline
DIS brain = Dissemination in space on brain MRI at baseline, DIS B&SC = Dissemination in space on brain and spinal cord MRI at 
baseline
PPV = positive predictive value, NPV = negative predictive value
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Figure 4.1 CIS patient: At baseline DIS (Barkhof) criteria are positive
37 year old lady with left optic neuritis 
4 periventricular lesions and 1 enhancing subcortical lesion.
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Figure 4.2 CIS patient: At 3 months, McDonald Poser criteria for MS are positive
Ventricular T2 lesions New Gadolinium
enhancing ventricular 
lesion
New symptomatic brainstem 
lesion
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4.2. Evaluation of new T2 lesions to enable an earlier diagnosis of MS in 
patients with CIS suggestive of MS
4.2.1. Aims
In CIS patients, new T2 lesions are detected more often than new gadolinium 
enhancing lesions after three months. Including new T2 lesions for MRI 
Dissemination in Time (DIT), may improve sensitivity but specificity must also 
remain high for the criteria to give an accurate diagnosis. Chapter 4.2 addresses the 
accuracy of new T2 lesions at a three month follow up visit in making a diagnosis of 
MS.[Dalton et al. 2003]
4.2.2. Introduction
New diagnostic criteria developed by an International Panel on MS [McDonald et al.
2001] allow MRI evidence of DIT [Brex et al 2001c] and Dissemination in Space 
(DIS) [Barkhof et al. 1997] [Tintore et al. 2000] enabling a diagnosis of MS to be 
made in patients with CIS. This contrasts with previous criteria that have required 
clinical evidence for DIS and DIT in order to diagnose CDMS.[Poser et al. 
1983][Schumacher et al. 1965] In Chapter 4.1, we reported application of the 
McDonald criteria to a cohort of CIS patients followed clinically and with MRI within 
three months of symptom onset, and again three months, one year and three years 
later. [Dalton et al. 2002b] If a first MRI is performed less than three months after the 
onset of the clinical event, a second scan performed three months or more after the 
clinical event must show a new gadolinium enhancing lesion in order to fulfill the 
MRI criteria for DIT. After three months of follow up, specificity of the new criteria 
for the development of CDMS at three years was high (93%). Sensitivity was low 
(59%), reflecting the low proportion of patients developing new gadolinium 
enhancing lesions. [Dalton et al. 2002b] Diagnosis of MS in patients with a new lesion
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that appears on a T2 weighted scan at the three month follow up scan is not permitted 
by the current criteria.
4.2.3. Methods:
Patients
Since 1995, patients between 16 and 50 years of age with CIS suggestive of MS have 
been recruited consecutively and imaged within three months of symptom onset. The 
majority of patients were recruited from a Neuro-ophthalmology clinic in Moorfields 
Eye Hospital. A CIS is defined as an acute isolated presumed demyelinating event of 
any part of the central nervous system, with no previous history of demyelinating 
events. Patients were assessed clinically and with MRI at baseline (within three 
months of clinical onset), and again three months, one year and three years later. 
Those with further relapses with new signs clinically disseminated in space and time 
were diagnosed as having CDMS [Poser et al. 1983].
Methods MRI
Patients underwent T2-weighted and gadolinium enhanced T1-weighted brain MRI at 
each visit. A fuller description of the imaging protocol is provided in Chapter 4.1. An 
experienced neuroradiologist, blinded to the clinical diagnosis, recorded the number 
and location of high signal T2/proton density and gadolinium enhancing lesions. The 
baseline and three-month scans were analyzed for MRI DIS and DIT using the 
McDonald criteria. [McDonald et al. 2001] In addition to the existing criteria for MRI 
DIT (gadolinium enhancing lesions at three months), the alternative of new T2 
weighted lesions at three months was investigated while retaining the original criteria 
for MRI DIS. Performance was assessed by comparing with the “gold standard”
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CDMS after three years. The performance of a new T2 lesion per se was also 
evaluated.
4.2.4. Results
Baseline clinical and MRI data
This study is based on the 56 patients who have been followed clinically for three 
years, after having MRI at baseline and three months later. Thirty-seven patients had 
optic neuritis, fourteen a brain stem syndrome, four a spinal cord syndrome and one 
had a demyelinating lesion of the optic tract. The median age of onset of symptoms 
was 32 years (range 17-50). There were 30 females and 26 males. The median number 
of weeks from onset of symptoms to the baseline scan was 5 (range 1-12). Thirty 
eight/56 (68%) had an abnormal baseline T2-weighted brain MRI, and 18 (32%) had 
MRI DIS [Barkhof et al 1997][Tintore et al. 2000].
Performance of the McDonald criteria & new T2 lesions at three months (Tables 
4.5 and 4.6)
The median number of weeks, from the baseline scan to the three month follow up 
scan, was 12 (range 10-20). Although 20 patients developed new T2 lesions at three 
months (Table 4.5), only 14 had new gadolinium enhancing lesions. Specificity of the 
McDonald criteria at three months for CDMS at three years was 95% but sensitivity 
was only 58% (Table 4.6). Eight patients, who did not fulfill the McDonald criteria at 
three months, developed CDMS at three years. Addition of a new T2 lesion to the 
criterion of MRI DIT at three months also had high specificity (92%) and better 
sensitivity than the McDonald criteria (74% versus 58%). Only five patients who 
failed to fulfill these MRI criteria at three months developed CDMS after three years
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(Table 4.6). A new T2 lesion, irrespective of the number of lesions on the baseline 
scan, was sensitive (84%) and specific (89%) for CDMS (Table 4.6; all patients with 
new T2 lesions at three months had one or more baseline MRI brain lesions). Four 
patients received IFNBeta during the three years of follow up but only after the three 
month MRI follow up and after they had developed CDMS. Only four patients 
received a course of steroids for their CIS, two before and two after the baseline scan.
4.2.5. Discussion
The present report extends our previous application of the McDonald criteria to 
patients with CIS in chapter 4.1.[Dalton et al. 2002b] In Chapter 4.1, the new criteria 
were shown to have a high specificity and positive predictive value for CDMS when 
applied after three months of follow up. Low sensitivity was due to the low frequency 
of new gadolinium enhancing lesions required to fulfill the criterion of MRI DIT. A 
new T2 lesion for MRI DIT increases the number diagnosed with MS after three 
months (Table 4.5) and the sensitivity for CDMS increases (from 58% to 74%) with a 
maintained high specificity (95% versus 92%). Thus, modifying the existing 
McDonald criteria to include a new T2 lesion at three months is both sensitive and 
specific in the early diagnosis of patients with CIS.
The higher sensitivity of T2 versus gadolinium enhanced lesions on a 3 month scan is 
because a new T2 lesion usually persists whereas a new area of enhancement lasts, on 
average, one month [Miller et al 1993] [Thompson et al. 1992] [Smith et al. 1993]. 
New T2 lesions reflect activity over the whole interval, whereas gadolinium 
enhancing lesions reflect only the previous month. The McDonald criteria require 
enhancement at this stage as the writing panel considered MRI DIT needed new
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activity to occur at least three months after the clinical episode. A new T2 lesion 
could arise at any time during follow up, including within three months of the 
episode. However, the sensitivity and specificity of new T2 lesions appears sufficient 
to warrant their inclusion in the criteria.
On their own, new T2 lesions at three months were both sensitive (84%) and specific 
(89%) for predicting CDMS at three years. All 20 patients with new T2 lesions had an 
abnormal baseline scan, but three did not have MRI DIT. Further evaluation to 
determine the optimal MRI criteria for DIS may be warranted.
As MRI criteria can now be used to make a diagnosis of MS in patients presenting 
with CIS a number of caveats are suggested to ensure reliable application. First, the 
diagnosis should be made by a clinician experienced in CNS demyelinating disease. 
Secondly, MRI evaluation should be performed by a neuroradiologist or other 
clinician, with extensive experience of MS and other white matter disorders. Thirdly, 
T2 lesions should be unequivocal - normally lesions are at least 3mm in diameter, 
observed on two different types of T2 sequence (e.g. on proton density and heavily T2 
weighted fast spin echo or on T2-weighted spin echo and FLAIR), and determined 
from high quality images. Fourthly, as our study was restricted to those aged between 
the age of 16 and 50 years, the accuracy of the MRI criteria outside these ages is 
uncertain. In children, acute disseminated encephalomyelitis (ADEM) is relatively 
common [Dale et al. 2000] and the specificity of the criteria in MS versus ADEM is 
unknown. In older adults, white matter lesions due to small vessel disease have the 
potential to reduce MRI specificity for MS. Fifthly, spinal cord MRI should also be 
performed when the CIS involves the cord, to exclude other disorders and to identify
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demyelinating cord lesions [Miller et al. 1987]. Finally, the detection of cerebrospinal 
fluid oligoclonal bands is sometimes useful. Both oligoclonal bands and MRI (Paty's 
and Fazekas' criteria) have high sensitivity for CDMS [Paty et al 1988][Fazekas et al 
1988][Tintore et al 2001].
In conclusion, we propose that in adults aged 16 to 50 years presenting with a CIS 
suggestive of MS, the McDonald MRI criteria for DIT are expanded to include new 
T2 lesions seen on a three month follow up scan when the first scan is obtained within 
three months of symptom onset.
Table 4.5 Patients with a diagnosis of MS at three months using MRI or clinical 
criteria
McDMS McDMS and new 
T2 lesion
Abnormal T2 scan, 
new T2 lesion and 
CDMS
MRI diagnosis only 8 12 15
CDMS only 1 0 0
MRI diagnosis and 4 5 5
CDMS
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Table 4.6 Performance of the McDonald criteria and new T2 lesions at 3 months 
in relation to the development of CDMS at 3 years
At 3 Months McDMS McDMS & new T2 
lesion
Abnormal T2 
scan, new T2 
lesion and 
CDMS
CIS/Criteria+ 2 3 4
CDMS/Criteria+ 11 14 16
ClS/Criteria- 35 34 33
CDMS/Criteria- 8 5 3
Sensitivity(95% Cl) 58% (34%-80%) 74% (49%-91%) 84 % (60%-97%)
Specificity (95% Cl) 95% (82%-99%) 92% (78%-98%) 89% (75%-97%)
PPV (95% Cl) 85 % (55%-98%) 82% (57%-96%) 80% (56%-94%)
NPV (95% Cl) 81% (67%-92%) 87 % (73%-96%) 92 % (78%-98%)
Accuracy (95% Cl) 82% (70%-91%) 86% (74%-94%) 87% (76%-95%)
CIS = clinically isolated syndrome at 3 years,
CDMS = clinically definite MS at 3 years
McDMS = Diagnosis of MS based on the McDonald criteria at 3 months 
Criteria+/- = fulfill/ do not fulfill the relevant diagnostic criteria at 3 months 
Cl = Confidence Interval
Sensitivity, specificity, positive predictive value (PPV), negative predictive value 
(NPV) and accuracy refer to the performance of the diagnostic criteria at 3 months in 
relation to the development of CDMS.
115
Chapter 5 
5. Atrophy: Ventricular volumes (MIDAS) and brain segmentation (SPM99)
5.1 Progressive ventricular enlargement in patients with CIS is associated with 
the early development of MS
5.1.1. Aims
The aims of the study were to confirm a preliminary study in a subgroup of this cohort 
of patients which showed measurable Ventricular Enlargement (VE) over one year in 
some patients with CIS. We also wanted to clarify whether VE is associated with the 
early development of MS, using conventional clinical criteria and the new McDonald 
criteria and finally we wanted to determine the relationship between VE and MR 
measurements of lesion load at this early stage of disease.
5.1.2. Introduction
Previous radiological and pathological studies have established that whole brain 
[Gross et al 1993] [Davie et al 1995] [Liu et al 1999][Ge et al 2000] and spinal cord 
atrophy [Filippi et al 1997a][Losseff et al 1996c] occur in MS in excess of that 
expected with age. In one study, progressive cerebral atrophy over one year has been 
detected using registered, volumetric MRI to measure both brain and ventricular 
volumes [Fox et al. 2000], with a rate of cerebral atrophy in MS shown to be twice 
that seen in normal controls and the rate of ventricular enlargement five times that of 
controls. There was also a good correspondence between global brain atrophy and 
ventricular enlargement [Fox et al 2000].
While the mechanisms of atrophy in MS are not well understood, it probably indicates 
loss of functionally important structures: myelin and axons, which are the majority 
bulk of brain white matter, although variable effects on tissue volumes may also arise
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from glial cell proliferation or loss, gliosis, inflammation and oedema. [Miller et al
2002] A correlation between reduced cerebral white matter N-acetyl aspartate (a 
neuronal marker) and cerebral atrophy suggests that axonal loss may make a 
contribution. [Coles et al. 1999] However the relationship between atrophy and 
decreased NAA is non linear,[Collins et al. 2000] and factors other than axonal loss 
are also likely to effect these MR measures. In general, disability in MS has been 
more strongly correlated with measures of atrophy than lesion load.[Kalkers et al 
2001a][Losseff et a l 1996b] However, only modest correlations between atrophy and 
lesion load have been observed. [Losseff et al 1996b][Paolillo et al 2000] This could 
indicate that atrophy develops by mechanisms, some of which are independent of 
lesions, or that there is a temporal dissociation between lesion accumulation which 
occurs early in the disease process and atrophy, which occurs late.
To investigate the onset of atrophy and its relationship to lesions and clinical events, 
we studied patients presenting with CIS suggestive of MS. The study of this cohort 
allows an investigation into the earliest clinical stages of MS, since long term follow- 
up indicates that the majority of CIS patients with MRI brain lesions will go on to 
develop CDMS.fO'Riordan et al 1998b][Brex et al 2002][Ghezzi et al 1999] In the 
present report, atrophy was evaluated using a measure of VE. [Dalton et al 2002a] 
This study follows a previous preliminary pilot study of a small, selected group of 17 
from within the present larger cohort of 55 patients. [Brex et al 2000]
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5.1.3. Methods
Patients
We recruited adult patients, aged between 17 and 50 years, who presented to our 
clinics at Moorfields Eye Hospital or the National Hospital for Neurology and 
Neurosurgery with CIS suggestive of MS. Appropriate investigations including full 
blood count, ESR, autoantibody screen, syphilis serology, vitamin B12, and MRI 
brain were used to exclude other diagnoses. Fifty five patients were recruited 
consecutively from January 1996 until June 1999 (16 patients, recruited prior to a 
hardware upgrade to the scanner in January 1996 were excluded from this study 
because serial evaluations pre and post upgrade revealed instability of volume 
measures. On going quality assurance protocols have confirmed the stability of 
measurements since January 1996). A CIS was defined as a single event of acute 
onset in the central nervous system suggestive of demyelination, e.g. unilateral optic 
neuritis, brainstem and partial spinal cord syndromes. Individuals with a history of 
previous neurological symptoms suggestive of demyelination were excluded. Other 
diagnoses were excluded by appropriate investigations.
Overall, 38 patients had optic neuritis, 1 1 a  brainstem syndrome, 5 a spinal cord 
syndrome (spinal MRI excluded an alternative structural cause in these cases) and 1 
patient had a hemianopia attributable to an MRI lesion in the optic tract. The age 
range at baseline was 17 to 50 years with a median age of 31 years. The upper age 
limit of 50 years was applied in order to reduce the likelihood of including patients 
with white matter lesions due to small vessel disease and because onset of MS above 
this age is less common. Local ethics committees approved the study and informed 
consent was obtained from each patient before entry. Patients were imaged on three
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occasions: (i) at baseline, which in all instances was within 3 months of the onset of 
symptoms, (ii) approximately 3 months later, and (iii) approximately one year later. 
Clinical examination and EDSS [Kurtzke 1983] were performed at each visit. The 
diagnosis of clinical MS (clinically definite or probable) was based on the Poser 
criteria,[Poser et al 1983] using clinical criteria alone (MRI or CSF findings were not 
incorporated). CDMS was diagnosed when a second relapse occurred more than one 
month after the CIS, which involved a separate part of the CNS and was accompanied 
by new findings on examination. Clinically probable MS was diagnosed when there 
was a history indicating a new relapse involving a separate location but there were no 
new signs on examination. The new McDonald MRI criteria, which additionally allow 
a diagnosis of MS in CIS patients based on MRI evidence of Dissemination of lesions 
in Time (DIT) and space (DIS), were also applied. [McDonald et al 2001]
Image acquisition
MRI was performed using a 1.5 Tesla GE scanner. At baseline, 3 months and one year 
each, a proton density/T2 weighted fast spin-echo (FSE) sequence (repetition time 
[TR] 3200 msec, effective echo time [TE] 15/95 msec) and a T1 weighted spin echo 
sequence (TR 600 ms TE 14 ms) were acquired in each patient, with 3mm contiguous, 
axial slices. The matrix used was 256x256 with a field of view of 24 cm. Each patient 
was given an intravenous bolus of 0.1 mmol/kg gadolinium DTPA 5-7 minutes prior 
to the commencement of image acquisition.
Ventricle Volume (VV) measurement
The ventricles were measured on baseline and one year follow up T1-weighted scans 
using the MIDAS interactive image analysis package by a single observer blinded 
both to patient details and scan acquisition order (the 3 month scan was not analyzed
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using MIDAS as it was considered unlikely that change would be detectable over this 
short period). The initial step was segmentation of the whole brain using a semi 
automated interactive morphologic technique with the image intensity threshold for 
the boundary between the CSF and brain set at 60% mean signal intensity. The 
inferior cut-off was taken at the lowest point of the cerebellum. VV consisted of the 
lateral ventricles and temporal horns but excluded the third and fourth ventricles. This 
was measured using a semi-automated seed placing technique, involving voxels with 
an image intensity of less than 60% of the mean (Figure 5.1). MIDAS also provides a 
measure of change in whole brain volume, but on the 2-dimensional images available 
for this study, this measure required considerable time and manual editing. The 
analysis was therefore confined to VV only.[Freeborough et al 1997]
Reproducibility of the ventricular measurement technique
Ten VVs were measured and re-measured after 7 days by a single observer blinded to 
both patient details and scan acquisition order. The mean coefficient of variation was 
0.89% prior to starting image analysis.
Lesion identification and lesion load measurement
The MRI scans were reviewed by an experienced neuroradiologist (KAM), who was 
blinded to the patients’ clinical status at follow up. T2 weighted lesions were 
identified on the PD weighted images with confirmatory support from the long TE 
image, on both the baseline and one year follow up scans. T1 hypointense and 
gadolinium enhancing lesions were identified on the T1 weighted scans. T1 
hypointense lesions were identified at baseline and one year follow up. Enhancing 
lesions were identified on all 3 scans (baseline, 3 months and 1 year). The volumes of
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T2 and T1 hypointense lesions at baseline and one year were subsequently calculated 
from electronic data on a Sun Workstation using a semi automated local thresholding 
technique to contour the lesions. [Plummer 1992]
Statistical analysis
Comparison was made between the baseline and one year VVs using the Wilcoxon 
signed rank test (Tables 5.2 and 5.4). The Mann Whitney U test was used to compare 
baseline lesion load measures in patients who developed MS and those who had no 
further symptoms (Table 5.3). Correlations between lesions measures and VV change 
were performed using Spearman’s non parametric correlations. The Bonferroni 
correction was applied by dividing the number of analyses into 0.05. The p value for 
significance was then calculated at 0.003 (Table 5.5).
5.1.4. Results
Baseline MRI findings (Table 5.2)
The median time delay between the onset of symptoms and baseline scan was 6 
weeks, with a range of 1 to 12 weeks. At baseline, 40/55 (73%) patients had one or 
more lesions detected on T2-weighted MRI, of whom 21 also exhibited one or more 
hypointense lesions on T1-weighted images and 15 displayed one or more gadolinium 
enhancing lesions. VVs varied markedly between subjects (range 1.2-39.2cm3; see 
Table 5.2, Figures 5.2 and 5.3). There was no significant difference in baseline VVs in 
patients depending on gender (p=0.8), with or without T2 lesions (p=0.3), T1 lesions 
(p=0.9) and gadolinium enhancing lesions (p=0.2) (Mann Whitney U test for all
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comparisons). There was no correlation between baseline VV and subsequent atrophy 
(r=0.17 and p=0.23).
Follow up findings (Tables 5.1-5.5) 
Clinical outcome
The median time between the baseline and one-year follow up was 12 months (range 
11-16 months). Thirty-seven patients remained asymptomatic, while 18 patients 
developed CDMS (n=14) or probable MS (n=4) during the 1-year follow-up period. 
Sixteen of the 18 patients who developed clinical MS had abnormalities on the T2 
scan at baseline.
The relationship between lesions and clinical outcome
The baseline number of T2, T1 hypointense and gadolinium enhancing lesions was 
significantly higher in those who went on to develop clinical MS compared with those 
who did not (Table 5.3). The baseline volumes of T2 and T1 hypointense lesions were 
also significantly higher in those who developed MS (Table 5.3).
The relationship between VE and clinical outcome
There was a significant increase in VV over one year in the 18 patients who 
developed clinical MS during the 1-year follow-up period (p=0.006, Table 5.2). A 
significant increase in VV was also seen in the 16 patients with T2 lesions at baseline 
who developed clinical MS at 1 year (median increase 0.9 cm3, p=0.002). There was 
no significant correlation between VE and baseline EDSS, month 12 EDSS or change 
in EDSS over the year, using the Bonferroni correction (Table 5.5).
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The relationship between VE and the McDonald criteria for MS
The baseline, three month and one year scans were retrospectively analyzed to see 
how many patients fulfilled the new McDonald criteria for the diagnosis of 
MS.[McDonald et al. 2001] Patients with CIS with MRI evidence of DIS and DIT 
were diagnosed as having McDonald MRI MS. Twenty-seven of the 55 patients were 
McDonald criteria positive at one year (Table 5.1).
The relationship between VE and lesion load measures 
Subgroup comparisons (Table 5.4)
Significant VE was seen in the group of 40 patients with T2 lesions at baseline 
(p=0.001) but not in the 15 patients with normal scans at baseline (p=0.46, Table 4). 
The 15 patients with gadolinium enhancing lesions at baseline had significant VE at 
one year (p=0.004, Table 5.4).
The 14 patients who had gadolinium enhancing lesions at 3 months also showed 
significant VE at one year (baseline median 5.7cm3 [2.6 -  25.9], one year median 
6.7cm [2.9 -  26.5], p=0.006). The 7 patients who had enhancing lesions at both 
baseline and 3 months exhibited a substantial increase in VV (baseline median 7.9cm3 
[3.2 -  25.9], one year median 12.9cm3 [3.7 -  26.5], p=0.02).
VVs in the 21 patients with T1 hypointense lesions at baseline showed significant 
enlargement over the following year (p=0.001), but there was no significant change in 
the 19 patients who had T2 lesions but no T1 hypointense lesions (Table 5.4).
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Correlations (Table 5.5)
Four correlations with VE were significant, namely the baseline T1 hypointense 
lesion number and volume and one year T1 hypointense and T2 lesions volumes.
5.1.5. Discussion
This study has confirmed previous reports in demonstrating that the presence and 
number of MRI lesions at presentation with a CIS influences the risk of future clinical 
relapses leading to an early diagnosis of CDMS or probable MS. Additionally, it 
revealed VE over one year in the subgroup of patients who developed clinical MS 
within that period. It also demonstrated VE in the larger cohort of patients with T2 
MRI lesions at presentation, the presence of which is associated with a high 
probability for developing CDMS after prolonged follow-up. [O'Riordan et al 
1998b][Brex et al 2002][Ghezzi et al. 1999] Finally, the study demonstrated 
significant, but only modest, correlations between T2 and T1 hypointense lesion load 
measures and subsequent VE.
A question arising is whether the VE might reflect a reduction in brain water content 
(pseudo atrophy) rather than true tissue loss. There was no significant difference in 
the gadolinium enhancing lesion number between the baseline and 1 year follow-up 
scans (data not shown), so that a spontaneous decrease in the number of inflammatory 
oedematous lesions did not account for the VE seen. Anti-inflammatory treatments 
such as corticosteroids [Hoogervorst et al. 2002] or IFNbeta can reduce the number of 
inflammatory oedematous lesions, but in the present study only three patients received 
steroids (one received IFNbeta) during the follow-up phase.
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There have been few prior studies investigating atrophy in CIS patients. My group 
previously reported a preliminary study of a small, selected group from within the 
present larger cohort, consisting of 9 patients with T2 lesions at baseline who 
developed MS during 1 year of follow-up and 8 patients with a normal baseline scan 
who had no further clinical events. In that study Brex et al reported significant VE in 
the subgroup with T2 lesions.[Brex et a l  2000] Secondly, Brex et al recently 
investigated cervical cord in 43 CIS patients demonstrated mild but significant 
atrophy of the upper cervical cord in those patients who had T2 abnormalities on brain 
imaging [Brex et al 2001a].
The present investigation of a large cohort of consecutively recruited CIS cases 
confirms our preliminary observation in the smaller cohort that early development of 
VE is associated with further clinical relapses leading to a diagnosis of MS. The 
development of ventricular atrophy in association with early clinical relapses suggests 
a potential for this MR measure to provide prognostic data, which needs to be 
confirmed with long term follow-up. There is some evidence from the literature, albeit 
inconsistent, that relapse rate in the first 1-2 years after a CIS is related to long term 
disability. [Weinshenker et a l 1989] The relationship between early atrophy and long 
term disability should be investigated by prolonged follow up.
A possible mechanism for the observed VE would be loss of myelin and axons within 
lesions per se, and Wallerian degeneration secondary to axonal transection within the 
lesions. Consistent with this mechanism are the correlations, albeit weak, between the 
baseline and month 3 number of enhancing lesions and VE. Enhancement is 
associated with pathological evidence of active inflammation [Katz et al 1993][Bruck
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et al. 1997] and inflammation is associated with axonal damage and 
transection. [Ferguson et al. 1997] [Trapp et al. 1998] The small group of patients with 
enhancing lesions at both baseline and month three exhibited more substantial VE. 
The more aggressive inflammatory disease may have contributed to this.
A modest correlation of VE was also found with baseline T2 and T1 hypointense 
loads but was somewhat stronger for T1 load. T1 hypointense lesions are associated 
pathologically with more severe axonal loss, [Van Waesberghe et al. 1999] and thus 
might be expected to result in a greater degree of secondary Wallerian degeneration 
and atrophy. It was notable that in the subgroup comparison of those with and without 
T1 hypointense lesions at baseline, significant VE was seen only in those with such 
lesions. T1 hypointense lesions in this study were detected on post contrast scans -  
they are thus likely to indicate irreversible changes associated with axonal loss rather 
than the reversible hypointensity sometimes seen in acute enhancing lesions. The lack 
of correlation between change in T1 hypointense load over the year and VE may 
reflect the fact that the magnitude of the former was very small.
Since none of the correlations between lesion measures and VE were strong, 
additional factors may contribute to atrophy. One possibility is a more diffuse process 
involving normal appearing tissues. To date, quantitative MR investigations of normal 
appearing brain tissues have provided conflicting evidence of abnormality in small 
CIS cohorts.[Brex et al. 1999a][Brex et al. 200lb][Kaiser et al. 2000][Iannucci et al. 
2000] An MR spectroscopy report demonstrated no significant reduction of N-acetyl 
aspartate in the normal appearing white matter. [Brex et al 1999a] Further quantitative
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MR investigations of the normal appearing brain tissue are needed in larger CIS 
cohorts.
The technique used in the present study does not resolve the site of atrophy. While the 
MIDAS method used in this study provides a reliable measure of change in whole 
brain volume on 3D images, we found it less reliable with the present 2D dataset. It is 
not therefore certain whether atrophy occurs close to lesions, in normal appearing 
white matter, or in grey matter, although the fact that the ventricles are close to white 
matter suggests that there may be atrophy in this region. There are alternative 
strategies for measuring segmented grey and white matter volumes which have been 
applied in Chapter 5.2.[Chard et al 2002c] Approaches such as voxel based 
morphometry may depict the regions in which atrophy is occurring. Application of 
such methods in future studies in CIS patients will be of interest.
The study of atrophy may help to understand the clinical effects of disease modifying 
treatments for MS. In established disease, beta interferons and glatiramer acetate 
markedly reduce the rate of new MRI lesions (by 50-70%; IFNB study 1993[Paty and 
Li 1993] [Jacobs et al 1996; 1998a] [Comi et al 2001b], but they have a smaller effect 
in preventing relapses, disability and atrophy [Rudick et al 1999][Rudick et al 
1999b][Molyneux et a l 2000] [Gasperini et al 2002] [Simon et al 1999] [Rudick et al 
2000] [Rovaris et a l 2001] [Fisher et al 2002]. Future reports of the effect of treatment 
on atrophy in CIS patients are awaited, but the present work highlights the potential 
for a mechanism of clinical deterioration that is independent of lesions.
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While the present knowledge suggests that atrophy is occurring at the earliest clinical 
stage of MS, a direct comparison with other studies at a later stage is not possible, 
since the methodology involved has differed. There are a number of sensitive and 
reproducible methods for detecting brain atrophy but they may produce quite a 
different absolute measure of change. [Miller et al. 2002] Further study of cohorts with 
later disease using the same MR acquisition and analysis method for measuring VE is 
now being undertaken. Further follow up of the CIS cohort is now needed to 
determine the longer term evolution of atrophy, and its relationship to lesion
evolution, quantitative MR changes in the normal appearing tissues, and clinical
;
outcome.
In conclusion, the present study reveals two MR features in patients with CIS who go 
on to develop early clinical MS - lesions and atrophy. While lesions contribute to 
atrophy, the correlation is modest, suggesting that the latter also develops by other 
mechanisms. Both measurement of lesions and atrophy are therefore complementary 
methods for monitoring the course of MS, even from its earliest stages.
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Table 5.1 Patient details
Clinical status after one year Early MS Asymptomatic
Sex, M/F 6/12 18/19
Age in years median (range) 30.5(17-49) 31(18-50)
Weeks from onset to baseline scan median (range) 6.5(1-12) 5(2-11)
Months from baseline to year 1 scan median (range) 12(11-15) 12(12-16)
EDSS at baseline median (range) 1.5 (0- 8) 2 (0- 4)
EDSS at one year median (range) 2 (0- 8) 1 (0- 3)
Clinical status after one year McD MS McD MS negative
Sex, M/F 10/17 14/14
Age in years median (range) 31(17-47) 31(18-50)
Weeks from onset to baseline scan median (range) 5(1-12) 6(2-11)
Months from baseline to year 1 scan median (range) 12(11-16) 12(12-14)
EDSS at baseline median (range) 1 (0- 8) 2 (0- 4)
EDSS at one year median (range) 1 (0- 8) 1 (0- 3.5)
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Table 5.2 Comparison of W  in patients who developed clinical MS and
McDonald MS versus those who did not develop clinical and McDonald MS
Baseline VV cm3 median Early MS n=18 Asymptomatic n=37 Total n=55
(range) *5.4(1.2- 39.2) **6.0(1.5-23.1) 5.9(1.2-39.2)
1 year follow up VV cm3 *7.7(1.3- 40.6) **6.2(1.7-24.1) 6.3 (1.3-40.6)
median (range)
***yy change cm3 median +0.5 (-0.6- 7.2) +0.06 (-0.9- 1.4) +0.1 (-0.9- 7.2)
(range)
Comparing baseline versus one year VVs *p=0.006, **p=0.402
Comparing VV change in MS and those with no further symptoms ***p=0.007
McDonald MS n=27 McDonald MS negative n=28
Baseline VV cm3 median *6.0(1.2- 39.2) **5.3 (1.7- 23.1)
(range)
1 year follow up VV cm3 *8.1(1.4- 40.6) **5.2(1.7- 24.1)
median (range)
***yy change cm3 median +0.3 (-0.7- 7.2) +0.05 (-0.9- 1.4)
(range)
Comparing baseline versus one year VVs *p=0.005, **p=0.632
Comparing VV change in patients with McDonald MRI MS (n=27) and those without
(n=28) ***p=0.03.
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Table 5.3: Comparison of baseline lesion measures in patients who developed MS
and those who remained asymptomatic
Early MS (18) Asymptomatic (37) P value
Number of T2 lesions at baseline 20 (0-70) 2 (0- 76) p=0.001
Volume of T2 lesions at baseline 1.7 (0-13.9) 0.3 (0- 5.2) p=0.001
cm3 median (range)
Number of Gd-DTPA lesions at 1.5 (0-21) 0(0- 13) p<0.001
baseline
Number of T1 hypointense 1 (0-18) 0 (0-2) P=0.001
lesions at baseline
Volume of T1 hypointense lesions 0.09 (0-4.5) 0 (0-0.6) p=0.001
at baseline cm median (range)
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Table 5.4: Ventricular volumes VV in patients with a normal and abnormal MRI, with and without Gadolinium (Gd) 
enhancing and T1 hypointense lesions at baseline.
Normal & abnormal baseline Abnormal baseline MRI Abnormal baseline MRI
MRI (n=55) (n=40) (n=40)
Normal MRI Abnormal Gd lesions No Gd lesions T1 hypointense No T1
(n=15) MRI (n=40) (n=15) («=25) lesions (n=21) hypointense
lesions (n=19)
Baseline VV cm3 
median (range)
4.3 (2.6- 23.1) 6.4 (1.2- 39.2) 7.9 (3.1-25.9) 5.9(1.2-39.2) 6(1.2-25.9) 6.9 (1.7- 39.2)
Year 1 VV cm3 
median (range)
4.4 (2.4- 24.1) 6.8 (1.4- 40.6) 10.3 (3.2-26.5) 6.5 (1.4- 40.6) 6.7(1.4-26.5) 7(1.7- 40.6)
VV change cm3 
median (range)
-0.2 (-0.9-1.0) 0.2 (-0.7 - 7.2) +0.7 (-0.6- 7.2) +0.1 (-0.7- 1.6) +0.5 (-0.6- 7.2) +0.03 (-0.7- 1.9)
Comparing baseline 
and year 1 VV
P=0.46 P=0.001 P=0.004 P=0.069 P=0.001 P=0.376
132
Table 5.5 Correlation of change in VV over one year with other MRI lesion 
measures and with EDSS
Correlation R value P value
Baseline T2 lesion number 0.339 0.011
Baseline T2 lesion volume 0.381 0.004
Change in T2 lesion volume over 1 year 0.202 0.138
Sum of baseline and new T2 lesion numbers at 1 year 0.386 0.006
Number of new T2 lesions at month 12 compared with baseline 0.254 0.061
1 year T2 lesion volume 0.447 0.001*
Baseline Gd lesion number 0.354 0.008
Month 3 Gd lesion number 0.367 0.007
Baseline and month 3 Gd lesion number 0.38 0.006
Month 12 Gd lesion number 0.206 0.132
Baseline, month 3 and month 12 Gd lesion number 0.385 0.005
Baseline T1 hypointense lesion number 0.495 <0.001*
Baseline T1 hypointense lesion volume 0.467 <0.001*
Change in T 1 hypointense lesion volume over 1 year 0.05 0.735
1 year T1 hypointense lesion volume 0.421 0.001*
Baseline EDSS 0.132 0.335
EDSS at ml2 0.317 0.019
EDSS change over 1 year 0.116 0.398
*significant correlations using Bonferroni correction p<0.003
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Figure 5.1 Baseline and 1 year ventricular volumes in MS
Baseline Ventricular Volume = 5.6 cm3 One Year Ventricular Volume =12.8 cm3
Ventricular segmentation: seeds are inserted into the lateral ventricles and temporal horns. High signal choroid is 
excluded. This 29 year old male presented with left optic neuritis in 1998. Two months later he developed numbness 
on the right side of his face. He had 3 relapses between his baseline and 1 year scans.
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Figure 5.2: Scatter plot of VVs at baseline and 1 year in the 37 patients with CIS
at one year
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Figure 5.3: VVs at baseline and one year in the 18 MS patients
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Figure 5.4: Error bar plot of VE in patients with CIS and MS.
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5.2. Early development of MS is associated with progressive grey matter 
atrophy in patients presenting with CIS
5.2.1. Aims
The aim of this study was to determine which tissues are affected by axonal loss or 
atrophy by segmentation into Grey Matter (GM), White Matter (WM) and CSF.
5.2.2. Introduction
MS initially presents as a CIS such as optic neuritis, brain stem or spinal cord 
syndromes in 85% to 90% of patients. Sixty-80% of patients presenting with CIS 
suggestive of MS who have MR visible brain lesions go on to develop CDMS.[Brex 
et al 2002] [Beck et al. 2003] However, while lesions are associated with the 
development of MS, there is only a limited relationship between lesion accrual and 
subsequent disability. This may reflect pathological heterogeneity within lesions, with 
variable effects on nerve conduction and clinical function. Axonal and neuronal 
damage have become the focus of significant attention [Trapp et al. 1998][Bjartmar et 
al 2001][Bjartmar and Trapp 2001 ] [Cifelli et al. 2002] and may be more salient when 
considering long-term outcomes, with atrophy measures potentially acting as a more 
specific marker of such pathology than lesion volume measures [Miller et al. 2002]. 
This is supported by the observation that in established MS, atrophy of the brain and 
spinal cord is more noticeable with increasing disability [Losseff et al. 1996b][Losseff 
et al. 1996c].
Relatively little investigation of atrophy has been undertaken in patients in the earliest 
stages of MS. Studies at the early stage of disease have potential to identify prognostic 
markers and techniques for therapeutic monitoring and may provide insights in to
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disease pathogenesis. In previous studies in patients with CIS, progressive Ventricular 
Enlargement (VE) was detected over one year in those with an abnormal MRI [Brex 
et al 2000]. In this study we report global (brain parenchymal fraction (BPF)) and 
regional (grey matter (GM) fraction (GMF), white matter (WM) fraction (WMF)) 
measures of brain volume changes, as well as a measures of ventricular volume (VV) 
change in 58 subjects with CIS, scanned within three months of the onset of the CIS 
and again three years later, when 31 (53%) of patients had developed MS as defined 
by the McDonald criteria. [McDonald et al 2001] The clinical and MRI lesion 
findings of most subjects in the present cohort have been previously reported [Dalton 
et al 2002b] [Dalton et al. 2003a]. The purposes of the present study were to 
determine: (i) the location of early brain atrophy; (ii) the relationship of early brain 
atrophy - both global and tissue specific - with the development of MS, and (iii) the 
relationship of early brain atrophy with focal lesion load measures.[Dalton et al 
2004]
5.2.3. Methods 
Patients
Subjects aged between 17 and 50 years presenting at Moorfields Eye Hospital or the 
National Hospital for Neurology and Neurosurgery with CIS suggestive of MS were 
invited to participate in this study. Fifty-eight patients were recruited from 1995 to 
1999, and followed up for approximately 3 years. A CIS was defined as the first acute 
neurological event suggestive of CNS demyelination, e.g. unilateral optic neuritis, 
brainstem and partial spinal cord syndromes, where no alternative diagnosis was 
identified upon appropriate investigation. Overall, 40 patients presented with optic 
neuritis, 13a brainstem syndrome, four a spinal cord syndrome (spinal MRI excluded
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an alternative structural cause in these cases) and one patient had a hemianopia 
attributable to an optic tract lesion. Patients were clinically assessed using the Kurtzke 
expanded disability status scale (EDSS) [Kurtzke 1983] and MRI scans obtained upon 
entry to the study (within 3 months of symptom onset) and approximately three 
months, one and three years later. A diagnosis of MS was determined according to the 
McDonald criteria and included both MRI and clinical evidence for Dissemination in 
Space (DIS) and Time (DIT).[McDonald et al 2001] The study was undertaken with 
approval by the local ethics committee and written informed consent was obtained 
from all the study subjects.
Image acquisition
Brain MRI was performed using a 1.5 Tesla GE scanner (General Electric Medical 
Systems, Milwaukee, WI, USA). At baseline, three months, one and three years, a 
proton density/T2 weighted fast spin-echo (FSE) sequence (repetition time [TR] 3200 
msec, effective echo time [TE] 15/95 msec) and a T1 weighted spin echo sequence 
(TR 600 ms, TE 14 ms) were acquired in each patient after IV administration of 0.1 
mmol/kg gadolinium (Gd) DTPA 5 to 7 minutes prior to the start of image 
acquisition. Patients were repositioned using a reproducible technique for serial 
imaging studies.[Gallagher et al. 1997] Forty-six, 3mm contiguous axial slices were 
obtained with an in-plane resolution of 0.9 by 0.9 mm.
Lesion identification and measurements
The MRI scans were reviewed by an experienced neuroradiologist (KAM), who was 
blinded to the patients’ clinical status at follow-up. T2, Gd-enhancing and T1 hypo­
intense lesions were identified at baseline, three months, one and three years of
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follow-up. Using a semi-automatic local thresholding technique, lesions were 
segmented on the PD-weighted FSE images and T1 -weighted post gadolinium 
enhanced images, which provided T2 hyper-intense and T1 hypo-intense lesion 
volumes respectively. [Plummer 1992]
Brain tissue segmentation
The baseline and 3-year follow-up T2-weighted images were segmented using a fully 
automated technique into images representing the probability of any given voxel 
containing GM, WM, CSF and other tissues using SPM99.[Chard, et al. 2002c] 
Lesions were identified and contoured using the same semi-automated lesion 
segmentation technique as noted above and used to allow for SPM99 misclassification 
of WM lesions as GM, CSF or other tissues. The lesion mask over-rode all SPM99 
tissue classifications, otherwise a voxel was classified as GM, WM, CSF or other 
tissue, dependent on which mask had the greatest probability at that location. Results 
were assessed as fractions of total intracranial (TI) volume, determined by adding 
GM, WM, lesion and CSF volumes. BPF was calculated as GM, WM plus lesion 
volume divided by TI volume. WMF was calculated as WM plus lesion volumes 
divided by TI volume. GMF was calculated as the GM volume divided by the TI 
volume.
The segmented brains were then visually checked for quality assurance to ensure GM, 
WM and CSF had been correctly segmented. In 13 scans, two measurements of the 
segmented were made at least one week apart in order to assess reproducibility of the 
method. The mean coefficients of variation for GM, WM and CSF were respectively
0.0002%, 0.0003%, 0.0006%.
140
To investigate whether the higher lesion loads in the MS group when compared with 
the CIS group (see Table 4) might have influenced the segmented atrophy measures, 
simulated lesions were added by Gerard Davies to the three year scans of the CIS 
group such that the group had a median and range of lesion load increase similar to 
the MS group. The size and signal intensity of the simulated lesions were 
characteristic of MS lesions seen on T2-weighted scans. The signal intensity of 
lesions was set at a level half way between GM and CSF intensity. The lesions were 
placed at multiple locations in the cerebral white matter of the T2-weighted scans 
used for subsequent atrophy analysis. Measurement of the GMF and WMF of the CIS 
group with simulated lesions were obtained and compared with the measures made 
without such lesions.
Ventricle volume measurement
The ventricles were measured on baseline and 3-year follow-up TI-weighted scans 
using the MIDAS interactive image analysis package by a single observer blinded to 
patient details in a previously described method [Freeborough et al. 1997] [Fox et al. 
2000] [Dalton et al. 2002a]. VV was estimated for the lateral ventricles and temporal 
horns but excluding the third and fourth ventricles; this approach has been previously 
applied in multiple sclerosis and demonstrated to have a good reproducibility and 
sensitivity to change [Fox et al. 2000].
Statistical Methods
Patients were divided into one of two principal groups according to their 3-year 
follow-up status:
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i. those with a diagnosis of MS by the McDonald criteria using both clinical 
and MRI evidence for DIS and DIT (31 subjects)
ii. those who still had a diagnosis of a CIS (27 subjects); for some analyses 
this group was further divided in to those who had MR visible brain 
lesions (13 subjects) and those without MR visible brain lesions (14 
subjects) at any time during follow-up.
Mean fractional volume changes over time within groups were estimated by linear 
regression adjusting for baseline value. Comparisons of differences in mean changes 
in fractional volumes over time between groups were assessed by adding a group 
indicator to the regression with baseline covariate. Baseline adjustment did not alter 
the point estimates, but improved precision. Where there was evidence of non- 
Normality the validity of inference was checked using a non-parametric bias- 
corrected bootstrap with 1000 replicates, [Carpenter and Bithell 2000] and where the 
bootstrap estimates differed these are reported. Non-parametric tests of change within 
group over time used the Wilcoxon signed rank test, and of differences in lesion 
volumes and changes between groups used the Mann-Whitney U test. Between group 
comparison in lesion numbers used negative binomial regression. Correlations 
between lesion load and atrophy measures were assessed using Spearman rank 
correlation.
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5.2.4. Results
Baseline clinical and MRI findings
The median time delay between the onset of symptoms and the baseline scan was five 
weeks, (range of 1 to 12 weeks). Thirty-nine patients (67%) had an abnormal baseline 
T2-weighted MRI scan with one or more focal high signal lesions. Of those, 16 had 
Gd-enhancing and 23 had TI hypo-intense lesions. The median EDSS at baseline in 
the group of patients with an abnormal baseline T2-weighted MRI scan was 2 (0 -  8) 
and 1 (0 -3 )  in those with a normal scan.
Diagnosis at three years
The median time between the baseline and the three-year follow-up scan was 37 
months (range of 31 to 72 months). At three years 31/58 (53%) had developed MS (13 
males and 18 females), and 27 had not. Of the latter group, 13 had a diagnosis of CIS 
with brain lesions (six males and seven females) and 14 had a diagnosis of CIS 
without brain lesions (eight males and six females). The median EDSS at 3 years was 
1 ( 0 - 8 )  in the MS group, 0 (0 -  1) in the CIS group with brain lesions and 0 (0 -  2) 
in the CIS group without brain lesions. The duration of follow up was not 
significantly different between those developing MS and those with a remaining CIS 
(median 1125 vs 1111 days, p = 0.47).
The relationship between atrophy and clinical outcome (Tables 5.6-5.8)
Table 5.6 shows global and regional brain and VV measures at baseline and 3 years 
for the MS and CIS subgroups. Table 5.7 shows absolute volume changes -  over 3 
years - in volume measures and Table 5.8 shows median and mean percentage volume 
changes for the MS and CIS subgroups. No statistically significant differences were
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found in mean 3yr -  baseline changes in BPF, GMF, WMF and VV between the CIS 
subgroups with and without lesions, and these two groups were combined for 
statistical comparisons.
A significant decrease in BPF over 3 years was seen in both the MS and combined 
CIS groups but the decrease was significantly larger in the MS group (Tables 5.7 & 
5.8). There was a significant increase in VV between baseline and year 3 in those who 
developed MS but not in the combined CIS group; the difference between the groups 
was significant. There was a significant decrease in GMF between baseline and year 3 
in both the MS and combined CIS groups but the decrease was significantly larger in 
the MS group (Tables 5.7 & 5.8). There was a weakly significant increase in mean 
WMF at 3 years compared to baseline in the patients who developed MS (Table 5.7; 
p=0.023); the median percentage change in these patients was +1.2% (Table 5.8; p = 
0.046). Though there was no significant change in WMF in the combined CIS group.
Seven patients were treated with short courses of steroids (three prior to the baseline 
scan; four between the baseline and year 3 scan); two of these were also treated with 
IFNbeta between baseline and year 3, and one patient received IFNbeta but not 
steroids. Five of these eight were in the group who developed MS, three were in the 
CIS non-lesion group. Exclusion of these eight patients did not affect MS versus CIS 
comparisons. Nor did exclusion of the patient with an EDSS of 8 affect these 
comparisons.
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Lesion measures in MS group versus CIS group with abnormal MRI (Table 5.9)
The MS group had higher T2 and TI hypointense lesion volumes and higher numbers 
of Gd enhancing lesions at baseline and year 3. The MS group also displayed a greater 
increase in T2 volume between baseline and year 3 but no difference was observed 
between the two groups in change in TI hypointense volume. Excluding patients 
treated with steroids and IFNbeta did not alter comparisons except for numbers of Gd 
enhancing lesions, which failed to reach significance.
Effect of simulated lesions on the segmented atrophy measures in the CIS group
When the three year CIS group segmented atrophy measures, with and without 
simulated lesions, were compared, the measures with simulated lesions displayed 
slightly higher GMFs and lower WMFs, but the differences were not significant 
(mean increase in GMF = +0.0032, 95% confidence intervals -0.00037, +0.0067, 
p=0.077, 2-tailed paired t-test; mean decrease in WMF = -0.00096, 95% confidence 
intervals -0.0022, +0.0003, p = 0.135, 2-tailed paired t-test).
Associations between lesion and atrophy measures (Table 5.10)
Change in BPF (3 year -  baseline) correlated negatively with the baseline number of 
Gd-enhancing lesions, and changes (3 year -  baseline) in TI hypo-intense and T2 
lesion volume. Change in VV (3 year -  baseline) correlated positively with baseline 
TI hypo-intense and T2 lesion volumes and Gd-enhancing lesion number, and with 
change (3 year -  baseline) in TI-hypointense and T2 lesion volumes. Change in GMF 
(3 year -  baseline) was modestly correlated negatively with changes (3 year -  
baseline) in TI hypo-intense and T2 volume. There were no significant correlations 
between lesion volumes and WMF changes.
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Associations between VV change and other tissue volume measurements
Three year -  baseline changes in VV correlated with changes in GMF (rs =- 0.393, p = 
0.002) and BPF (rs = - 0.453, p < 0.001), but not with changes in WMF (rs = +0.027, p 
= 0.839).
5.2.5. Discussion
Previous cross sectional studies have reported both total and neocortical GM atrophy 
-  in excess of that seen in healthy controls -  in early relapsing-remitting MS with 
disease durations of less than 3,[Chard et al. 2002b] 5,[De Stefano et al. 2003] and 
later RR and SPMS of disease duration 6.1 [Sailer et al. 2003] years respectively. The 
present study extends these observations in demonstrating that there is increasing GM 
atrophy in patients developing MS over 3 years following presentation with a CIS. 
The MS cohort also exhibited a significant increase in VV during the follow-up 
period. Although decreasing GMF was also seen in the 27 patients in the remaining 
CIS group, the decrease was significantly less than that observed in the MS group.
While it is likely that some individuals in the CIS group will develop MS with longer 
follow-up, the present study shows that progressive GM atrophy is more prominent in 
those CIS patients who develop MS within 3 years using the McDonald criteria. 
Although the small sample size limits the sensitivity of the analysis, no significant 
atrophy was detected in the 14 CIS patients with normal imaging, this being a group 
that has a relatively low risk for developing MS [Brex et al. 2002]. There was 
significantly greater VE seen in the MS versus the remaining CIS group, and the 
amount of increase in the MS group is also more than that reported from healthy 
young adult populations in the literature.[Fox et al. 2000].
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This study investigates tissue volume changes in MS at an early stage. This has been 
enabled by the recently developed McDonald criteria which allow a diagnosis based 
on MRI evidence for DIS and DIT in patients with single clinical episodes [McDonald 
et al. 2001]. Studying early MS has potential to identify markers which predict the 
future clinical course, and to find useful techniques for treatment trial monitoring that 
can be applied prior to the emergence of persistent neurological deficits.
In contrast to the development of GM atrophy, there was no decrease in WM volume 
in the MS group over the 3 years. Indeed there was a suggestion of an increase in the 
amount of WM. The MS group had a large increase in WM lesion load during the 
study. Lesions in early MS often display inflammation, and increased glial cellularity 
is also reported in MS normal-appearing WM (NAWM).[Allen et al. 2001] Such 
processes might contribute to an increase in tissue volume. Alternatively, loss of 
axons and myelin within inflammatory lesions,[Trapp et al. 1998] and axonal loss in 
NAWM would be expected to cause tissue loss. The observed result would be 
compatible with WM volume gain from inflammation compensating for loss due to 
axonal degeneration. Two previous MR spectroscopy studies of NAWM in CIS have 
shown no significant reduction of N-acetyl-aspartate, an axonal marker, which 
suggests that substantial WM axonal loss is not prominent this early stage.[Brex et al. 
1999a][Tourbah et al. 1999] Other techniques that assess intrinsic tissue 
characteristics may be of greater use than atrophy measures when evaluating 
longitudinal WM processes in early MS.
Because in the present study no healthy control group was available for comparison 
using an identical image acquisition sequence, we were unable to directly investigate
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whether the CIS cohort already had GM or WM atrophy at presentation. However, in 
a previous study of 40 CIS patients that used a different (5 mm thick) acquisition 
sequence for tissue volume analysis, we observed a significant decrease in WMF but 
not GMF compared with healthy controls, within 6 months of onset of the 
CIS.[Traboulsee et al. 2002] Taking that observation together with the present study 
raises the possibility that there are differences in the temporal evolution of GM and 
WM atrophy in CIS and early relapse onset MS, with GM atrophy emerging later and 
then evolving more rapidly. Further studies of other patient and control cohorts are 
warranted to define the temporal evolution of GM and WM atrophy in early MS.
GM atrophy might reflect neuronal degeneration secondary to anterograde or 
retrograde degeneration from WM lesions in which there has been axonal transection. 
Alternatively it could reflect the development of focal lesions within GM in which 
there is axonal loss. Current MRI methods are largely unable to detect focal GM 
lesions, although they are well recognised pathologically. [Kidd et al. 1999] [Peterson 
et al. 2001] GM lesions exhibit less inflammation than those seen in WM.[Kidd et al. 
1999] Volume changes in GM may thus provide a more direct measure of the 
neurodegenerative component of MS pathology, being relatively unaffected by 
fluctuations due to inflammation.
Perhaps surprisingly, the increase in VV was not accompanied by a decrease in WM 
volume. Possibly ventricular enlargement is more related to the focal effects of tissue 
loss in periventricular lesions rather than to global WM volumes.[Kalkers et al. 2002] 
The robust correlation of VE with lesion volume measures indicates that there is a 
notable relationship between focal lesions and this particular measure of atrophy. VE
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was also correlated with GMF changes, and a generalised remodeling of the brain 
secondary to GM atrophy may contribute to VE. In addition, the GMF includes deep 
periventricular structures such as thalamus and caudate nucleus, and atrophy in these 
regions may have contributed more directly to the VE.
VV, GMF and BPF are potentially useful outcome measures for monitoring disease 
modifying therapies in early MS, as in this study they were sensitive to progressive 
tissue loss. The GMF change correlated only modestly with lesion volume changes 
(Strongest correlation with T2 volume change: r=0.428; Table 5) suggesting that it 
provides additional information in understanding disease evolution and monitoring 
treatment effects. The Limited correlation between GMF and lesion load, accounting 
for <20% of variability in either measure (r2=0.17), also suggested segmentation bias 
associated with focal signal abnormalities does not alone account for the observed tissue 
specific volume changes.[Chard et al 2002b][Quarantelli et al 2003] Furthermore, 
we found only minimal changes to the 3 year GMF and WMF measures in the CIS 
group when simulated lesion loads approximating the increases seen in the MS cohort 
were introduced. The small changes observed were to slightly increase GMF and 
decrease WMF thus increasing the differences between the MS and CIS groups.
Further studies are warranted to confirm the present findings using different scan 
acquisitions and segmentation methodologies. Future studies should investigate the 
potential for early VV and GM volume measures to predict disability or cognitive 
impairment, and thereby help to identify patients in whom early disease modifying 
treatments are most needed. It will also be relevant to investigate the effect of current 
or future disease modifying treatments on these atrophy measures.
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Tables 5.6 Brain and VV measures at baseline and 3 years. Mean, median (range).
Total cohort
(n=58)
McDonald MS 
(n=31)
CIS
With lesions (n=13) Without lesions (n=14) CIS Combined (n=27)
BPF Year 0 0.864, 0.860 0.863, 0.856 0.868, 0.860 0.862, 0.861 0.865, 0.860
(0.80, 0.91) (0.80, 0.91) (0.85, 0.90) (0.83, 0.91) (0.83, 0.91)
BPF Year 3 0.855, 0.853 0.851,0.848 0.862, 0.856 0.858, 0.855 0.860, 0.855
(0.80-0.91) (0.80-0.91) (0.85 - 0.89) (0.83 - .91) (0.83, 0.91)
GMF Year 0 0.494, 0.490 0.490, 0.489 0.504, 0.500 0.494, 0.486 0.499, 0.491
(0.440 -  0.570) (0.44 -  0.55) (0.47 -  0.54) (0.47 - 0.57) (0.47, 0.57)
GMF Year 3 0.483, 0.479 0.473, 0.473 0.497, 0.497 0.490, 0.482 0.493, 0.493
(0.430 -  0.550) (0.43 -  0.54) (0.46 -  0.55) (0.46 -  0.55) (0.46, 0.55)
WMF Year 0 0.370, 0.369 0.373, 0.369 0.363, 0.363 0.368, 0.372 0.366, 0.365
(0.33-0.41) (0.35-0.41) (0.33 -  0.40) (0.33 -  0.40) (0.33, 0.40)
WMF Year 3 0.372, 0.371 0.377, 0.373 0.365, 0.363 0.368, 0.368 0.367, 0.365
(0.33 -  0.40) (0.33-0.40) (0.33 -  0.40) (0.34 -  0.39) (0.33, 0.40)
VV (ml) Year 0 8.605, 6.286 9.718, 8.569 6.844,4.572 7.776, 6.563 7.327, 5.848
(0.610-26.86) (1.22-26.86) (1 .6 8 - 19.88) (0.61-23.12) (0.61,23.12)
VV (ml) Year 3 9.972, 7.499 12.128, 11.198 7.335, 5.247 7.647, 6.307 7.497,5.701
(0 .740-28.91) (1.42-28.91) (1.79-22.31) (0.74-23.49) (0.74, 23.49)
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Table 5.7: Year three minus baseline changes in BPF, GMF, WMF and VV in the MS and CIS Groups
Atrophy MS
Mean change (Cl) and p value
CIS (combined)
Mean change (Cl) and p value
Baseline adjusted between 
group difference, Mean MS -  
CIS difference (Cl) and p value
BPF -0.012 (-0.016, -0.008) p = 0.001 -0.005 (-0.010, -0.0003) p = 0.038 -0.008 (-0.014, -0.001) p = 0.022
GMF -0.017 (-0.022, -0.011) p = 0.001 -0.005 (-0.011, 0.004) p = 0.03* -0.014 (-0.021, -0.006) p = 0.001
WMF 0.005 (0.0007, 0.009) p = 0.023 0.0005 (-0.004, 0.005) p = 0.820 0.006 (0.0003, 0.0123) p = 0.040
VV (mis) 2.410(1.301, 3.518) p = 0.001 0.170 (-1.018, 1.358) p = 0.775 2.305 (0.651, 3.958) p = 0.007
No statistical differences were noted in mean differences in BPF, GMF, WMF and VV changes from baseline to year 3 between the CIS groups
with and without lesions so these groups were combined for statistical purposes.* Bootstrap derived p value, Cl = 95% Confidence Interval
Table 5.8: Median and mean % change in 3-year BPF, GMF, WMF and VV (relative to baseline values)
MRI MS (n=31) CIS
parameter Median, Mean With MRI lesions (n=13) Without MRI lesions (n=14) CIS Combined (n=27)
Median, Mean Median, Mean Median, Mean
BPF -0.8% -1.4% -0.4 % -0.7% -0.6 % -0.5% -0.5 % -0.6%
GMF -2.1%-3.3% -1.4%-1.4% -1.2%-0.7% -1.4%-1.1%
WMF +1.2%+1.3% +1.1 % +0.4% +0.2 % +0.1% +0.8 % +0.2%
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Table 5.9 Comparison of lesion load measures and changes in lesion load 
measures (median plus ranges) in MS subjects versus CIS group with MRI 
lesions.
M RI param eter MS (n=31) CIS with MRI p-value
lesions (n=13) (Mann-Whitney U)
Baseline T2 lesion volume (ml) 1.1 (0.0 to 13.9) 0.2 (0.0 to 0.5) <0.001
3 year T2 lesion volume (ml) 2.5 (0.3 to 58.5) 0.2 (0.03 to 1.4) <0.001
T2 lesion volume change 0-3 (ml) 1.2 (-1.5 to 44.6) 0.1 (-0.3 to 1.0) <0.001
Baseline T1 lesion volume (ml) 0.1 (0.0 to 4.5) 0.0 (0.0 to 0.3) 0.008
3 year T1 volume (ml) 0.1 (0.0 to 18.3) 0.0 (0.0 to 0.4) 0.006
T1 lesion volume change 0-3 (ml) 0.1 (-2.0 to 13.8) 0.0 (-0.3 to 0.2) 0.196
Baseline Gd lesion number 0 (0  to 21) 0 (0 to 3) 0.0133
3 Year Gd lesion number 1 (0 to 6) 0 (0 to 1) 0.0163
aNegative binomial regression
Table 5.10: Spearman correlations between lesion load and atrophy measures.
A trophy measures Lesion load measures rs P
VV change year 3 - 0 Volume of T2 lesions at baseline 0.528 0.0002
Number of Gd-enhancing lesions at baseline 0.514 0.0004
Volume of T1 hypo-intense lesions at baseline 0.529 0.0002
T2 lesion volume change year 3-0 0.440 0.0028
T1 lesion volume change year 3-0 0.369 0.0137
BPF change year 3 - 0 Volume of T2 lesions at baseline -0.258 0.091
Number of Gd-enhancing lesions at baseline -0.440 0.0028
Volume of T1 hypo-intense lesions at baseline -0.167 0.2791
T2 lesion volume change year 3-0 -0.410 0.0057
T1 lesion volume change year 3-0 -0.306 0.0432
GMF change year 3 - 0 Volume of T2 lesions at baseline -0.0003 0.9986
Number of Gd-enhancing lesions at baseline -0.1193 0.4405
Volume of T1 hypo-intense lesions at baseline -0.0049 0.9751
T2 lesion volume change year 3-0 -0.4280 0.0037
T1 lesion volume change year 3-0 -0.3071 0.0426
(No significant correlations between the change in WMF and lesion load changes)
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Figure 5.5: Box plot showing the medians, interquartile ranges (box), highest and
lowest values, excluding outliers (whiskers), outlier and extreme values (circles)
for GMF percentage change in CIS patients with and without MRI lesions, and 
MS patients.
 1---- I
CIS Normal MRI Brain McDonald MS
CIS and  MRI Lesions
Diagnosis at thee years
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Figure 5.6 SPM99 T2 image segmentation: Grey Matter, White Matter and CSF
T2 image Grey Matter White Matter CSF
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Chapter 6
6.1 Discussion and conclusions
6.1.1 Background to MRI and the diagnosis of MS
This thesis has focused on MRI in the earliest phase of MS. Although MRI 
abnormalities were present in over 62% of patients with CIS followed for 3 years, the 
specificity of an abnormal MRI for a diagnosis of CDMS at 3 years is low at 56%. 
The McDonald MRI criteria enable an earlier MS diagnosis in patients with CIS and 
an abnormal MRI scan. Conventional MRI techniques using lesion number, type and 
location predict relapses and a diagnosis of CDMS. Lesions are not as helpful 
predicting disability where atrophy may be a more useful surrogate marker.
6.1.2 Aims of this thesis
The Aims of this thesis were two fold. Firstly, we wanted to evaluate MRI predictors 
for the diagnosis of CDMS at 3 years. To this end, we evaluated baseline MRI 
imaging of the brain and spinal cord and the combination with imaging three months 
later as predictive tests for the diagnosis of CDMS. Secondly, we wanted to determine 
whether atrophy occurred from onset of CIS and how atrophy related to lesions. This 
was done using two techniques: MIDAS and SPM99.
6.1.3 Baseline MRI in patients with CIS
Conventional T2 lesions at baseline MRI scan remain the most sensitive indicator for 
CDMS at 3 years (95%). High specificity using a baseline MRI brain scan could only 
be achieved by the requirement of 9 or more Gadolinium enhancing lesions (100%). 
This is rarely present in patients presenting with CIS, hence the poor sensitivity 
(14%).
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6.1.4 Spinal cord MRI in patients with clinically isolated optic neuritis
This thesis has clarified the limited usefulness of spinal cord imaging in patients with 
Clinically Isolated Optic Neuritis (although imaging of the Spinal Cord is essential in 
Spinal Cord Syndromes). Using the existing McDonald criteria, which allow one cord 
lesion to substitute for one brain lesion, cord lesions are of limited value only in 
patients with between one and eight brain lesions. Any expansion in the use of spinal 
cord lesions in updated MS diagnostic criteria should first be validated to ensure 
accuracy for predicting a second relapse.
6.1.5 Accurate criteria for MS diagnosis in patients with CIS
We have clarified the accuracy of the new McDonald diagnostic criteria by applying 
them in a prospective study of 119 patients with CIS suggestive of MS, 50 of whom 
were followed for 3 years. The specificity of the criteria at 3 months of follow-up was 
high (93%), sensitivity was lower (65%). Specificity is more important than 
sensitivity in diagnosing a lifelong condition such as MS. Low sensitivity means 
patients may be given a falsely negative diagnosis, or that the diagnosis is delayed.
New T2 lesions are detected more often than new Gadolinium enhancing lesions on 
the three month follow up scan. Using the existing criteria for DIS, a new T2 lesion 
applied for DIT was more sensitive (74%) without loss of specificity (92%) for the 
diagnosis of CDMS at 3 years.
A new T2 lesion per say at three months was both sensitive (84%) and specific (89%) 
for predicting CDMS at three years. A number of caveats must be reiterated, before
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considering modifications of the existing criteria most importantly that the MRI is 
performed in an experienced centre and read by a clinician or neuroradiologist with 
extensive experience with MRI and MS as well as other white matter disorders to 
ensure all lesions are unequivocal.
6.1.6 Atrophy in CIS patients associated with MS diagnosis
This thesis has confirmed VE in patients with CIS is associated with the development 
of CDMS as early as one year form the onset of initial symptoms. The correlations 
between VE and lesion load parameters were modest (Baseline T1 Hypointense 
Lesion Volume r = 0.495 and p < 0.001), suggesting that additional factors may 
contribute to atrophy. Further investigations using quantitative MT and NMR 
spectroscopy are needed in large CIS cohorts to evaluate the causal relationship 
between factors in the NAWM and the evolution of atrophy.
In a cohort of 58 CIS patients followed for 3 years, this thesis has confirmed the early 
development of MS is associated with progressive GM but not WM atrophy. Again 
the correlations between lesion load measures and atrophy were only modest 
(Baseline T1 Hypointense lesion volume r = 0.5 and p < 0.001).
6.1.7 Concluding remarks
Baseline MRI brain and cord lesions are highly sensitive for the development of 
CDMS, but lack specificity. Early follow up MRI brain was used to evaluate MRI 
evidence of DIT and DIS using the McDonald MRI criteria and provides specificity 
for CDMS at three years. Application of the criteria in their present form has revealed 
they are specific but less sensitive for CDMS at three years. Longer follow up is 
required to
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evaluate disability. Non conventional MRI techniques including atrophy may be more 
helpful predicting longer term disability.
6.1.8 Future Work
Longer term follow up is required to evaluate disability, in the first instance at 5 years. 
MRI markers for disability may be used to evaluate therapeutic and rehabilitation 
strategies for treatment of MS. Finally we are auditing patients’ perceptions of 
research. The future aim is the dissemination of the information which patients would 
like to receive as part of this research project.
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Appendix 1: Optic Neuritis Patient Information Sheet
We think the symptoms you are having are due to optic neuritis. This is the medical 
term used for inflammation of your optic nerve. The optic nerve is the nerve of vision 
and carries images of what we see coded as electrical impulses from the eye to the 
brain. If the nerve fibers do not do their job, vision becomes blurred.
Most patients with optic neuritis complain of painful subacute visual loss aggravated 
by eye movements, which progresses over a period of a few days to two weeks. The 
pain is variable in severity but usually does not interfere with sleep. The maximal 
visual loss varies from blurred to complete loss of vision in the affected eye, but 
recovery always occurs. 80% of patients show signs of improvement by three weeks 
and 90% by five weeks from the onset of symptoms. In 95% the recovery is to near 
normal vision and only 5% have significant loss of vision. Slower visual recovery can 
occur for up to 2 or 3 years. Some patients develop symptoms such as deterioration of 
vision with exercise or in bright light or difficulty judging direction of moving 
objects. Routine blood tests will be performed in clinic in order to exclude Optic 
Neuritis associated with infections or inflammatory conditions. Occasionally 
intravenous methylprednisolone (steroid) is used for optic neuritis; however steroids 
can cause side effects. It has been shown that steroids speed up the recovery but do 
not improve the eventual outcome. In some patients with optic neuritis treatment with 
steroids is essential.
There is an association between Optic Neuritis and Multiple Sclerosis (MS). MS can 
be diagnosed clinically after the occurrence of a second episode of inflammation at a
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different site in the central nervous system, for example numbness in both legs lasting 
three weeks. More recently MRI scans of the brain are being used to make an earlier 
diagnosis of MS. About 50-70% of patients have areas of inflammation on their MRI 
brain, when they present with optic neuritis. In long term studies of patients with 
Clinically Isolated Syndromes including optic neuritis, over 80% of patients with an 
abnormal scan developed MS and less than 20% of patients with a normal scan 
developed MS. MS may not become clinically apparent for many years and does not 
inevitably lead to disability. Earlier diagnosis in the future may lead to earlier 
treatment.
In clinical practice, if there is any doubt about the diagnosis a scan may be carried out 
to look for another cause of visual loss. Otherwise the only reason for carrying out a 
scan is to more accurately predict the likelihood of the development of MS and this 
issue will be discussed with you.
160
References
Abbruzzese G, Gandolfo C, Loeb C. "Bolus" methylprednisolone versus ACTH in the 
treatment of multiple sclerosis. Ital.J.Neurol.Sci. 1983; 4: 169-172.
Allen IV, McQuaid S, Mirakhur M, Nevin G. Pathological abnormalities in the 
normal-appearing white matter in multiple sclerosis. Neurol.Sci. 2001; 22: 141-144.
Allison RS. Disseminated sclerosis in North Wales: an inquiry into its incidence, 
frequency, distribution and other etiological factors. Brain 53, 391-430. 1931.
Alter M, Good J, Okihiro M. Optic neuritis in Orientals and Caucasians. Neurology 
1973; 23: 631-639.
Alvarez G, Cardenas M. Multiple sclerosis following optic neuritis in Chile. 
J.Neurol.Neurosurg.Psychiatry 1989; 52: 115-117.
Andersson PB, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: a 
critical review. J.Neurol.Sci. 1998; 160: 16-25.
Anmarkrud N, Slettnes ON. Uncomplicated retrobulbar neuritis and the development 
of multiple sclerosis. Acta Ophthalmol.(Copenh) 1989; 67: 306-309.
Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance 
spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: 
assessment of the load of disease. Magn Reson.Med. 1990; 14: 154-159.
Ashbumer J, Friston KJ. Voxel-based morphometry—the methods. Neuroimage. 2000; 
11: 805-821.
Bakshi R, Benedict RH, Bermel RA et al. T2 hypointensity in the deep gray matter of 
patients with multiple sclerosis: a quantitative magnetic resonance imaging study. 
Arch.Neurol. 2002; 59: 62-68.
Barkhof F, Filippi M, Miller DH et al. Comparison of MRI criteria at first 
presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 
120 (P t 11): 2059-2069.
Barkhof F, Karas GB, van Walderveen MA. T1 hypointensities and axonal loss. 
Neuroimaging Clin.N.Am. 2000; 10: 739-752.
Barkhof F, Rocca M, Francis G et al. Validation of diagnostic magnetic resonance 
imaging criteria for multiple sclerosis and response to interferon betala. Ann.Neurol. 
2003;53: 718-724.
Barkhof F, Scheltens P, Frequin ST et al. Relapsing-remitting multiple sclerosis: 
sequential enhanced MR imaging vs clinical findings in determining disease activity. 
AJR Am.J.Roentgenol. 1992; 159: 1041-1047.
Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. 
Arch.Ophthalmol. 1993; 111: 773-775.
161
Beck RW, Cleary PA, Trobe JD et al. The effect of corticosteroids for acute optic 
neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis 
Study Group. N.Engl.J.Med. 1993; 329: 1764-1769.
Beck RW, Trobe JD, Moke PS et al. High- and low-risk profiles for the development 
of multiple sclerosis within 10 years after optic neuritis: experience of the optic 
neuritis treatment trial. Arch.Ophthalmol. 2003; 121: 944-949.
Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. Axonal loss in normal- 
appearing white matter in a patient with acute MS. Neurology 2001; 57: 1248-1252.
Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: 
mechanisms and functional consequences. Curr.Opin.Neurol. 2001; 14: 271-278.
Boman J, Roblin PM, Sundstrom P, Sandstrom M, Hammerschlag MR. Failure to 
detect Chlamydia pneumoniae in the central nervous system of patients with MS. 
Neurology 2000; 54: 265.
Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A 
longitudinal study of abnormalities on MRI and disability from multiple sclerosis. 
N.Engl.J.Med. 2002; 346: 158-164.
Brex PA, Gomez-Anson B, Parker GJ et al. Proton MR spectroscopy in clinically 
isolated syndromes suggestive of multiple sclerosis. J.Neurol.Sci. 1999a; 166: 16-22.
Brex PA, Jenkins R, Fox NC et al. Detection of ventricular enlargement in patients at 
the earliest clinical stage of MS. Neurology 2000; 54: 1689-1691.
Brex PA, Leary SM, O'Riordan JI et al. Measurement of spinal cord area in clinically 
isolated syndromes suggestive of multiple sclerosis. J.Neurol.Neurosurg.Psychiatry 
2001a; 70: 544-547.
Brex PA, Leary SM, Plant GT, Thompson AJ, Miller DH. Magnetization transfer 
imaging in patients with clinically isolated syndromes suggestive of multiple 
sclerosis. AJNR Am.J.Neuroradiol. 2001b; 22: 947-951.
Brex PA, Miszkiel KA, O'Riordan JI et al. Assessing the risk of early multiple 
sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI. 
J.Neurol.Neurosurg.Psychiatry 2001c; 70: 390-393.
Brex PA, O'Riordan JI, Miszkiel KA et al. Multisequence MRI in clinically isolated 
syndromes and the early development of MS. Neurology 1999b; 53: 1184-1190.
Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA. Autoimmune disease in 
first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 2000; 
123 (Pt 6): 1102-1111.
Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory 
central nervous system demyelination: correlation of magnetic resonance imaging 
findings with lesion pathology. Ann.Neurol. 1997; 42: 783-793.
162
Bruck W, Kuhlmann T, Stadelmann C. Remyelination in multiple sclerosis. 
J.Neurol.Sci. 2003; 206: 181-185.
Campi A, Filippi M, Comi G et al. Acute transverse myelopathy: spinal and cranial 
MR study with clinical follow-up. AJNR Am.J.Neuroradiol. 1995; 16: 115-123.
Capra R, Marciano N, Vignolo LA, Chiesa A, Gasparotti R. Gadolinium-pentetic acid 
magnetic resonance imaging in patients with relapsing remitting multiple sclerosis. 
Arch.Neurol. 1992; 49: 687-689.
Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical 
guide for medical statisticians. Stat.Med. 2000; 19: 1141-1164.
Chard DT, Griffin CM, McLean MA et al. Brain metabolite changes in cortical grey 
and normal-appearing white matter in clinically early relapsing-remitting multiple 
sclerosis. Brain 2002a; 125: 2342-2352.
Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH. Brain 
atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002b; 125: 
327-337.
Chard DT, Parker GJ, Griffin CM, Thompson AJ, Miller DH. The reproducibility and 
sensitivity of brain tissue volume measurements derived from an SPM-based 
segmentation methodology. J.Magn Reson.Imaging 2002c; 15: 259-267.
Ciccarelli O, Parker GJ, Toosy AT et al. From diffusion tractography to quantitative 
white matter tract measures: a reproducibility study. Neuroimage. 2003a; 18: 348-359.
Ciccarelli O, Werring DJ, Barker GJ et al. A study of the mechanisms of normal- 
appearing white matter damage in multiple sclerosis using diffusion tensor imaging— 
evidence of Wallerian degeneration. J.Neurol. 2003b; 250: 287-292.
Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic 
neurodegeneration in multiple sclerosis. Ann.Neurol. 2002; 52: 650-653.
Cohen MM, Lessell S, Wolf PA. A prospective study of the risk of developing 
multiple sclerosis in uncomplicated optic neuritis. Neurology 1979; 29: 208-213.
Coles AJ, Wing MG, Molyneux P et al. Monoclonal antibody treatment exposes three 
mechanisms underlying the clinical course of multiple sclerosis. Ann.Neurol. 1999; 
46: 296-304.
Collins D.L., Narayanan, S., Caramanos Z., De Stefano, N., Tartaglia, M. C., and 
Arnold, D. L. Relation of Cerebral Atrophy in Multiple Sclerosis to Severity of 
Disease and Axonal Injury. Neurology 54(7), A17. 5-1-2000.
Collins DL, Montagnat J, Zijdenbos AP, Evans AC, Arnold DL. Automated 
estimation of brain volume in multiple sclerosis with BICCR. Lect Notes Comput Sci 
2001; 2082:141-147.
163
Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion 
to definite multiple sclerosis: a randomised study. Lancet 2001a; 357: 1576-1582.
Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, 
randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic 
resonance imaging—measured disease activity and burden in patients with relapsing 
multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann.Neurol. 
2001b; 49:290-297.
Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-1231.
Compston DA, Batchelor JR, Earl CJ, McDonald WI. Factors influencing the risk of 
multiple sclerosis developing in patients with optic neuritis. Brain 1978; 101: 495- 
511.
Compston DAS, Matthews WB, McDonald WI, Ebers G, Wekerle H, Lassmann H. 
McAlpine's multiple sclerosis. 3rd ed. Edinburgh Scotland: Churchill Livingstone 
1998.
Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis 
assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281- 
300.
Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of 
irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770- 
782.
Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of 
disability in multiple sclerosis. N.Engl.J.Med. 2000; 343: 1430-1438.
Congia S, Mellino GA, Porcella A, Borghero G, Cannas A. Primary optic neuritis 
evolved in multiple sclerosis: an epidemiological study. Acta Neurol.(Napoli) 1993;
15:433.441.
Corona-Vazquez T, Ruiz-Sandoval J, Arriada-Mendicoa N. Optic neuritis progressing 
to multiple sclerosis. Acta Neurol.Scand. 1997; 95: 85-89.
Cutter GR, Baier ML, Rudick RA et al. Development of a multiple sclerosis 
functional composite as a clinical trial outcome measure. Brain 1999; 122 ( Pt 5): 871- 
882.
Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute 
disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and 
multiple sclerosis in children. Brain 2000; 123 Pt 12: 2407-2422.
Dalton CM, Brex PA, Jenkins R et al. Progressive ventricular enlargement in patients 
with clinically isolated syndromes is associated with the early development of 
multiple sclerosis. J.Neurol.Neurosurg.Psychiatry 2002a; 73: 141-147.
Dalton CM, Brex PA, Miszkiel KA et al. Application of the new McDonald criteria to 
patients with clinically isolated syndromes suggestive of multiple sclerosis. 
Ann.Neurol. 2002b; 52: 47-53.
164
Dalton CM, Brex PA, Miszkiel KA et al. New T2 Lesions Enable an Earlier 
Diagnosis of Multiple Sclerosis in Clinically Isolated Syndromes. Ann.Neurol. 2003a 
53:673-676.
Dalton CM, Brex PA, Miszkiel KA et al. Spinal cord MRI in clinically isolated optic 
neuritis. J.Neurol.Neurosurg.Psychiatry 2003b; 74: 1577-1580.
Dalton CM, Chard DT, Davies GR et al. Early development of multiple sclerosis is 
associated with progressive grey matter atrophy in patients presenting with clinically 
isolated syndromes. Brain 2004.
DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: 
management strategies. Drugs 2003; 63: 153-166.
Davie CA, Barker GJ, Thompson AJ, Tofts PS, McDonald WI, Miller DH. 1H 
magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal 
appearing white matter in multiple sclerosis. J.Neurol.Neurosurg.Psychiatry 1997; 63: 
736-742.
Davie CA, Barker GJ, Webb S et al. Persistent functional deficit in multiple sclerosis 
and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995; 
118 ( Pt 6): 1583-1592.
Davie CA, Hawkins CP, Barker GJ et al. Serial proton magnetic resonance 
spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117 ( Pt 1): 49-58.
De Stefano N, Iannucci G, Sormani MP et al. MR correlates of cerebral atrophy in 
patients with multiple sclerosis. J.Neurol. 2002; 249: 1072-1077.
De Stefano N, Matthews PM, Filippi M et al. Evidence of early cortical atrophy in 
MS: relevance to white matter changes and disability. Neurology 2003; 60: 1157- 
1162.
De Stefano N, Matthews PM, Fu L et al. Axonal damage correlates with disability in 
patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic 
resonance spectroscopy study. Brain 1998; 121 ( Pt 8): 1469-1477.
Deya E, Sevilla T, Coret F. [A risk of developing multiple sclerosis following an 
outbreak of optic neuritis during a mean follow-up of 4.5 years]. Neurologia 1998; 13: 
377-381.
Druschky A, Heckmann JG, Claus D, Katalinic A, Druschky KF, Neundorfer B. 
Progression of optic neuritis to multiple sclerosis: an 8-year follow-up study. 
Clin.Neurol.Neurosurg. 1999; 101: 189-192.
Durelli L, Verdun E, Barbero P et al. Every-other-day interferon beta-lb versus once- 
weekly interferon beta-la for multiple sclerosis: results of a 2-year prospective 
randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-1460.
Ebers GC. Natural history of multiple sclerosis. J.Neurol.Neurosurg.Psychiatry 2001; 
71 Suppl 2: iil6-iil9.
165
Edan G, Miller D, Clanet M et al. Therapeutic effect of mitoxantrone combined with 
methylprednisolone in multiple sclerosis: a randomised multicentre study of active 
disease using MRI and clinical criteria. J.Neurol.Neurosurg.Psychiatry 1997; 62: 112- 
118.
Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological 
evidence for axonal loss in normal appearing white matter in multiple sclerosis. 
Ann.Neurol. 2000; 47: 391-395.
Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Size-selective 
neuronal changes in the anterior optic pathways suggest a differential susceptibility to 
injury in multiple sclerosis. Brain 2001; 124: 1813-1820.
Fazekas F, Offenbacher H, Fuchs S et al. Criteria for an increased specificity of MRI 
interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988; 
38: 1822-1825.
Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple 
sclerosis lesions. Brain 1997; 120 ( Pt 3): 393-399.
Filippi M, Colombo B, Rovaris M, Pereira C, Martinelli V, Comi G. A longitudinal 
magnetic resonance imaging study of the cervical cord in multiple sclerosis. 
J.Neuroimaging 1997a; 7: 78-80.
Filippi M, Colombo B, Rovaris M, Pereira C, Martinelli V, Comi G. A longitudinal 
magnetic resonance imaging study of the cervical cord in multiple sclerosis. 
J.Neuroimaging 1997b; 7: 78-80.
Filippi M, Horsfield MA, Morrissey SP et al. Quantitative brain MRI lesion load 
predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. 
Neurology 1994; 44: 635-641.
Filippi M, Yousry TA, Alkadhi H, Stehling M, Horsfield MA, Voltz R. Spinal cord 
MRI in multiple sclerosis with multicoil arrays: a comparison between fast spin echo 
and fast FLAIR. J.Neurol.Neurosurg.Psychiatry 1996; 61: 632-635.
Filippini G, Comi GC, Cosi V et al. Sensitivities and predictive values of paraclinical 
tests for diagnosing multiple sclerosis. J.Neurol. 1994; 241: 132-137.
Firth D. The Case of Augustus d’Este. Cambridge, UK: Cambridge University Press, 
1948.
Fisher E, Rudick RA, Simon JH et al. Eight-year follow-up study of brain atrophy in 
patients with MS. Neurology 2002; 59: 1412-1420.
Forbes RB, Swingler RJ. Estimating the prevalence of multiple sclerosis in the United 
Kingdom by using capture-recapture methodology. Am.J.Epidemiol. 1999; 149: 
1016-1024.
Forbes RB, Wilson SV, Swingler RJ. The prevalence of multiple sclerosis in Tayside, 
Scotland: do latitudinal gradients really exist? J.Neurol. 1999; 246: 1033-1040.
166
Ford B, Tampieri D, Francis G. Long-term follow-up of acute partial transverse 
myelopathy. Neurology 1992; 42: 250-252.
Fox NC, Jenkins R, Leary SM et al. Progressive cerebral atrophy in MS: a serial study 
using registered, volumetric MRI. Neurology 2000; 54: 807-812.
Francis DA, Compston DA, Batchelor JR, McDonald WI. A reassessment of the risk 
of multiple sclerosis developing in patients with optic neuritis after extended follow- 
up. J.Neurol.Neurosurg.Psychiatry 1987; 50: 758-765.
Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat.Rev.Neurosci. 
2002; 3: 705-714.
Frederiksen JL, Larsson HB, Olesen J, Stigsby B. MRI, VEP, SEP and biothesiometry 
suggest mono symptomatic acute optic neuritis to be a first manifestation of multiple 
sclerosis. Acta Neurol.Scand. 1991; 83: 343-350.
Frederiksen JL, Petrera J, Larsson HB, Stigsby B, Olesen J. Serial MRI, VEP, SEP 
and biotesiometry in acute optic neuritis: value of baseline results to predict the 
development of new lesions at one year follow up. Acta Neurol.Scand. 1996; 93: 246- 
252.
Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and 
quantitation of 3-D MRI brain scans. Comput.Methods Programs Biomed. 1997; 53: 
15-25.
Frith JA, McLeod JG, Hely M. Acute optic neuritis in Australia: a 13 year prospective 
study. J.Neurol.Neurosurg.Psychiatry 2000; 68: 246.
Fu L, Matthews PM, De Stefano N et al. Imaging axonal damage of normal-appearing 
white matter in multiple sclerosis. Brain 1998; 121 ( Pt 1): 103-113.
Gallagher HL, MacManus DG, Webb SL, Miller DH. A reproducible repositioning 
method for serial magnetic resonance imaging studies of the brain in treatment trials 
for multiple sclerosis. J.Magn Reson.Imaging 1997; 7: 439-441.
Ganter P, Prince C, Esiri MM. Spinal cord axonal loss in multiple sclerosis: a post­
mortem study. Neuropathol.Appl.Neurobiol. 1999; 25: 459-467.
Gasperini C, Paolillo A, Giugni E et al. MRI brain volume changes in relapsing- 
remitting multiple sclerosis patients treated with interferon beta-1 a. Mult.Scler. 2002; 
8:119-123.
Gawne-Cain ML, O’Riordan JI, Thompson AJ, Moseley IF, Miller DH. Multiple 
sclerosis lesion detection in the brain: a comparison of fast fluid-attenuated inversion 
recovery and conventional T2-weighted dual spin echo. Neurology 1997; 49: 364- 
370.
Ge Y, Grossman RI, Udupa JK et al. Brain atrophy in relapsing-remitting multiple 
sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative 
analysis. Radiology 2000; 214: 665-670.
167
Ghalie RG, Edan G, Laurent M et al. Cardiac adverse effects associated with 
mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002; 59: 909- 
913.
Ghezzi A, Martinelli V, Rodegher M, Zaffaroni M, Comi G. The prognosis of 
idiopathic optic neuritis. Neurol.Sci. 2000; 21: S865-S869.
Ghezzi A, Martinelli V, Torri V et al. Long-term follow-up of isolated optic neuritis: 
the risk of developing multiple sclerosis, its outcome, and the prognostic role of 
paraclinical tests. J.Neurol. 1999; 246: 770-775.
Ghezzi A, Torri V, Zaffaroni M. Isolated optic neuritis and its prognosis for multiple 
sclerosis: a clinical and paraclinical study with evoked potentials. CSF examination 
and brain MRI. Ital.J.Neurol.Sci. 1996; 17: 325-332.
Giovannoni G, Munschauer FE, III, Deisenhammer F. Neutralising antibodies to 
interferon beta during the treatment of multiple sclerosis. 
J.Neurol.Neurosurg.Psychiatry 2002; 73: 465-469.
Gonsette RE. Mitoxantrone in progressive multiple sclerosis: when and how to treat? 
J.Neurol.Sci. 2003; 206: 203-208.
Granieri E, Casetta I, Govoni V et al. The increasing incidence and prevalence of MS 
in a Sardinian province. Neurology 2000; 55: 842-848.
Grimaud J, Barker GJ, Wang L et al. Correlation of magnetic resonance imaging 
parameters with clinical disability in multiple sclerosis: a preliminary study. J.Neurol. 
1999; 246: 961-967.
Gronning M, Mellgren SI, Schive K. Optic neuritis in the two northernmost counties 
of Norway. A study of incidence and the prospect of later development of multiple 
sclerosis. Arctic Med.Res. 1989; 48: 117-121.
Gross KR, Tomberg TA, Kokk AA, Kaasik AE. [The prognosis of multiple sclerosis: 
computed tomographic comparisons]. Zh.Nevropatol.Psikhiatr.ini S.S.Korsakova 
1993;93:32-35.
Guttmann CR, Benson R, Warfield SK et al. White matter abnormalities in mobility- 
impaired older persons. Neurology 2000; 54: 1277-1283.
Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple 
sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 
2002; 360: 2018-2025.
Hashemi RH, Bradley WG. MRI the basics. Baltimore, Mariland, USA. Williams and 
Wilkins 1997.
Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term 
follow up, and assessment of prognostic factors. J.Neurol.Neurosurg.Psychiatry 1999; 
67: 148-152.
168
Hely MA, McManis PG, Doran TJ, Walsh JC, McLeod JG. Acute optic neuritis: a 
prospective study of risk factors for multiple sclerosis. J.Neurol.Neurosurg.Psychiatry 
1986; 49: 1125-1130.
Hennig J, Nauerth A, Friedburg H. RARE imaging: a fast imaging method for clinical 
MR. Magn Reson.Med. 1986; 3: 823-833.
Heman MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two 
prospective studies of US women. Neurology 1999; 53: 1711-1718.
Hickman SJ, Brierley CM, Brex PA et al. Continuing optic nerve atrophy following 
optic neuritis: a serial MRI study. Mult.Scler. 2002; 8: 339-342.
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact 
of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 
2003;60:31-36.
Hoogervorst EL, Polman CH, Barkhof F. Cerebral volume changes in multiple 
sclerosis patients treated with high-dose intravenous methylprednisolone. Mult.Scler. 
2002;8:415-419.
Hutchinson WM. Acute optic neuritis and the prognosis for multiple sclerosis. 
J.Neurol.Neurosurg.Psychiatry 1976; 39: 283-289.
Iannucci G, Tortorella C, Rovaris M, Sormani MP, Comi G, Filippi M. Prognostic 
value of MR and magnetization transfer imaging findings in patients with clinically 
isolated syndromes suggestive of multiple sclerosis at presentation. AJNR 
Am.J.Neuroradiol. 2000; 21: 1034-1038.
IFNB Multiple Sclerosis Study Group and the University of British Columbia 
MS/MRI Analysis Group. Interferon beta-lb in the treatment of multiple sclerosis: 
final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
Ingle GT, Stevenson VL, Miller DH, Thompson AJ. Primary progressive multiple 
sclerosis: a 5-year clinical and MR study. Brain 2003.
Jacobs L, Munschauer FE, Kaba SE. Clinical and magnetic resonance imaging in 
optic neuritis. Neurology 1991; 41: 15-19.
Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-la therapy 
initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study 
Group. N.Engl.J.Med. 2000; 343: 898-904.
Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-la for 
disease progression in relapsing multiple sclerosis. The Multiple Sclerosis 
Collaborative Research Group (MSCRG). Ann.Neurol. 1996; 39: 285-294.
Jacobs LD, Kaba SE, Miller CM, Priore RL, Brownscheidle CM. Correlation of 
clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic 
neuritis. Ann.Neurol. 1997; 41: 392-398.
169
Jin YP, Pedro-Cuesta J, Soderstrom M, Stawiarz L, Link H. Incidence of optic 
neuritis in Stockholm, Sweden 1990-1995: I. Age, sex, birth and ethnic-group related 
patterns. J.Neurol.Sci. 1998; 159: 107-114.
Johnson KP, Brooks BR, Cohen JA et al. Extended use of glatiramer acetate 
(Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis 
relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. 
Neurology 1998; 50: 701-708.
Kahana E, Alter M, Feldman S. Optic neuritis in relation to multiple sclerosis. 
J.Neurol. 1976; 213: 87-95.
Kaiser JS, Grossman RI, Polansky M, Udupa JK, Miki Y, Galetta SL. Magnetization 
transfer histogram analysis of monosymptomatic episodes of neurologic dysfunction: 
preliminary findings. AJNR Am.J.Neuroradiol. 2000; 21: 1043-1047.
Kalkers NF, Bergers E, Castelijns JA et al. Optimizing the association between 
disability and biological markers in MS. Neurology 2001a; 57: 1253-1258.
Kalkers NF, Bergers L, de G, V et al. Concurrent validity of the MS Functional 
Composite using MRI as a biological disease marker. Neurology 2001b; 56: 215-219.
Kalkers NF, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F. Brain atrophy in 
multiple sclerosis: impact of lesions and of damage of whole brain tissue. Mult.Scler. 
2002; 8:410-414.
Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. 
Correlation between magnetic resonance imaging findings and lesion development in 
chronic, active multiple sclerosis. Ann.Neurol. 1993; 34: 661-669.
Khan O, Zabad R, Caon C, Zvartau-Hind M, Tselis A, Lisak R. Comparative 
assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis. 
CNS.Drugs 2002; 16: 563-578.
Khan OA, Tselis AC, Kamholz JA, Garbem JY, Lewis RA, Lisak RP. A prospective, 
open-label treatment trial to compare the effect of IFNbeta-la (Avonex), IFNbeta-lb 
(Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing- 
remitting multiple sclerosis: results after 18 months of therapy. Mult.Scler. 2001; 7: 
349-353.
Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in 
multiple sclerosis. Brain 1999; 122 ( Pt 1): 17-26.
Kidd D, Thorpe JW, Kendall BE et al. MRI dynamics of brain and spinal cord in 
progressive multiple sclerosis. J.Neurol.Neurosurg.Psychiatry 1996; 60: 15-19.
Kinnunen E. The incidence of optic neuritis and its prognosis for multiple sclerosis. 
Acta Neurol.Scand. 1983; 68: 371-377.
Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Part one. Acta 
Neurol.Scand. 1975; 51: 110-136.
170
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded 
disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
Kurtzke JF. Multiple sclerosis in time and space—geographic clues to cause. 
J.Neurovirol. 2000; 6 Suppl 2: S134-S140.
Kurtzke JF, Hyllested K. Multiple sclerosis in the Faroe Islands. II. Clinical update, 
transmission, and the nature of MS. Neurology 1986; 36: 307-328.
Lana-Peixoto MA, Lana-Peixoto MI. The risk of multiple sclerosis developing in 
patients with isolated idiopathic optic neuritis in Brazil. Arq Neuropsiquiatr. 1991; 49: 
377-383.
Landy PJ. A prospective study of the risk of developing multiple sclerosis in optic 
neuritis in a tropical and sub-tropical area. J.Neurol.Neurosurg.Psychiatry 1983; 46: 
659-661.
Landy PJ. The probability of developing multiple sclerosis following an episode of 
optic neuritis. J.Clin.Neurosci. 1999; 6: 378-379.
Landy PJ, Ohlrich GD. Optic neuritis and its relationship to disseminated sclerosis. 
Proc.Aust.Assoc.Neurol. 1970; 7: 67-70.
Lassmann H. Mechanisms of demyelination and tissue destruction in multiple 
sclerosis. Clin.Neurol.Neurosurg. 2002; 104: 168-171.
Lassmann H, Bruck W, Lucchinetti C, Rodriguez M. Remyelination in multiple 
sclerosis. Mult.Scler. 1997; 3: 133-136.
Lee KH, Hashimoto SA, Hooge JP et al. Magnetic resonance imaging of the head in 
the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of 
clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1991; 
41: 657-660.
Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a 
randomized, double-blind, placebo-controlled study of interferon-betala in relapsing- 
remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon- 
betala Subcutaneously in Multiple Sclerosis. Ann.Neurol. 1999; 46: 197-206.
Lipton HL, Teasdall RD. Acute transverse myelopathy in adults. A follow-up study. 
Arch.Neurol. 1973; 28: 252-257.
Liu C, Edwards S, Gong Q, Roberts N, Blumhardt LD. Three dimensional MRI 
estimates of brain and spinal cord atrophy in multiple sclerosis. 
J.Neurol.Neurosurg.Psychiatry 1999; 66: 323-330.
Losseff NA, Kingsley DP, McDonald WI, Miller DH, Thompson AJ. Clinical and 
magnetic resonance imaging predictors of disability in primary and secondary 
progressive multiple sclerosis. Mult.Scler. 1996a; 1: 218-222.
Losseff NA, Wang L, Lai HM et al. Progressive cerebral atrophy in multiple sclerosis. 
A serial MRI study. Brain 1996b; 119 ( Pt 6): 2009-2019.
171
Losseff NA, Webb SL, O'Riordan JI et al. Spinal cord atrophy and disability in 
multiple sclerosis. A new reproducible and sensitive MRI method with potential to 
monitor disease progression. Brain 1996c; 119 ( Pt 3): 701-708.
Lovas G, Szilagyi N, Majtenyi K, Palkovits M, Komoly S. Axonal changes in chronic 
demyelinated cervical spinal cord plaques. Brain 2000; 123 ( Pt 2): 308-317.
Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of 
an international survey. National Multiple Sclerosis Society (USA) Advisory 
Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 
46: 907-911.
Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. 
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of 
demyelination. Ann.Neurol. 2000; 47: 707-717.
Lucchinetti CF, Kiers L, O'Duffy A et al. Risk factors for developing multiple 
sclerosis after childhood optic neuritis. Neurology 1997; 49: 1413-1418.
MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime 
prevalence of neurological disorders in a prospective community-based study in the 
UK. Brain 2000; 123 ( Pt 4): 665-676.
Mapelli G, De Palma P, Fini M, Pavoni M, Franco F, Pirazzoli G. [Retrobulbar optic 
neuritis as an initial symptom of multiple sclerosis. Results of a prospective study]. 
Riv.Neurol. 1985; 55: 53-77.
Mapelli G, Pavoni M, De Palma P, Modestino R, Pavoni V. Progression of optic 
neuritis to multiple sclerosis: a prospective study in an Italian population. 
Neuroepidemiology 1991; 10: 117-121.
Matthews PM, De Stefano N, Narayanan S et al. Putting magnetic resonance 
spectroscopy studies in context: axonal damage and disability in multiple sclerosis. 
Semin.Neurol. 1998; 18: 327-336.
McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for 
multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple 
sclerosis. Ann.Neurol. 2001; 50: 121-127.
McDonnell GV, Hawkins SA. Clinical study of primary progressive multiple sclerosis 
in Northern Ireland, UK. J.Neurol.Neurosurg.Psychiatry 1998; 64: 451-454.
McDonnell GV, Hawkins SA. Multiple sclerosis in Northern Ireland: a historical and 
global perspective. Ulster Med.J. 2000; 69: 97-105.
McFarland HF, Frank JA, Albert PS et al. Using gadolinium-enhanced magnetic 
resonance imaging lesions to monitor disease activity in multiple sclerosis. 
Ann.Neurol. 1992; 32: 758-766.
Miller DH. Guidelines for MRI monitoring of the treatment of multiple sclerosis: 
recommendations of the US Multiple Sclerosis Society's task force. Mult.Scler. 1996; 
1: 335-338.
172
Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophy 
in multiple sclerosis: pathological basis, methodological aspects and clinical 
relevance. Brain 2002; 125: 1676-1695.
Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of 
MRI in detecting disease activity in multiple sclerosis. Brain 1993; 116 ( Pt 5): 1077- 
1094.
Miller DH, Khan OA, Sheremata WA e/ al. A controlled trial of natalizumab for 
relapsing multiple sclerosis. N.Engl.J.Med. 2003; 348: 15-23.
Miller DH, McDonald WI, Blumhardt LD et al. Magnetic resonance imaging in 
isolated noncompressive spinal cord syndromes. Ann.Neurol. 1987; 22: 714-723.
Miller DH, Ormerod IE, McDonald WI et al. The early risk of multiple sclerosis after 
optic neuritis. J.Neurol.Neurosurg.Psychiatry 1988; 51: 1569-1571.
Miller DH, Ormerod IE, Rudge P, Kendall BE, Moseley IF, McDonald WI. The early 
risk of multiple sclerosis following isolated acute syndromes of the brainstem and 
spinal cord. Ann.Neurol. 1989; 26: 635-639.
Minderhoud JM, van der Hoeven JH, Prange AJ. Course and prognosis of chronic 
progressive multiple sclerosis. Results of an epidemiological study. Acta 
Neurol.Scand. 1988; 78: 10-15.
Molyneux PD, Kappos L, Polman C et al. The effect of interferon beta-lb treatment 
on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. 
European Study Group on Interferon beta-lb in secondary progressive multiple 
sclerosis. Brain 2000; 123 ( Pt 11): 2256-2263.
Morrissey SP, Miller DH, Kendall BE et al. The significance of brain magnetic 
resonance imaging abnormalities at presentation with clinically isolated syndromes 
suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993; 116 ( Pt 1): 
135-146.
Nijeholt G, Barkhof F. Differences between subgroups of MS: MRI findings and 
correlation with histopathology. J.Neurol.Sci. 2003; 206: 173-174.
Nijeholt GJ, van Walderveen MA, Castelijns JA et al. Brain and spinal cord 
abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical 
subtypes and symptoms. Brain 1998; 121 ( Pt 4): 687-697.
Nikoskelainen E, Frey H, Salmi A. Prognosis of optic neuritis with special reference 
to cerebrospinal fluid immunoglobulins and measles virus antibodies. Ann.Neurol. 
1981; 9: 545-550.
Nikoskelainen E, Riekkinen P. Retrospective study of 117 patients with optic neuritis. 
Acta Ophthalmol.Suppl 1974; 123: 202-208.
Noseworthy JH, Paty DW, Ebers GC. Neuroimaging in multiple sclerosis. 
Neurol.Clin. 1984; 2: 759-777.
173
Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the 
Optic Neuritis Treatment Trial. Arch.Ophthalmol. 1991; 109: 1673-1678.
Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of 
the optic neuritis treatment trial. Neurology 1997; 49: 1404-1413.
O'Riordan JI, Gomez-Anson B, Moseley IF, Miller DH. Long term MRI follow-up of 
patients with post infectious encephalomyelitis: evidence for a monophasic disease. 
J.Neurol.Sci. 1999; 167: 132-136.
O'Riordan JI, Losseff NA, Phatouros C et al. Asymptomatic spinal cord lesions in 
clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of 
demyelination. J.Neurol.Neurosurg.Psychiatry 1998a; 64: 353-357.
O'Riordan JI, Thompson AJ, Kingsley DP et al. The prognostic value of brain MRI in 
clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998b; 121 ( Pt 
3): 495-503.
Panitch H, Goodin DS, Francis G et al. Randomized, comparative study of interferon 
beta-la treatment regimens in MS: The EVIDENCE Trial. Neurology 2002; 59: 1496- 
1506.
Paolillo A, Pozzilli C, Gasperini C et al. Brain atrophy in relapsing-remitting multiple 
sclerosis: relationship with 'black holes', disease duration and clinical disability. 
J.Neurol.Sci. 2000; 174: 85-91.
Paolino E, Fainardi E, Ruppi P et al. A prospective study on the predictive value of 
CSF oligoclonal bands and MRI in acute isolated neurological syndromes for 
subsequent progression to multiple sclerosis. J.Neurol.Neurosurg.Psychiatry 1996; 60: 
572-575.
Parker GJ, Wheeler-Kingshott CA, Barker GJ. Estimating distributed anatomical 
connectivity using fast marching methods and diffusion tensor.Trans.Med.Imaging 
2002; 21: 505-512.
Paty D.W. Multiple sclerosis edited by Donald W. Paty, George C. Ebers. 
Philadelphia, Pa. F. A. Davis 1997.
Paty DW, Li DK. Interferon beta-lb is effective in relapsing-remitting multiple 
sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, 
placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis 
Study Group. Neurology 1993; 43: 662-667.
Paty DW, Li DK, Oger JJ et al. Magnetic resonance imaging in the evaluation of 
clinical trials in multiple sclerosis. Ann.Neurol. 1994; 36 Suppl: S95-S96.
Paty DW, Oger JJ, Kastrukoff LF et al. MRI in the diagnosis of MS: a prospective 
study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, 
and CT. Neurology 1988; 38: 180-185.
Percy AK, Nobrega FT, Kurland LT. Optic neuritis and multiple sclerosis. An 
epidemiologic study. Arch.Ophthalmol. 1972; 87: 135-139.
174
Perkin GD. Optic neuritis and its differential diagnosis . Oxford Oxford University 
Press, 1979.
Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic 
neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann.Neurol. 
2001;50:389-400.
Pluchino S, Quattrini A, Brambilla E et al. Injection of adult neurospheres induces 
recovery in a chronic model of multiple sclerosis. Nature 2003; 422: 688-694.
Plummer DL. Dispimage: a Display and Analysis Tool for Medical Images. Rivista di 
Neuroradiologia 5, 489. 1992.
Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple 
sclerosis: guidelines for research protocols. Ann.Neurol. 1983; 13: 227-231.
PRISMS (Prevention of Relapses and Disability by Interferon beta-la Subcutaneously 
in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled 
study of interferon beta-la in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 
1498-1504.
PRISMS Study Group and the University of British Columbia MS/MRI Analysis 
Group..PRISMS-4: Long-term efficacy of interferon-beta-la in relapsing MS. 
Neurology 2001; 56: 1628-1636.
Provencher SW. Estimation of metabolite concentrations from localized in vivo 
proton NMR spectra. Magn Reson.Med. 1993; 30: 672-679.
Quarantelli M, Ciarmiello A, Morra VB et al. Brain tissue volume changes in 
relapsing-remitting multiple sclerosis: correlation with lesion load. Neuroimage. 
2003; 18: 360-366.
Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Poliak CP, Nagaraja HN. 
Efficacy and safety of modafmil (Provigil) for the treatment of fatigue in multiple 
sclerosis: a two centre phase 2 study. J.Neurol.Neurosurg.Psychiatry 2002; 72: 179- 
183.
Redmond IT, Barbosa S, Blumhardt LD, Roberts N. Short-term ventricular volume 
changes on serial MRI in multiple sclerosis. Acta Neurol.Scand. 2000; 102: 99-105.
Rinne UK, Sonninen V, Tuovinen T. Corticotrophin treatment in multiple sclerosis. 
Acta Neurol.Scand. 1968; 44: 207-218.
Rio J, Nos C, Rovira A, Tintore M, Codina A, Montalban X. [The development of 
multiple sclerosis following an isolated episode of optic neuritis. Magnetic resonance 
study]. Med.Clin.(Barc.) 1997; 109: 370-372.
Rizzo JF, III, Lessell S. Risk of developing multiple sclerosis after uncomplicated 
optic neuritis: a long-term prospective study. Neurology 1988; 38: 185-190.
175
Rodriguez M, Lucchinetti CF. Is apoptotic death of the oligodendrocyte a critical 
event in the pathogenesis of multiple sclerosis? Neurology 1999; 53: 1615-1616.
Rodriguez M, Siva A, Cross SA, O'Brien PC, Kurland LT. Optic neuritis: a 
population-based study in Olmsted County, Minnesota. Neurology 1995; 45: 244-250.
Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW. 
Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. 
placebo-final report. Neurology 1970; 20: 1-59.
Rose FC. The aetiology of optic neuritis. Clin.Sci. 1970; 39: 17P.
Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M. Short-term brain volume 
change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and 
implications. Brain 2001; 124: 1803-1812.
Rudick RA, Fisher E, Lee JC, Duda JT, Simon J. Brain atrophy in relapsing multiple 
sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1 a. 
Mult.Scler. 2000; 6: 365-372.
Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal 
fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis 
Collaborative Research Group. Neurology 1999; 53: 1698-1704.
Sailer M, Fischl B, Salat D et al. Focal thinning of the cerebral cortex in multiple 
sclerosis. Brain 2003; 126: 1734-1744.
Sailer M, Losseff NA, Wang L, Gawne-Cain ML, Thompson AJ, Miller DH. T1 
lesion load and cerebral atrophy as a marker for clinical progression in patients with 
multiple sclerosis. A prospective 18 months follow-up study. Eur.J.Neurol. 2001; 8: 
37-42.
Saiz A, Marcos MA, Graus F, Vidal J, Jimenez de Anta MT. No evidence of CNS 
infection with Chlamydia pneumoniae in patients with multiple sclerosis. J.Neurol. 
2001;248:617-618.
Sandberg HO. Acute retrobulbar neuritis—a retrospective study. Acta
Ophthalmol.(Copenh) 1972; 50: 3-8.
Sandberg-Wollheim M. Optic neuritis: studies on the cerebrospinal fluid in relation to 
clinical course in 61 patients. Acta Neurol.Scand. 1975; 52: 167-178.
Sandberg-Wollheim M, Bynke H, Cronqvist S, Holtas S, Platz P, Ryder LP. A long­
term prospective study of optic neuritis: evaluation of risk factors. Ann.Neurol. 1990; 
27: 386-393.
Sastre-Garriga J, Tintore M, Rovira A et al. Conversion to multiple sclerosis after a 
clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, 
cerebrospinal fluid and neurophysiological findings. Mult.Scler. 2003; 9: 39-43.
176
Sawcer S, Maranian M, Setakis E et al. A whole genome screen for linkage 
disequilibrium in multiple sclerosis confirms disease associations with regions 
previously linked to susceptibility. Brain 2002; 125: 1337-1347.
Scholl GB, Song HS, Wray SH. Uhthoffs symptom in optic neuritis: relationship to 
magnetic resonance imaging and development of multiple sclerosis. Ann.Neurol. 
1991; 30: 180-184.
Schumacker GA, Beebe G, Kilber RE et al. Problems of experimental trials of therapy 
in multiple sclerosis: Report of the panel on the evaluation of experimental trials of 
therapy in multiple sclerosis. Ann.N.Y.Acad.Sci. 1965; 122: 552-568.
Scolding N, Franklin R, Stevens S, Heldin CH, Compston A, Newcombe J. 
Oligodendrocyte progenitors are present in the normal adult human CNS and in the 
lesions of multiple sclerosis. Brain 1998; 121 ( Pt 12): 2221-2228.
Sharief MK, Thompson EJ. The predictive value of intrathecal immunoglobulin 
synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent 
development of multiple sclerosis. Ann.Neurol. 1991; 29: 147-151.
Silver NC, Good CD, Sormani MP et al. A modified protocol to improve the detection 
of enhancing brain and spinal cord lesions in multiple sclerosis. J.Neurol. 2001; 248: 
215-224.
Simon JH. Brain and spinal cord atrophy in multiple sclerosis: role as a surrogate 
measure of disease progression. CNS.Drugs 2001; 15: 427-436.
Simon JH, Jacobs LD, Campion M et al. Magnetic resonance studies of intramuscular 
interferon beta-la for relapsing multiple sclerosis. The Multiple Sclerosis 
Collaborative Research Group. Ann.Neurol. 1998; 43: 79-87.
Simon JH, Jacobs LD, Campion MK et al. A longitudinal study of brain atrophy in 
relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group 
(MSCRG). Neurology 1999; 53: 139-148.
Smith ME, Stone LA, Albert PS et al. Clinical worsening in multiple sclerosis is 
associated with increased frequency and area of gadopentetate dimeglumine- 
enhancing magnetic resonance imaging lesions. Ann.Neurol. 1993; 33: 480-489.
Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate 
measurement of longitudinal brain change. J.Comput.Assist.Tomogr. 2001; 25: 466- 
475.
Soderstrom M. The clinical and paraclinical profile of optic neuritis: a prospective 
study. Ital.J.Neurol.Sci. 1995; 16: 167-176.
Soderstrom M, Lindqvist M, Hillert J, Kail TB, Link H. Optic neuritis: findings on 
MRI, CSF examination and HLA class II typing in 60 patients and results of a short­
term follow-up. J.Neurol. 1994; 241: 391-397.
Soderstrom M, Ya-Ping J, Hillert J, Link H. Optic neuritis: prognosis for multiple 
sclerosis from MRI, CSF, and HLA findings. Neurology 1998; 50: 708-714.
177
Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with Chlamydia 
pneumoniae infection of the CNS. Neurology 1998; 50: 571-572.
Sriram S, Stratton CW, Yao S et al. Chlamydia pneumoniae infection of the central 
nervous system in multiple sclerosis. Ann.Neurol. 1999; 46: 6-14.
Stendahl-Brodin L, Link H. Optic neuritis: oligoclonal bands increase the risk of 
multiple sclerosis. Acta Neurol.Scand. 1983; 67: 301-304.
Stevenson VL, Gawne-Cain ML, Barker GJ, Thompson AJ, Miller DH. Imaging of 
the spinal cord and brain in multiple sclerosis: a comparative study between fast 
FLAIR and fast spin echo. J.Neurol. 1997; 244: 119-124.
Stone LA, Smith ME, Albert PS et al. Blood-brain barrier disruption on contrast- 
enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: 
relationship to course, gender, and age. Neurology 1995; 45: 1122-1126.
Tas MW, Barkhol F, van Walderveen MA, Polman CH, Hommes OR, Valk J. The 
effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of 
multiple sclerosis. AJNR Am.J.Neuroradiol. 1995; 16: 259-264.
Thompson AJ, Kennard C, Swash M et al. Relative efficacy of intravenous 
methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 
1989; 39: 969-971.
Thompson AJ, Kermode AG, Wicks D et al. Major differences in the dynamics of 
primary and secondary progressive multiple sclerosis. Ann.Neurol. 1991; 29: 53-62.
Thompson AJ, Miller D, Youl B et al. Serial gadolinium-enhanced MRI in 
relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992; 
42: 60-63.
Thompson AJ, Montalban X, Barkhof F et al. Diagnostic criteria for primary 
progressive multiple sclerosis: a position paper. Ann.Neurol. 2000; 47: 831-835.
Thompson AJ, Polman CH, Miller DH et al. Primary progressive multiple sclerosis. 
Brain 1997; 120 (Pt 6): 1085-1096.
Thorpe JW, Kidd D, Moseley IF et al. Serial gadolinium-enhanced MRI of the brain 
and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996a; 46: 
373-378.
Thorpe JW, Kidd D, Moseley IF et al. Spinal MRI in patients with suspected multiple 
sclerosis and negative brain MRI. Brain 1996b; 119 ( Pt 3): 709-714.
Tintore M, Rovira A, Brieva L et al. Isolated demyelinating syndromes: comparison 
of CSF oligoclonal bands and different MR imaging criteria to predict conversion to 
CDMS. Mult.Scler. 2001; 7: 359-363.
Tintore M, Rovira A, Martinez MJ et al. Isolated demyelinating syndromes: 
comparison of different MR imaging criteria to predict conversion to clinically 
definite multiple sclerosis. AJNR Am.J.Neuroradiol. 2000; 21: 702-706.
178
Tintore M, Rovira A, Rio J et al. New diagnostic criteria for multiple sclerosis: 
application in first demyelinating episode. Neurology 2003; 60: 27-30.
Tourbah A, Stievenart JL, Abanou A et al. Normal-appearing white matter in optic 
neuritis and multiple sclerosis: a comparative proton spectroscopy study. 
Neuroradiology 1999; 41: 738-743.
Traboulsee A, Dehmeshki J, Brex PA et al. Normal-appearing brain tissue MTR 
histograms in clinically isolated syndromes suggestive of MS. Neurology 2002; 59: 
126-128.
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in 
the lesions of multiple sclerosis. N.Engl.J.Med. 1998; 338: 278-285.
Van Waesberghe JH, Kamphorst W, De Groot CJ et al. Axonal loss in multiple 
sclerosis lesions: magnetic resonance imaging insights into substrates of disability. 
Ann.Neurol. 1999; 46: 747-754.
van Walderveen MA, Barkhof F, Pouwels PJ, van Schijndel RA, Polman CH, 
Castelijns JA. Neuronal damage in Tl-hypointense multiple sclerosis lesions 
demonstrated in vivo using proton magnetic resonance spectroscopy. Ann.Neurol. 
1999; 46: 79-87.
van Walderveen MA, Kamphorst W, Scheltens P et al. Histopathologic correlate of 
hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 
1998; 50: 1282-1288.
Weinshenker BG. The natural history of multiple sclerosis. Neurol.Clin. 1995; 13: 
119-146.
Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a 
geographically based study. 2. Predictive value of the early clinical course. Brain 
1989; 112 (Pt 6): 1419-1428.
Werring DJ, Bullmore ET, Toosy AT et al. Recovery from optic neuritis is associated 
with a change in the distribution of cerebral response to visual stimulation: a 
functional magnetic resonance imaging study. J.Neurol.Neurosurg.Psychiatry 2000; 
68:441-449.
Williams R, Rigby AS, Airey M, Robinson M, Ford H. Multiple sclerosis: it 
epidemiological, genetic, and health care impact. J.Epidemiol.Community Health 
1995; 49: 563-569.
Wolinsky JS, Narayana PA, Johnson KP. United States open-label glatiramer acetate 
extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple 
Sclerosis Study Group and the MRI Analysis Center. Mult.Scler. 2001; 7: 33-41.
Young IR, Hall AS, Pallis CA, Legg NJ, Bydder GM, Steiner RE. Nuclear magnetic 
resonance imaging of the brain in multiple sclerosis. Lancet 1981; 2: 1063-1066.
179
Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden 
Markov random field model and the expectation-maximization algorithm. 
Trans.Med.Imaging 2001; 20: 45-57.
Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of 
fatigue in multiple sclerosis. Results of an open-label study. J.Neurol. 2002; 249: 983- 
987.
180
Appendix 2: Addendum
The publishing of the McDonald criteria of the International Panel almost four years 
ago has been a starting point for efforts to evaluate their robustness and reliability. 
There are a number of issues raised in this thesis, which need to be addressed in a 
final discussion.
1. The studies in this thesis focus on application of the McDonald criteria in with 
monosymptomatic CIS (presenting in the majority with optic neuritis). 
Reassuringly the results subsequently from another cohort of CIS patients - in 
whom optic neuritis, brainstem and spinal cord syndromes were equally 
represented - are very similar, suggesting the robustness of the McDonald 
criteria for DIS and DIT in patients with CIS.[Tintore et al 2003] Future MRI 
studies should concentrate on larger cohorts of patients with polysymptomatic 
CIS with clinical DIS, which may be indicative of a higher risk of MS. They 
might also concentrate on modifications that improve sensitivity in making an 
early diagnosis, this still being a limitation of the McDonald criteria.
2. EDSS is the only measure of clinical disability used in this thesis. Evaluation 
of parameters used to measure clinical severity of optic neuritis, including 
visual acuity, visual fields, colour vision and fundoscopic findings, were not 
evaluated in this thesis as tests predicting clinical outcome at three years.
3. The presence of CSF oligoclonal bands can significantly change the 
requirements for the diagnosis of MS. The MRI components are less strict, 
with only two or more lesions consistent with MS rather than the full imaging 
DIS criteria being required. The majority of patients in the studies in this 
thesis did not have lumbar punctures performed. There are a number of
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patients who may only fulfill the new McDonald criteria by the inclusion of 
the oligoclonal bands. This addition could improve sensitivity to the values 
given in this thesis. However, in another cohort, CSF findings within the DIS 
criteria were evaluated and were found to lower specificity and accuracy of the 
full imaging DIS criteria, suggesting limited usefulness when considered in 
isolation. [Tintore et al. 2003]
4. Few patients in the cohort reported in this thesis received steroids or disease 
modifying agents. In the Optic Neuritis Treatment Trial, high-dose intravenous 
steroids were shown to have a short-term beneficial effect, delaying the time to 
the development of a second demyelinating event. However, there was no 
proven long-term benefit from a single course of steroid treatment. [Optic 
Neuritis Study Group 1997] There is no large trial of yearly or recurrent pulses 
of steroids in patients with CIS given with the aim of preventing a second 
relapse. There is evidence that IFNp-la delays the development of MS in 
patients with CIS. [Jacobs et al. 2000, Comi et al 2001] IFNp-la in RRMS 
reduces relapses by approximately 30% [Jacobs et al. 1996, PRISMS study 
1998] It is not surprising therefore that IFNp-la delays a second relapse in 
those with a CIS. The effect of steroids and IFNp-la were not evaluated in 
this thesis.
5. Data used to create the McDonald criteria for dissemination in time may have 
been partly based on an earlier short term follow up study of patients from the 
cohort reported in this thesis [Brex et al. 2001] which was published around 
the time that the Panel convened, although it is not clear that this is actually 
the case from either reading the International Panel’s paper or from discussion 
with members of the Panel. The DIS criteria were certainly not derived from
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our cohort and were indeed based on earlier reports of other cohorts studied by 
Barkhof et al (1997) and Tintore et al (2000). [Barkhof et al 1997, Tintore et 
al 2000] I have now followed the majority of these patients for three years 
and report the findings in this thesis. Validation studies imply use of a 
different population. Chapters 4.1 and 4.2 are studies on the application of the 
new criteria, rather than validation studies, per se. Similar results achieved in a 
patient group from Spain with a different genetic background are, however, 
very reassuring. [Tintore et al 2003]
Proposed Revisions of the McDonald Criteria
While the McDonald criteria have by and large been seen to be a useful improvement 
in clinical practice, they have a number of limitations that have thoroughly reviewed 
recently by Polman et al (2005), and in the near future an International Panel will be 
reconvening to consider whether they should be revised. [Polman et al 2005] This 
thesis presents data arguing for expansion of the existing criteria to include a new T2 
lesion 3 months after a CIS as evidence of DIT. However, unlike the more 
unequivocal nature of the gadolinium enhancing lesion, the detection of a new T2 
lesion is sometimes harder to be sure about. In this respect, I must reiterate the advice 
given in Chapter 4.2, namely that MRI evaluation should be performed by a 
neuroradiologist or a clinician with experience of MS. Also, T2 lesions should be 
unequivocal, at least 3mm in diameter, and observed on two different types of high 
quality T2 sequence. Furthermore, it is recommended that the application of MRI 
criteria is restricted to those aged between 16 and 50 years in order to maintain a high 
diagnostic accuracy. Finally, spinal cord MRI should also be performed when the CIS
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involves the cord, to exclude other disorders and to identify demyelinating cord 
lesions.[Miller et al. 1987]
Proposed evaluation of grey matter atrophy in patients with CIS
The significant decrease in GMF between baseline and year 3 in MS contrasts with 
the weakly significant increase in mean WMF at 3 years compared to baseline. 
Addition of simulated WM lesions to healthy control images resulted in slightly 
higher GMFs and lower WMFs, suggesting that lesions per se are not causing this 
GM and WM volume abnormalities seen in early MS. It is possible that there are a 
number of distinct pathological processes at work, including an increased glial 
cellularity in the NAWM [Allen et al. 2001] due to inflammation causing volume 
gain, and also grey matter neuroaxonal loss causing volume loss. Also, demyelinating 
grey matter lesions, which are not visible on MRI, are less inflammatory and may be 
important in the development of grey matter tissue loss. A multifactorial regression 
approach may help to determine the importance of each of the new non-conventional 
MRI techniques as predictors of disability in future longer term follow up studies (few 
patients were disabled after 3 years). Information gained from measuring grey matter 
atrophy and inflammatory lesion load accumulation following CIS might -  in future - 
be used to select groups of CIS patients with the greatest inflammation and atrophy 
who can be targeted for intervention in clinical trials of novel MS therapies that aim to 
arrest the MRI-detected pathological processes at an early stage, and thereby prevent 
disability.
Proposed Clinical Practice in the Management of Patients with Optic Neuritis
The MAGNIMS network evaluated studies on the role of MRI within diagnostic 
criteria. [Miller et a l 2004] The following is a summary of the main
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recommendations of the MAGNIMS group, with additional comment included from a 
current UK perspective:
1. At the time of diagnosis of optic neuritis, or any other CIS, patients should be 
told of the risk of MS. Many patients attending clinics in the UK have read of 
the association between optic neuritis and MS on the Internet and will want to 
discuss the risk. In this respect, it is important to reiterate in clinic that the 
course of MS may be mild and non-disabling. In my experience, only a very 
small percentage of patients will not want further discussion.
2. An MRI of the brain should be offered, including T2 weighted and 
gadolinium-enhanced sequences. It should be explained that an abnormal MRI 
brain scan is associated with a 60-80% likelihood of developing MS. [Brex et 
al. 2002, Beck et al 2003]. If the MRI brain imaging is normal, the patient can 
be reassured the likelihood for developing MS is approximately 20%. [Brex et 
al 2002][Beck et al 2003]
3. If the MRI brain scan is performed more than 3 months after the onset of the 
attack and the McDonald MRI criteria are fulfilled, then a diagnosis of MS can 
be made.
4. If the MRI brain scan performed less or more than 3 months after the attack is 
abnormal (but at this stage it is not possible to fulfill the DIT criteria for MS), 
then a repeat MRI scan can be performed 3-6 months after the original scan to 
see whether MS can be diagnosed. If the criteria are not fulfilled, further 
scanning is not recommended.
5. At present, two significant relapses in the previous two years are required in 
the UK before patients are commenced on disease-modifying drugs. Earlier 
diagnosis with MRI does not therefore influence the treatment decision.
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However, if the UK guidelines (developed by the Association of British 
Neurologists) are revised in the future to include CIS patients who fulfill the 
McDonald criteria for MS, the use of MRI to investigate CIS patients would 
take on a more pressing role.
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